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Abstract 
Health systems around the world are concerned by the same topic: How their national health 
budgets can be spent efficiently and economically1.  Some related factors, such as the ageing 
population, an increase in sophistication and costs of treatments and an increase in the demand 
for imaging services, have all contributed to the rise in healthcare spending, placing further 
burdens on limited resources. The healthcare system of the United States of America has found 
this particularly challenging, where the use of cardiovascular imaging had grown persistently 
for the previous two decades1. This increase, associated with marked geographical variation of 
imaging utilisation, the spread of imaging equipment, repetition of use due to poor quality tests, 
and defensive medicine, have led to the concern about the value of cardiac imaging1, 2. Part of 
the response in the United States of America to the disconnection between the use in imaging 
and its value has been the development of the Appropriate Use Criteria (AUC) for Cardiac 
imaging1. The first criteria were introduced in 2005, with subsequent versions being published 
to include different cardiac imaging techniques, aiming to improve utilisation of imaging 
technologies in an efficient way, contributing to improvement in patient care, doctors’ decision 
making, standardisation of medical practice and control of health expenditure. The concept of 
appropriate use of cardiovascular imaging has remarkably influenced the relationship between 
clinicians, health policymakers and insurance companies to the point that from January 2017, 
all doctors and hospitals must certify their use and adherence to the criteria in order to receive 
reimbursement under the United States Medicare schedule3.  
Despite the utilisation of the AUC for the past 12 years, several problems are apparent. Issues 
related to the scientific evidence of the criteria; the uncertainty of the impact of the AUC on 
clinicians’ requesting behaviour, and on health outcomes, question the widespread use of them 
to achieve appropriate use of cardiovascular imaging in the United States and other countries 
like Australia.  
Due to an increased interest in the utilisation of these criteria in the Australian practice, this 
thesis which comprises quantitative and qualitative research methods, investigates the use of 
cardiac imaging techniques in Australia and if the American Appropriate Use Criteria are 
suitable to use in the Australian health care system.  
The work in this thesis is divided into three parts. The first part (Chapter 3), aims to determine 
if the use of cardiac imaging in Australia is appropriate based on the analyses of growth and 
geographical variation of imaging used in different regions of the country. Data from Medicare 
Abstract 
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Australia Statistics, Australian Health Survey, and Health Workforce were analysed to define 
the growth and regional variation in the use of imaging4. The increase of imaging was 
determined using rate of tests per 100,000 people in each geographical area (Medicare locals) 
and Spearman correlations, negative binomial regression and zero-inflated negative binomial 
regressions, were used to investigate univariable and multivariable associations between age-
weighted testing and characteristics of each Medicare local4. The results identified the ongoing 
growth of cardiac imaging use per 100,000 people in Australia, more pronounced in 
echocardiography modalities (transthoracic, trans-oesophageal, and stress echocardiography). 
Stress echocardiography was the technique with the highest increase since 2002 (423%), and 
there was a substantial regional variation in the use of all echocardiography modalities4. 
Greater regional echocardiography use was associated with females, proximity to major cities, 
higher socioeconomic status, and local concentration of physicians, but not with disease burden 
or deaths due to cardiovascular causes. The medical workforce appears to be the strongest 
independent driver of echocardiography use4. 
The next section (Chapters 4 to 7) aims to determine whether the Appropriate Use Criteria are 
suitable for use in Australia to achieve appropriate use of imaging. Several studies were 
undertaken to understand this. First, we related similarities and relationships between cardiac 
guidelines and Appropriate Use Criteria; second, we assessed the impact of the criteria on 
clinicians’ requesting behaviour. Third, we evaluated the impact on health outcomes, and 
finally, factors that lead doctors to order “inappropriate”. echocardiograms.  
For examining the similarities of Appropriate Use Criteria with guidelines (Chapter 4), the 
criteria and the published Cardiology guidelines were matched to identify concordance 
between both. Concordance was determined when “appropriate” items in the criteria had 
recommendation class I or IIa in the guidelines; “inappropriate” scenarios had recommendation 
class III, and “uncertain” items had recommendation class IIb5. The results identified that 91% 
of the criteria had a counterpart on the guidelines for the use of echocardiography5. However, 
only 82% of them were concordant, and the rest were inconsistent. These results suggest that 
the potential incorporation of an AUC process into Australian practice might face challenges 
to achieve appropriate use and to improve quality of care5. 
Chapter 5 was a systematic review of published manuscripts related to the AUC use in 
cardiovascular imaging to study the impact of the appropriateness criteria on clinicians’ 
ordering behaviour. The aim was to determine the proportion of “appropriate” and 
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“inappropriate” testing over time using meta-regressions. More than 5,200 manuscripts were 
found in online databases and were analysed. The results showed that there was a positive 
association with the percentage of appropriate tests for Transthoracic Echocardiography (TTE), 
as well as a negative association of the ratio of uncertain tests over time, but inappropriate 
testing remained the same, that is no decrease in the proportion of inappropriate tests over time. 
These results suggest no impact on clinicians’ ordering behaviour6. 
Chapter 6 aimed to determine the effect of the definition of appropriateness on survival time in 
stable heart failure patients. The analysis was made using survival analysis with time-
dependent variables for the combined endpoint of Heart Failure (HF) readmission and death, 
and a separate analysis for HF readmission, with death as a competing risk7. The results showed 
no differences in the event-free time for combined outcomes; HF readmission was not 
associated with routine follow-up TTE timing; there were no differences in the cumulative 
incidence of death between groups7. 
For chapter 7, a qualitative analysis was performed using semi-structured face-to-face 
interviews with open-ended questions to analyse the factors that lead doctors to order 
echocardiograms and the relationship with inappropriate testing. Seventeen physicians 
(cardiologists and non-cardiologists) participated in the study. Personal factors such as lack of 
expertise, limited experience and inability to manage uncertainty were the most important 
factors that impacted the decisions of doctors leading to the ordering of inappropriate tests. 
Other factors included accessibility of tests and adherence to protocols. These results suggest 
a mismatch between the clinical reasoning of physicians and the AUC for echocardiography.  
Due to the results of the previous chapters indicating that the AUC are not the ideal tools to 
achieve appropriate use, to improve health outcomes, and to change doctors’ ordering 
behaviour, a third and final section evaluated a proposed methodology to determine possible 
inappropriate testing and the way to give answers to doctors without the need for performing a 
formal test. This third section includes chapters 8 and 9.  
For Chapter 8, general characteristics of inappropriate TTE were determined and summarised 
in a questionnaire of four binary questions most commonly associated with inappropriate tests. 
These questions are related to the absence or change of cardiovascular symptoms or signs, 
routine surveillance as the purpose of the exam, echocardiograms in the previous twelve 
months, and if endocarditis with no murmur or positive blood cultures was the reason for the 
scan8. These questions were applied to two different validation groups. Analyses of specificity, 
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sensitivity, and predictive values were performed to determine the accuracy of the prediction 
of inappropriate requests. Two or more affirmative questions had a high sensitivity and 
specificity to determine inappropriate requests according to the criteria. The time to answer the 
questions was limited to up to 2 minutes when it could not be answered directly from the echo 
request. In only 19% of the requests was there a need to the review the digital record to respond 
to the questions. Only 18% of the total amount of requests to the echo laboratory, warranted a 
comparison with the Appropriate Use Criteria8.  
Two approaches to inappropriate requests (standard TTE versus hand-held echocardiography) 
were compared in a case-control study (Chapter 9). Patients were followed for a period of 6 
months and outcomes such as time until the scan, repeat echocardiography, the cost of each 
strategy, new findings, and impact on management were determined9. The results of this study 
showed no differences in the finding of new pathologies or change in management between 
hand-held echocardiography and standard TTE. However, people in the portable echo group 
had less time to scan if they were inpatients and the average cost of the approach was lower 
than the standard echocardiography group ($145 AUD vs $241 AUD)9.  
Statistical analyses in all chapters were performed using R software; geo-mapping for Chapter 
2 was done using QGIS 2.4.0.; hand-held ultrasonography was performed using the GE Vscan 
V 1.2 portable device and standard TTE was performed GE Vivid 9, Philips IE33 and Acuson 
SC2000.  
Conclusions 
The results of the studies contained within this thesis suggest there is a need for appropriate 
use of cardiac imaging in Australia because there is a vast difference of use in Medicare locals 
and no association of cardiac imaging use with the burden of cardiovascular disease. However, 
the use of the American AUC may face critical challenges for use in Australia because of a 
number of factors, these being: the discordance of the criteria with the cardiology guidelines, 
the lack of evidence of impact of the Appropriate Use Criteria on physicians’ ordering 
behaviour, the absence of improvement of survival or readmission in patients with stable heart 
failure, and the mismatch between the clinical reasoning process of doctors and the criteria4-7.   
Those issues aside, our studies found that the use of a simple questionnaire at the point-of-
service assists in determining a high proportion of inappropriate tests in an unbiased way with 
minimal interruption of workflow. The use of hand-held echocardiography appears to be a safe 
and cost-saving strategy that can be used to give the answers to doctors without the need for 
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performing standard echocardiograms. The combination of these, enable point-of-service staff 
to determine appropriateness and provide a viable alternative to costly tests, helping to reduce 
the economic burden while still providing doctors with access to information in support of their 
patients’ care8, 9.  
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Chapter 1. Introduction 
Part of the research contained in this chapter has been published as1, 2: 
 Fonseca R, Marwick TH. How I do it: judging appropriateness for TTE and TEE. 
Cardiovasc Ultrasoun. 2014;12(1):22. 
 Fonseca R, Marwick TH. Appropriateness and outcomes: is it time to adopt appropriate 
use criteria outside of North America? Heart. 2014;100(5):357-8. 
 
One of the most challenging tasks during my years of experience as a physician and as a 
specialist of healthcare administration has been to balance the intricate relationship between 
the practice of medicine per se and the economic concept of it. Unfortunately,  medical practice 
is no longer simply a service to our patients with a strong code of ethics; we are also finding 
ourselves incresingly bound by finite resources and laws of economy that drive decisions of 
care in our practices and healthcare systems. Our actions as medical practitioners are readily 
measured by analysing health care expenditure against health outcomes. It is difficult to 
identify the proportion of practitioners acutely aware of the breadth of economic implications 
their work causes to society. And it is here, with the unrecognised concepts of appropriate use 
and value of healthcare, that the battle between governments, managers, economists, and 
policymakers vs. health professionals, has its origins. 
The rise of healthcare expenditure: the cornerstone 
Health care spending has been increasing worldwide regardless of wealth, population 
characteristics, or region 10-12. This trend is marked in developed countries since the 1990’s 10, 
13, 14, the United States of America being the country with the highest health expenditure in the 
world 11 (Figure 1- 1).
  
Figure 1- 1 Health spending as a share of GDP, 2012 or latest year 
 
Reproduced from OECD. Fiscal Sustainability of Health Systems: OECD Publishing11
  
Although the medical-care industry’s problems have been analysed for decades15,  a particular 
situation occurred that “set the alarm bells ringing” in recent years. This situation was the 
increase of imaging use and its significant impact on health budgets, raising the question as to 
how the imaging component of the health budget can be spent wisely1. 
There is perhaps no space where this is more challenging than cardiovascular imaging, the 
growth of which has exceeded the overall increase of medical costs over the last decades, which 
has been more pronounced in the United States of America (USA)1, 11, 16.  The contribution of 
imaging to the medical budget started to be highlighted in the United States more than 20 years 
ago. At this time, the Medicare Payment Advisory Commission (MedPAC) showed a 10%/year 
increase in spending for cardiac imaging between 1999 and 2002, when the average growth per 
year of all services was 5.2%2, 17. This trend continued throughout the following decade: the 
imaging payments to Cardiologists in 2000 were US$1.6 billion, increasing to US$5.1 billion 
in 2006 2, 18 (Figure 1- 2).
  
Figure 1- 2 Medicare reimbursements to cardiologists in the US (Reproduced from Shaw, et al.18). 
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Contributors to this growth included the rapid proliferation of imaging machines, limited 
experience with new imaging modalities among non-specialists, automated referral pathways 
and self-referrals 2, 19, poor quality of imaging (requiring repetition of tests) and defensive 
medicine 2, 20, 21. In addition to these previous contributors, the differences in the use of imaging 
amongst regions supported the contention that the selection of imaging tests was discretionary 
rather than disease-related 22-24 (Figure 1-3), rising concerns about the poor value of imaging 
tests.  
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Figure 1- 3 Differences in the use of echocardiography in the US in 1996. Regional variations 
by hospital referral region expressed as a ratio to the US average. From Wennberg, et al. The 
Dartmouth Atlas of Cardiovascular Health Care. P65. 1999 24. 
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Strategies to content use of cardiac imaging  
Several strategies have been implemented in an attempt to control the use of cardiac imaging 
and reduce spending in the United States. These approaches include (but not limited to): 
 Changes in reimbursement models, which aims to reduce refund costs of cardiac 
imaging to discourage the overuse of tests18;  
 Use of Radiology Benefit Manager Companies by health insurers, which adopt pre-
authorisation processes seeking to deny payment of services if no pre-authorisation has 
been granted18;  
 Adoption of the Appropriate Use Criteria 18, 25.   
 
Development and application of the Appropriate Use Criteria 
Part of the response to the disconnect between the growth in imaging and its value in North 
America has been the development of the Appropriate Use Criteria (AUC)1. The criteria were 
designed to improve physicians’ decision making, to enhance patient’s care, and to control the 
use of imaging and therefore, health expenditure1, 26.  
Although the initial application of Appropriate Use Criteria was not directed towards 
cardiovascular imaging but towards medical procedures27, the American College of Cardiology 
Foundation (ACCF), along with other medical associations, formed the Appropriateness 
Criteria Working Group (now called ACCF AUC Task Force) 2, 28. The ACCF AUC Task Force 
used a modified Delphi process (based on the Delphi method employed by the RAND/UCLA 
appropriate use criteria methodology) 2, 27, 29  to select the appropriateness criteria.  
The original Delphi process (in respect to healthcare) employed by the RAND Corporation 
(“Research and Development”) and the University of California, Los Angeles (UCLA), was 
developed in the 1980s to address the problem of overuse and underuse of health procedures27. 
The aim of the method was to “combine the best available scientific evidence with the collective 
judgment of experts to yield a statement regarding the appropriateness of performing a 
procedure at the level of patient-specific symptoms, medical history, and test results” 27. The 
original methodology involves a list of questions being compiled and sent to a panel of experts 
who answer anonymously. Their responses are collated and summarised to reflect the “group 
response”. This summary is sent back to the members of the panel as statistical analysis, to 
protect respondent anonymity. The process is repeated, over some iterations, to formulate an 
“expert” collective agreement27. 
Chapter 1. Introduction 
 
35 
 
The modified Delphi process used to develop the Appropriate Use Criteria for different cardiac 
imaging technologies is an evaluation of a list of medical indications (in which a cardiac 
imaging test could be performed) by a panel of experts (comprising 9 to 15 individuals who 
are physicians, health professionals, and policy makers)30. A review committee compiles a list 
of clinical scenarios after assessing the scientific evidence available 30. Individually, the expert 
panel members analyse the risks, benefits and recommendations of evidence for performing 
the imaging test in each medical situation. They then indicate their response by providing a 
score between 1 to 9 according to the appropriateness of the test. In their review of the medical 
cases, the panel members also reference the Cardiac Guidelines to assist in determining their 
grading for appropriateness30 (Figure 1- 4).  
 
Figure 1- 4 Guides for panel reviewers to consider (Reproduced from Patel, et al.30)  
 
 
 
An assessor gives a score between 7 to 9 to what they deem to be an “appropriate” test for that 
particular indication. In this case, the test is considered mostly acceptable and is an adequate 
approach for the clinical scenario or indication. When the score is between 1 to 3, the test would 
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not be considered broadly “acceptable” and therefore “not a reasonable approach” for the 
situation (“Inappropriate”)26, 30. Finally,  scores between 4 to 6, identify those “uncertain” or 
“may be appropriate” tests for that particular situation. In this case, the test may be acceptable 
and accordingly may be considered a reasonable approach for the situation. However, an 
“uncertain” test may be the result of ambiguity which implies that more research or information 
is necessary to determine the status as appropriate or inappropriate30.  
After the first ranking round as described above (done privately by each panel member without 
interactions with other individuals of the group), a second round is done to reach consensus 
among the members of the committee. This meeting is conducted collectively, to allow 
discussion and debate on the various scenarios before a final ranking is submitted. The averages 
of the ranks are split between 7 to 9, 4 to 6 and 1 to 3 following the second round. The 
indications, respective to the splits noted above, are defined as “appropriate”, “uncertain” or 
“inappropriate” (the latter two now being referenced as “may be appropriate” and “rarely 
appropriate” by the new terminology)28, 30. (Figure 1- 5).  
 
Figure 1- 5 Process to determine appropriateness based on RAND/UCLA method (Reproduced 
from Patel et al. 30) 
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The concept of appropriateness defined by the RAND/UCLA methodology in the 1980’s was 
the cornerstone for developing the first attempt at appropriate use criteria (AUC)2. The initial 
concept suggested that “an appropriate procedure is one in which ‘the expected health benefit 
(e.g., increased life expectancy) exceeds the expected negative consequences (e.g., mortality, 
morbidity, anxiety, pain, time lost from work) by a sufficiently wide margin that the procedure 
is worth doing, regardless of  cost”2, 27, 29. However, no management decisions in medical 
practice are exempt from having to address an abstract concept that is difficult to measure: 
appropriateness2. In common language, an appropriate choice is one which is suitable or proper 
in the circumstances, but this is surprisingly different from the medical definitions2.  
In an attempt to address this difference when  adopting  the concept to cardiac imaging, the 
Appropriateness Criteria Working Group (ACCF AUC Task Force) 28 defined an appropriate 
test as “one in which the expected incremental information, combined with clinical judgement, 
exceeds the expected negative consequences (risks of the procedure i.e. radiation or contrast 
exposure and the downstream impact of poor test performance, such as delay in diagnostic 
(false negatives) or inappropriate diagnosis (false positives)) by a sufficiently wide margin for 
specific indication that the procedure is generally considered acceptable care and a 
reasonable approach for the indication” 2, 30.  Because of the low risk of non-invasive imaging, 
there are many circumstances where this definition could be deemed as insufficient – the risk 
is almost zero, so the balance of benefit and risk is positive, but the information obtained is still 
inadequate to justify the performance of the test2. A new definition overcomes these concerns 
by framing the decision in the context of a consensus about “reasonable care”28, and resource 
utilisation: “The concept of appropriateness, as applied to health care, balances the risk and 
benefit of a treatment, test, or procedure in the context of available resources for an individual 
patient with specific characteristics”2, 28. Importantly, it is now acknowledged that Appropriate 
Use Criteria should provide guidance to supplement the clinician’s judgment, rather than being 
prescriptive2. While the risk of harm with inappropriate intervention is an important motivator 
to the application of AUC, the focus on appropriate use in imaging is mainly rooted in resource 
utilisation and medical expenditure2. 
The first AUC (for Single-photon Emission Computed Tomography SPECT) were launched at 
the end of 2005, and the first transthoracic (TTE) and transoesophageal (TEE/TOE) 
echocardiography AUC document was released two years later 2, 31, 32. Stress echocardiography 
(SE) AUC was not developed until 2008, therefore not included in the first version of the 
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echocardiography AUC 33, but the criteria were merged in the updated 2011 version 26. 
Previous versions of AUC for the different cardiac imaging techniques were also redesigned 
and re-evaluated, due to several common clinical scenarios which were not included in the first 
editions. The AUC continue to evolve, and criteria for multimodality cardiac imaging and the 
re-definition of “inappropriateness” are counted amongst recent changes 2, 28, 34. 
The concept of appropriate use has had an extraordinary influence on the relationships between 
patients, physicians, administrators and insurance companies over the last decade2. However, 
the most important step commenced January 1, 2017:  All health professionals and medical 
practices must certify their use of appropriate use criteria when ordering advanced diagnostic 
imaging, as payments under the Medicare & Medicaid Services program in the US3 will no 
longer be made for ‘inappropriate’ tests. 
However, new research studies have shown that some tests labelled “inappropriate” have 
provided significant results leading to a change in management in the patient 35-37. 
Disadvantages of the Appropriate Use Criteria 
While the AUC have become a foundation of the efforts to improve quality and control 
expenditure in the US, their uptake in other jurisdictions has been less enthusiastic due to some 
challenges2, 35, 38-63:  
1. The AUC differ importantly from clinical guidelines in that they are developed by 
consensus30 based on a modified Delphi process which has important disadvantages1, 
64. The AUC are situation-specific though not necessarily evidence-based. The 
scientific evidence basis of some AUC is weak as they are based on levels of evidence  
B or C.  A potential question, therefore, is whether they are necessarily correct1. This 
is especially problematic when the only difference between an appropriate or 
inappropriate test is the time of evaluation or the symptom status of the patient1 (Table 
1- 1).  
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Table 1- 1 Comparison between some guidelines for the clinical application of 
echocardiography indications and their corresponding AUC indications (Reproduced from 
Fonseca, et al.1) 
                                                                                
 
In some situations (asymptomatic non-severe valve disease), the test could be expected 
to have limited or no prognostic value, irrespective of timing and appropriateness2. 
Contrarywise, the mandate of symptomatic criteria to define appropriateness for 
example in hypertensive heart disease, may allow heart failure events to occur even 
after tests labelled as inappropriate2.   
2. AUC represent a compilation of indications, but not all situations in which an 
echocardiogram could be performed are listed in the criteria1. Although some studies 
ACC/AHA Guidelines for the Clinical 
Application of Echocardiography
Class AUC for echocardiography
AUC 
Score
40. Routine surveillance (< 1 y) of moderate 
or severe valvular stenosis without cange in 
clinical status or cardiac exam
I  (3)
41. Routine surveillance (≥1 y) of moderate or 
severe valvular stenosis without cange in 
clinical status or cardiac exam
A (8)
38. Routine surveillance  (< 3 y) of mild 
valvular stenosis without change in clinical 
status or cardiac exam
I  (3)
39. Routine surveillance  (≥ 3 y) of mild 
valvular stenosis without change in clinical 
status or cardiac exam
A (7)
45. Routine surveillance (< 1 y) of moderate 
or severe valvular regurgitation  without 
cange in clinical status or cardiac exam
U (6)
46. Routine surveillance (≥ 1 y) of moderate 
or severe valvular regurgitation  without 
cange in clinical status or cardiac exam
A (8)
43. Routine surveillance (< 3y) of mild 
valvular regurgitation  without cange in 
clinical status or cardiac exam
I (2)
44. Routine surveillance (≥ 3 y) of mild 
valvular regurgitation  without cange in 
clinical status or cardiac exam
U (4)
45. Routine surveillance (< 1 y) of moderate 
or severe valvular regurgitation  without 
cange in clinical status or cardiac exam
U (6)
46. Routine surveillance (≥1 y) of moderate or 
severe valvular regurgitation  without cange 
in clinical status or cardiac exam
A (8)
I
Reevaluation of patients with mild to 
moderate regurgitation with ventricular 
dilation without clinical symptoms
III
I
Reevaluation of asymptomatic patients with 
severe stenosis
I
Routine reevaluation of asymptomatic 
patients with mild to moderate mitral 
stenosis and stable physical signs
Reevaluation of asymptomatic patients with 
severe regurgitation
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of AUC indicate all tests to have been classified 35, 39, 40, 46, 52, 57, 58, in reality, as several 
indications are often present in the same patient, any non-identified scenario may 
remain unclassified as secondary reasons for requesting the test are nominated. 
3. Several recommendations for echocardiography in current practice guidelines (not just 
in echocardiography but for disease entities) lack counterparts in the AUC2. For 
example, a class I recommendation is given for follow-up or surveillance after surgery 
of masses known to have a high likelihood of recurrence (e.g., myxoma 65). The AUC 
classification of “suspected cardiac mass” – or even screening – does not cover the 
described scenario2.   
4. The lack of follow-up events does not itself define inappropriateness1. We should 
expect three outcomes from testing – that the test should provide benefit, that it should 
reclassify risk, and that the risk should be alterable with intervention. While the link 
between a low risk for future cardiovascular events and unnecessary testing of patients 
with a low probability of coronary artery disease is readily understood, this is an 
imperfect example of inappropriate testing1. The original interpretation of 
“appropriateness” was a situation where the benefit of the test result exceeded the risk 
(to which we might add financial burden) associated with testing. A gratifyingly 
negative echocardiogram that reassures an anxious patient and confirms the correctness 
of a conservative strategy is perhaps the most “appropriate” of scenarios1. Conversely, 
a positive test for ischemia that predicts an adverse event in a patient who is unsuitable 
for intervention is actually inappropriate. It is the reclassification of risk assessment 
that provides the most return on the investment of testing1. 
5. The application of AUC to patient selection may be problematic as an audit tool2. When 
an appropriate indication is required to order the test at point-of-service (the facility or 
location where the test is being performed), the referring clinician may list a co-existing 
appropriate indication rather than the actual clinical problem (which may be 
inappropriate)2. This is particularly likely when the proportion of inappropriate tests is 
assessed as part of the echocardiography accreditation process 66. Additionally, the 
application of AUC is bedevilled by the reliability and reproducibility of the assessment 
of appropriateness2.  
6. Retrospective auditing may be especially challenging. For example, a false positive 
may arise when a test is labelled as “inappropriate”, being “appropriate” due to the 
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possible lack of information that auditors have at the time. The reason for requesting an 
echocardiogram is often inadequately detailed in the medical records2.  
7. After almost a decade of this work, there are concerns about the actual impact the AUC 
has had on physician ordering behaviour1, 2. Although there has been a steady decrease 
in the cardiac imaging growth (excluding Cardiac Computed Tomography and Cardiac 
Magnetic Resonance 67) since 2006 (more than 15% of the Medicare reimbursement 
between 2006 and 2011)25, 67, we see very little evidence of any real impact on the 
decline of “inappropriate” tests despite continuous attention to the problem of improper 
use2. The literature gives the impression that a similar proportion of “inappropriate” 
testing, despite experience, educational campaigns and close follow-up continues. 
Moreover, the correlation between appropriateness and clinical impact has not been 
well studied 35. Analysis of the six most relevant studies for assessment of the 2011 
AUC for stress echocardiography 44, 50, 68-71, shows that the average of appropriate use 
is around 61% and that there is no significant correlation between the rate of 
appropriateness and the enrolment years of the studies1.  Indeed, the work of 
Bhattacharyya et al72 provides a scenario for appropriate selection of stress 
echocardiography that is neither different nor encouraging1. The study shows that 
62.4% of the stress echocardiograms were “appropriate”, 28.4% were “inappropriate”, 
and 9.2% were “uncertain”. Interestingly, these results are similar to the results obtained 
by Cortigiani et al.,68 who found that 63.4% of SE were “appropriate”, 27.3% 
inappropriate and 9.3% uncertain under the same AUC. However, with a noticeable 
difference: the SE evaluated by Cortigiani et al.,68 were performed between January 
2001 and December 2007, and the SE assessed in the study by Bhattacharyya et al., 
were conducted between October 2010 and September 20111. These results should lead 
us to focus on the actual impact of Appropriate Use Criteria on health professionals 
throughout this time. While interventions directed towards interns and residents at the 
Massachusetts General Hospital,73 and the development of software to link AUC to 
ordering in the electronic medical record are promising,74 it remains uncertain as to 
whether the processes merely change the attribution of studies based upon these new 
rules. Certainly, the effects of teaching interventions have not been uniformly 
favourable, with a prominent  study of an intervention based on lectures and training 
returning negligible results.1, 70 
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8. New studies have shown that some tests labelled “inappropriate”  have led to a change 
in management (around 20%) due to new significant findings (~30%)35-37, 75. This is 
particularly important because the AUC process aims to avoid the performance of 
labelled “inappropriate” requests in order to control cardiac imaging use and health 
expenditure. Therefore, by following the AUC, physicians may not discover key 
findings leading to inappropriate patient care.  
 
Although there is an increased interest in adopting the AUC to the Australian practice, the 
application of AUC remains primarily a North American phenomenon. There are many aspects 
of medical care in the USA which are mysterious to foreigners. Are AUC merely a component 
of this difference, or is it time to declare victory for AUC and apply them more widely than in 
the USA?1  
The listed disadvantages of the AUC should caution us regarding more widespread adoption 
of AUC1. There is no doubt that we need a method to reduce the over-use of cardiovascular 
imaging. The AUC appear to be a part of the imaging landscape in North America, but it may 
not be the solution to the challenges of imaging selection elsewhere1. Perhaps those of us 
outside the USA should contemplate a metric that better measures the information content of 
testing, in order to find the desired balance between clinical utility and reduction of health 
expenditure. Judging appropriateness in echocardiography is a process based on knowledge, 
experience, information, resources and the real desire to provide an adequate service to the 
patient. It does not sit well with formulaic approaches based on uncritical applications of AUC1. 
Importantly, physicians should be formulating their own conclusions regarding test 
requirements and using the AUC as a supplement to this rather than the sole arbitrator28. 
Hypothesis and aims of this thesis 
The disadvantages and limitations described previously are unfortunate as AUC may have 
significant health economic implications. Due to those issues, the overall objectives of this 
thesis were first to examine the use of cardiac imaging in Australia and secondly, if the AUC 
are suitable to use in this country in the event Australia needs an appropriate use improvement 
program. However, taking into account the lack of transparency and risks that the AUC process 
entails when used at the point-of-care/request (the location where the test is requested) due to 
the possible change of indications and the risk that cancelling the labelled “inappropriate” 
requests has for patients, we also sought to find an alternative process which can be used at the 
Chapter 1. Introduction 
 
43 
 
point-of-service in an easy and efficient way to avoid inappropriate testing with the safety of 
the cardiac evaluation. In order to accomplish these objectives, the following are the hypothesis 
and specific objectives of this thesis. 
Hypothesis: the AUC are an inconclusive tool to improve appropriateness and use of cardiac 
imaging. 
Objectives:  
1. To define the use of cardiac imaging in Australia and to analyse related factors in 
order to establish if a program for appropriate use is needed in this country. 
2. To identify if the actual AUC are suitable for use in Australia by addressing the 
following objectives: 
a. To determine differences between AUC and guidelines.  
b. To determine the trends of the percentage of appropriateness in the different cardiac 
imaging.  
c. To determine the impact of the AUC in doctors’ ordering behaviour. 
d. To determine if the concept of appropriateness used by the AUC affects health 
outcomes. 
e. To define factors that influence ordering behaviour in clinicians. 
3. To propose an improvement plan to avoid possible inappropriate requests without the 
risk of missing significant cardiac findings. 
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Structure of the thesis 
Chapter 1. Introduction 
Chapter 2. Methodology 
Chapter 3. Appropriate use of imaging in Australia.  
Chapter 4. Evidence status of the Appropriate Use Criteria. 
Chapter 5. Impact of Appropriate Use Criteria on clinician’s behaviour. 
Chapter 6. Impact of Appropriate Use Criteria on health outcomes: Heart Failure Survival 
Chapter 7. Understanding Cardiac Imaging Decision-Making: Appropriate Use Determinants 
Chapter 8. Identification of inappropriate request at the point-of-service 
Chapter 9. Usefulness of hand-held echocardiography in inappropriate requests 
Chapter 10. Summary and discussion  
 
Concluding remarks 
This chapter provided an overview of the AUC, their motivation and aims. An overview of the 
findings suggests that the AUC have important limitations that should be addressed before 
adoption for the use of the criteria outside the USA. 
Knowing the characteristics and use of cardiac imaging in Australia and understanding the 
challenges of the AUC provides us with the opportunity to determine if the criteria are suitable 
for use in this environment. 
This thesis aims to evaluate the potential problems of using the American AUC and to identify 
a solution that avoids inappropriate tests in Australia. Findings of this research will fill the 
current evidence gaps. 
The following chapter describes the methodology used for this research.   
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Preface 
In the previous section, background information was provided regarding the significant growth 
of national health care budgets globally and the recent shift to understand how the imaging 
component can be spent wisely.  
It was identified that cardiovascular imaging has seen the most significant growth rate in the 
last two decades in the USA. The need to utilise a method for determining appropriateness of 
imaging use and controlling the use of cardiac imaging services was discussed. As a response 
to this need, it was shown that the Appropriate Use Criteria for different cardiac imaging 
techniques were developed. However, it was considered that these criteria have some 
disadvantages and flaws, which interfere with the ability of the criteria to impact clinician’s 
behaviour to achieve appropriate use of imaging. Moreover, the intention to use the criteria 
broadly outside the USA, including Australia, has been the basis for this research.   
The present chapter briefly describes the methodology employed in this thesis. This thesis 
comprises quantitative and qualitative research methods. Additional factors that are unique to 
each chapter are described in more detail within the methodology section of each of the 
subsequent chapters. More details related to particular investigations are addressed in their 
respective studies that are presented in chapters 3 to 9.  
This research was framed by the Tasmanian Health and Medical Human Research Ethics 
Committee approvals H0014017 and H0015516.   
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Methodology 
This thesis was developed in three stages. The first phase, contained in Chapter 3, determined 
how cardiac imaging is used in Australia to define the need (or not) of appropriate use. Two 
areas were analysed. First, the growth of cardiac imaging use in Australia and second, the 
associations of imaging use with demographic characteristics, availability of medical 
workforce and cardiovascular burden of disease for each Medicare Locals4. Data from 
Medicare Australia Statistics, Australian Health Survey, and Health Workforce were analysed 
to define the growth and regional variation in the use of cardiac imaging in the last decade. The 
Medicare Statistics website contains quarterly and annualised data (financial and calendar years) 
relating to Medicare 76.The increase of imaging was determined using use of tests per 100,000 
people in each geographical area over time intervals. Medicare locals were chosen as the 
regional areas for analysis due to them being the smallest geographical areas with available 
information. Spearman correlations, negative binomial regression and zero-inflated negative 
binomial regressions, were used to investigate univariable and multivariable associations 
between age-weighted testing and characteristics of each Medicare local4. 
The second stage addressed the disadvantages and challenges that the criteria have faced during 
the last decade to determine if the AUC are the correct tools to use in Australia. This phase was 
developed through Chapters 4 to 7.  
The core research question was: Are the AUC suitable to use in this country? Figure 2- 1 shows 
the topics that were taken into account to develop this aim.  
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Figure 2- 1 Topics 
 
The matters to investigate were the disadvantages and challenges of the criteria that were 
explained in the Introduction. In order to understand the evidence status of Appropriate Use 
Criteria (Chapter 4), a comparison between the criteria and the published Cardiology guidelines 
was performed to find concordance between both5. Concordance was determined when 
“appropriate” items in the criteria had recommendations class I or IIa in the guidelines, 
“inappropriate” scenarios had recommendations class III, and “uncertain” items had 
recommendations class IIb5. Figure 2- 2 shows the definition of recommendations in clinical 
guidelines77.  
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Figure 2- 2 Guidelines’ recommendations (Adapted from Gibbons, et al.77) 
 
As shown in Figure 1-4, the appropriateness designation and guidelines recommendations must 
be consistent.  
The second topic addressed to determine the suitability of AUC use was an investigation 
regarding the temporal changes in the appropriateness of cardiac imaging, documenting the 
impact of the criteria on clinicians’ ordering behaviour. This investigation determined the 
change of proportion of “appropriate/uncertain/inappropriate” tests over time, which implies 
impact on requesting behaviour. This exploration is included in Chapter 5 which was a 
systematic review of published manuscripts related to the AUC use in cardiovascular imaging. 
Two reviewers conducted the literature search of online databases. Papers were included in the 
analysis if they specified type and edition of AUC used, year of data collection, sample size of 
tests evaluated, proportion of “appropriate” and inappropriate or uncertain studies and 
proportion of “classified” studies, which correspond to the percentage of studies whose reasons 
were found in the list of criterion of the AUC6. The proportions of “appropriate”, “uncertain”, 
and “inappropriate” testing over time were analysed in meta-regressions using logit 
transformation to calculate the weighted summary proportion with random-effect models. Ten 
pooled analysis were conducted for each cardiac imaging found and edition of AUC used: TTE 
using 2007 AUC, TTE using 2011 AUC, TEE using 2007 AUC, TEE using 2011 AUC, SE 
using 2008 AUC, SE using 2011 AUC, CCT using 2006 AUC, CCT using 2010 AUC, and 
SPECT using 2005 and 2009 AUC. Publication bias was examined using funnel plots and 
Egger’s test6. 
The impact of the criteria on health outcomes in Chapter 6 was an analysis of event-free 
survival, cause-specific hazard and cumulative incidence of Heart Failure (HF) readmission 
and death of patients with HF utilising Kaplan-Meier and Cox proportional hazard regression 
and competing risk analyses7. This was a cohort study of patients hospitalised for HF at a 
tertiary referral hospital. Patients were included if they were adults (≥18 years old), had a 
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diagnosis of HF and a TTE before or during hospitalisation. Participants were divided into four 
groups according to the definitions of follow-up TTE in the AUC for echocardiography26, 78: 
patients with no follow-up TTE after discharge, patients with “inappropriate” follow-up TTE 
according to AUC, after discharge (follow-up <1 year with no change in symptoms or clinical 
status), patients with “uncertain” follow-up TTE according to AUC after discharge (>1 year 
with no change in symptoms of clinical status) and patients with “appropriate” follow-up TTE 
according to AUC (TTE due to change in symptoms or clinical status)7.  
Chapter 7 is a qualitative analysis performed using semi-structured face-to-face interviews with 
open-ended questions to analyse factors leading doctors to order echocardiograms and the 
relationship with inappropriate testing. Cardiologists and non-cardiologists were included in 
the study.  
The third stage of this work was to provide a solution to avoid the performance of tests labelled 
“inappropriate” in a safe way. This phase was based on the findings of the previous studies, 
which demonstrated inconsistencies between clinical guidelines and AUC, nominal impact on 
the request of inappropriate testing over time, a lack of clear effect on event-free survival, and 
a mismatch between the clinical reasoning process of doctors and the AUC. These results with 
the assumption that doctors can choose “appropriate” indications instead of the presenting 
problem of the patient (which could be classified as “inappropriate”), and that some tests 
labelled “inappropriate” have provided information leading to a change in patient management, 
gave cause to a further two studies which were developed to avoid these issues. These studies 
are included in chapters 8 and 9.  
In chapter 8, the objective was to find a transparent way to determine labelled “inappropriate” 
tests at the point of service (e.g. echo-laboratory). This approach aimed to nullify the possibility 
of shifting indications at the point of request by practitioners. General characteristics of 
inappropriate TTE were determined and summarised in a questionnaire of four binary questions 
most commonly associated with “inappropriate” tests8. These questions are related to the 
absence or change of cardiovascular symptoms or signs, routine surveillance as the purpose of 
the test, previous tests in the last year and if endocarditis with no murmur or positive blood 
cultures was the reason for the scan8. These questions were applied to two different validation 
groups. Analyses of specificity, sensitivity, and predictive values were performed to determine 
the accuracy of the prediction of inappropriate requests.  
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In Chapter 9, two approaches to “inappropriate” requests (standard TTE versus hand-held 
echocardiography) were compared in a case-control study. Patients were followed for a period 
of 6 months and outcomes such as time until the scan, repeat echocardiography, the cost of 
each strategy, new findings and impact on management were determined9.  
Statistical analyses in all chapters were performed using R software79; geo-mapping for 
Chapter 2 was done using QGIS 2.4.0 (QGIS 2.4.0, Open Source Geographic Information 
System; OpenSource Geospatial Foundation, Beaverton, OR, USA); hand-held 
ultrasonography was performed using the GE Vscan V 1.2 hand-held device and standard TTE 
was performed GE Vivid 9, Philips IE33 and Acuson SC20009.  
The following chapter addresses the first objective of this thesis:  the growth in use of cardiac 
imaging in Australia and related factors of use in order to understand the ‘appropriateness use’ 
status in this country.  
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Chapter 3. Appropriate use of cardiac imaging in Australia 
The research contained within this chapter has been published as 4: 
 Fonseca R, Otahal P, Wiggins N and Marwick TH. Growth and geographical variation 
in the use of cardiac imaging in Australia. Intern Med J. 2015;45:1115-27. 
 
Preface 
In Australia, health expenditure has increased from $50.3 billion (6.5% of GDP) in 1990 to 
$154.6 billion (9.7% of GDP) in 201480, 81. Moreover, cardiovascular disease (CVD) has the 
highest level of health-care expenditure of any disease group80, 81.  
In 2015, the Medicare reimbursement for TTE only was approximately $186.0 million 
Australian dollars76. Assuming that low-value tests oscillate between 7% and 20% (according 
to international literature), the Medicare reimbursement in Australia would be expected to 
fluctuate between $13.0 and $37.2 million dollars8, 76.  
In this country, several studies have shown a wide difference in the use of healthcare services 
by geographical areas indicating ineffective use 80-82. The key factors of increases in use and 
local variations in the usage of health services are possible measurements of quality of care and 
appropriate use12.  
In the previous chapter, general information was provided on why the Appropriate Use Criteria 
(AUC) were needed to control the use of cardiac imaging in the USA. However, despite the 
increased interest in using the same criteria within the Australian practice, the potential impact 
and relevance of the AUC have not been assessed in this country.  
The present chapter aims to determine the growth in cardiac imaging use in Australia during 
the last decade and most importantly, to establish the associations of imaging use with 
demographics and burden of disease in order to analyse potential misuse of this health resource.   
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Abstract 
Growth rates and regional differences in the use of cardiac imaging are potential metrics of 
quality of care. This study sought to define growth and regional variation in outpatient cardiac 
imaging in Australia.  
Methods.  
Analyses are based on the rate of outpatient transthoracic (TTE), trans-oesophageal (TOE) and 
stress echocardiography (SE) and single-photon emission computed tomography (SPECT) per 
100,000 people in each geographic insurance region in Australia (Medicare Local, ML). 
Numbers of tests from 2002-13 were obtained from Medicare Australia Statistics, and the 
number of doctors was obtained from the Health Workforce data. Demographic information 
(total population, rural areas, and quintiles of disadvantage) were obtained from census data.  
Results. 
 Over the last eleven years, TTE reimbursements/100,000 people increased from 1,780 to 3,497 
(8.8% annualised growth), TOE from 33 to 61, SE from 181 to 947 and SPECT from 287 to 
337. SE had the biggest incremental growth, with an average rate of increase at 38.5% per year. 
The relationships between the use of each cardiac imaging technique and demographic, medical 
and illness factors were explored through outpatient tests reimbursed in 2012. It was found that 
for each additional medical practitioner per 1,000 people, there was an increase of 1.25 times 
the rate of TTE (95% CI: [1.17, 1.33], p<0.001, and TOE use (B=1.13 [1.04, 1.24], p=0.005), 
independent of regional burden of cardiovascular disease and social determinants. For SPECT 
the largest independent correlate for testing was the percentage of women within the ML; each 
additional percentage increase resulted in doubling of the rate of testing (B=2.25 [1.72, 2.94], 
p<0.001). 
Conclusions.  
Variation in the use of TTE in Australia is not illness-related and may be evidence of under 
and over-utilization. An appropriate use process may contain this variation. 
Keywords  
Clinical Practice Variation, Echocardiography, SPECT, Misuse of Health Services, Healthcare 
Costs   
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Introduction 
Increased life expectancy, population growth - especially of the elderly - and access to new 
treatments and technology have all contributed to the rise in costs and demand in the Australian 
health system over the last decade 80, 83.  
Cardiovascular disease continues to be associated with the highest level of health-care 
expenditure 81, and has been a major contributor to this growth. Prior to a recent reduction in 
the pace of imaging growth in the USA 25, 67, 84, imaging costs had exceeded the growth of many 
other medical activities 18. Cardiovascular imaging was a significant contributor to that process. 
Besides the increase in demand of imaging services, studies have shown a wide difference in 
the use of healthcare services by geographical areas that indicates ineffective use85, 86.    
Geographical differences in resource utilisation provide a potential means to understanding the 
causes of variations in care 82, 87, 88.  Such an analysis can identify the relationship between 
demographics, disease burden, and access to care 24.  Available data about regional variation 
in the use of echocardiography 24, 89  includes USA data from the Dartmouth Atlas (which 
preceded the development of appropriate use criteria (AUC) and the reduction in the rate of 
imaging growth) and local echocardiography numbers in the UK 89 .  
As there are a number of differences in care delivery in Australia (including universal health 
cover, remoteness and access)87 we sought to analyse the growth of the use of cardiac imaging 
as well as the causes of variation of use in this country.  
Methods 
Study design.  
We used available Medicare statistics between2002 and 2013 to measure trends in the use of 
outpatient transthoracic (TTE), transesophageal (TOE) and stress echocardiography (SE) and 
single-photon emission computed tomography (SPECT) per 100,000 Medicare beneficiaries in 
Australia. The 2011-2012 Australian Health Survey provided data, which permitted a cross-
sectional study of regional associations of cardiac imaging performed in the 2012 calendar year.   
The geographic units of measurement were Medicare Locals (ML), made up of  61 regional 
primary health care organisations covering the whole of Australia, which were developed to 
connect local health services better 90. Health utilisation statistics are available for each ML 
and statistics from other sources can be mapped to these regions. As MLs differ in population, 
health status, demographics, remoteness and socioeconomic levels, this study additionally  
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used seven clusters of MLs called peer groups (Metro 1, Metro 2, Metro 3, Regional 1, Regional 
2, Rural 1 and Rural 2) taking into account proximity of each ML to a metropolitan area, 
proximity to large hospitals and socioeconomic characteristics as described by  the National 
Health Performance Authority 87. 
Data sources.  
Data were obtained from Medicare Australia Statistics, the Australian Bureau of Statistics 
(ABS) and ABS Health Survey and Health Workforce Data.  
The numbers of imaging tests were extracted from the Medicare Australia Statistics,76 using 
the cardiac ultrasound codes 55113, 55114, 55115, 55119, 551120, 55121 for TTE; 55118, 
55125 for TOE; 55116, 55117, 55122 , 55123 for SE and 61307, 61654 for SPECT 91.  In order 
to compensate for the age-dependent nature of many illnesses requiring cardiac imaging, the 
rate of use of each modality per 100,000 people was age-weighted to reflect the age of each 
region relative to 37 years (the mean age for Australia)92. 
Demographic data (total population, rural areas, and quintiles of disadvantage) were obtained 
from the "Estimated Resident Population" statistics for MLs for 2012 93. Areas were 
categorised as most socioeconomically disadvantaged if they were in quintiles 1, 2, and 3 of 
the Socioeconomic Index for Areas (SEIFA) scores.  We defined “metropolitan area” as the 
MLs listed in the Metro 1, 2 and 3 groups, regional area as MLs in the Regional 1 and 2 peer 
groups and rural area as the MLs in Rural 1 and 2 peer groups. For multivariable models, metro 
areas were compared with grouped regional and rural areas.   
Medical workforce information was extracted from the National Health Workforce Dataset, a 
national database 94. The number of “non-cardiologists” was outlined as the difference between 
the total number of practitioners and the number of cardiologists in each ML. Data were 
analysed taking into account the number of non-cardiologists per 1,000 persons instead of the 
number of cardiac specialists, as the latter group, in most cases, receives a referral and actually 
perform the tests.  
The burden of disease was obtained from the percentage of people with cardiovascular disease 
(extracted from the ABS Health Survey for persons aged 18 and over95), and cardiovascular 
mortality per 1,000 (from the national death index). 
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Statistical analysis.  
We used Medicare data from 2002 to 2013 to calculate the trend in utilisation of cardiac 
imaging per 100,000 people. Detailed analyses were performed only on data from 2012 for 
which most information was available.  
Spearman rank correlations were used to investigate univariate associations between age-
weighted testing and characteristics of each ML.  For TTE and SPECT analyses, we used 
negative binomial regression to build models for each rate (age-weighted tests per 100,000); 
SE and TOE outcomes contained many MLs with zero testing, therefore we switched to zero-
inflated negative binomial (ZINB) for these analyses using the number of cardiologists to 
predict the inflation model.  
The coefficients for independent variables coded as percentages (e.g. women) are interpreted 
as a change in rate ratio of age-weighted tests per 1% rise in the variable. Maps were made 
using standard software (QGIS 2.4.0, Open Source Geographic Information System) and all 
statistical analyses were made using R 3.2.1.79 
Results. 
Population characteristics.  
Appendix Table 1 displays the population, number of doctors and burden of cardiovascular 
disease in Australian Medicare Locals. Most of the Australian population lives in metropolitan 
areas, and MLs in or near large urban centres (Metro 1 and 2) have the least disadvantaged 
people.   
In general, metro areas 1 and 2 have the most doctors (cardiologists and non-cardiologists) per 
100,000 people. Access to medical practitioners decreases in progressively more remote MLs. 
Regional Australia (ML peer groups Regional 1 and 2) have the highest mean age and 
percentage of people >65 years. However, remote areas (Rural area 2) have the lowest mean 
age and percentage of individuals more than 65 years, as well as the highest proportion of men.  
In general, MLs listed as regional or rural areas, have the highest rates of cardiovascular deaths 
per 100,000 people. The same trend is apparent when cardiovascular disease burden is analysed 
as the percentage of people >18 years old with CV disease.  
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Growth of cardiac imaging in Australia.   
Medicare Australia reimbursed 973,284 outpatient echocardiograms in the year 2012 (TTE, 
TOE and SE). Among the cardiac imaging modalities that we are discussing, SE had the biggest 
change over the last eleven years: a total growth of 423% with an average yearly growth rate 
of 38.5%.  
TTE had an increase of 96% during this period (an average growth per year of 8.8%). SPECT 
showed an initial rise followed by a relative decrease of its growth rate after 2006. However, 
there was a rise of 17% in the rate of SPECT per 100,000 people compared to eleven years ago.  
The upsurge in testing volume over the last eleven years is detailed in Figure 3- 1. 
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Figure 3- 1 Increment in testing volume in Australia between 2002 and 2013 
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Associations of the regional variation of transthoracic echocardiography.  
The national rate for TTE (age weighted) was 3,106 per 100,000 people but the rate varied 
from 382.8 to 7,184 per 100,000 people, an 18.8-fold variation among regions (Appendix Table 
2).  
The highest rates of use were found in central metropolitan regions (Inner North West 
Melbourne, Eastern Sydney and Central Adelaide and Hills, ranging between 6,831 and 7,184 
per 100,000 people). The lowest rates were mainly found, but not exclusively, in rural areas 
(Central and North West Queensland, South West Western Australia, Perth North Metro, and 
Bentley – Armadale; range 383 – 806 tests per 100,000 people). Far West New South Wales 
was not included in the study as no data were available.  (Appendix Table 2, Figure 3- 2).  
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Figure 3- 2 Rate of transthoracic echocardiography (age-standardized) per 100,000 people by Medicare Locals in Australia in 2012 
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In general, the age-weighted rate of TTE was substantially lower in regional and rural than 
metropolitan areas, and there was a negative correlation between remoteness and use of TTE 
(rho= -0.35) (Table 3- 1).  
An interesting exception is Wide Bay ML, which has the highest rate of TTE per 100,000 
people (6,073) in the Regional 1 peer-group. This rate is higher than some Medicare Locals in 
metropolitan areas such as Inner East Melbourne, Fremantle or Inner West Sydney (Appendix 
Table 2, Figure 3- 2 and Figure 3- 3).
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Table 3- 1 Correlations between each modality of cardiac imaging and other independent variables 
 
 
 
 
 
Correlations TTE TOE SE SPECT 
rho* p rho* p rho* p rho* p 
More disadvantaged (%) -0.30 0.02 -0.46 0.01 -0.50 <0.01 0.12 0.45 
Women (%) 0.59 <0.01 0.33 0.02 0.50 <0.01 0.35 0.03 
Non cardiologist (/1,000) 0.75 <0.01 0.65 <0.01 0.63 <0.01 0.14 0.38 
Older than 65years (%) 0.32 0.01 0.03 0.86 0.03 0.83 0.49 <0.01 
Cardiovascular disease (%) -0.05 0.71 -0.18 0.22 -0.20 0.13 0.18 0.28 
Cardiovascular deaths(/1,000) 0.11 0.41 -0.03 0.83 -0.05 0.72 0.39 0.01 
Region(1=Metro/2=Regional/3=Rural)  -0.35 0.01 -0.38 0.01 -0.58 <0.01 0.15 0.36 
*Spearman correlation coefficient 
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Figure 3- 3 Variation in the TTE use in Australia from the lowest to the highest rate in 2012 
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Performance of TTE per 100,000 people (age weighted) was positively correlated with 
percentage of women, Metropolitan MLs, older people and number of non-cardiologist 
physicians per 1,000. There was no significant correlation between TTE per 100,000 people 
and percentage of people over 18 years old with cardiovascular diseases or deaths due to 
cardiovascular causes (Table 3- 1). Additionally, testing was negatively correlated with more 
disadvantaged people.  
The association of these variables in the use of TTE is shown in Appendix Table 3. For each 
additional 1% rise in the percentage of women within a ML the rates of TTE testing rose 1.22 
times [95% CI 1.12-1.34], p <0.001. Furthermore, as non-cardiologists increase by one per 
1,000, there is a corresponding increase in rates of testing (β =1.22 [95% CI 1.14-1.31], p 
<0.001).  
Conversely, as the percentage of more disadvantaged people increases the rates tend to 
decrease (β =0.99 [95% CI 0.99-1.00], p =0.039). In addition, rates of TTE are lower in regional 
and rural zones compared to metropolitan areas (β =0.80 [95% CI: 0.59, 1.07], p =0.133; 
β=0.51 [95% CI: 0.34, 0.76], p <0.001, respectively). However, the number of non- 
cardiologists per 1,000 people and the percentage of women were independently associated 
with testing, regardless of prevalence of cardiovascular disease, socioeconomic status and 
metropolitan zone (Table 3- 2).  
Interestingly, burden of disease, shown as percentage of people older than 18 years with 
cardiovascular disease (β=0.99 [95% CI 0.96, 1.02] p=0.420), and cardiovascular deaths 
(β=1.05 [95% CI 0.87, 1.27] p =0.616), were not associated with testing.  
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Table 3- 2 Independent associations of population of characteristics in Medicare Locals with age-weighted numbers of tests/100,000 persons 
 
* Estimates from inflation part of zero-inflated negative binomial (ZINB) model, only for TOE and SE models.  
 
  TTE TOE SE SPECT 
  Β 95%CI p Β 95%CI p Β 95%CI p Β 95%CI p 
Women (%) 1.164 1.081 1.254 <0.001 1.096 0.835 1.439 0.509 1.148 0.703 1.875 0.580 2.247 1.720 2.936 <0.001 
Metro Medicare 
Locals 
0.960 0.734 1.257 0.768 1.021 0.618 1.686 0.935 1.152 0.547 2.427 0.709 0.409 0.197 0.851 0.017 
Cardiovascular 
disease (%) 
1.017 0.995 1.040 0.134 0.979 0.939 1.021 0.332 0.981 0.920 1.046 0.563 _ _ _ _ 
Cardiovascular 
deaths (/1,000) 
_ _ _ _ _ _ _ _ _ _ _ _ 0.896 0.546 1.468 0.662 
Non cardiologist 
(/1,000) 
1.247 1.171 1.327 <0.001 1.134 1.038 1.240 0.005 1.127 0.966 1.315 0.129 1.117 0.988 1.262 0.077 
More 
disadvantaged 
(%) 
1.002 0.995 1.009 0.511 0.995 0.984 1.007 0.400 1.000 0.982 1.019 0.973 1.006 0.991 1.020 0.448 
Cardiologists 
(/100,000)* 
    0.338 0.179 0.637 0.001 0.411 0.255 0.661 <0.001     
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Correlates of the regional variation of TOE.  
Data for TOE were available in 50 of 61 Medicare locals (64%), which showed a variation of 
0 to 242 per 100,000 (Figure 3- 4). When the lowest rate was excluded, the range of TOE per 
100,000 people was 5 to 242, a 46.5-fold variation. The use of TOE was positively correlated 
with the proportion of women, number of non-cardiologists per 1,000 people, residing in big 
urban areas and having higher socioeconomic status (Table 3- 1).  
The use of TOE was found to be less frequent in regions with a large cardiovascular disease 
burden (β=0.93 [95% CI 0.91-0.96] p <0.001) or mortality (β=0.77 [95% CI 0.58-1.02] 
p=0.064), and rates of TOE tests were independently associated with numbers of non-
cardiologists (Table 3- 2).  
The inflation part of the ZINB regression model shows a decrease of 66% in the odds of a true 
zero (no testing) as the number of cardiologists increases by 1 per 1,000 people (β=0.34 [95% 
CI 0.18, 0.64], p =0.001).  
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Figure 3- 4 Rate of trans-oesophageal echocardiography per 100,000 people (age-standardized) by Medicare Locals in Australia in 2012 
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Correlates of the regional variation of stress echocardiography.  
The rate varied from 0 to 2,992 tests per 100,000 people (Figure 3- 5). Excluding the lowest 
rate, there was still a 9.6-fold variation for SE (range 311-2,992) (Appendix Table 2).  
The use of SE was similarly associated with regions having a larger proportion of women, 
number of doctors, metropolitan areas and higher socioeconomic status (Table 3- 1), but none 
of these were shown to be independent associations (Table 3- 2).  
Further, there was a decrease in the odds of a true zero (no tests) associated with an increase in 
cardiologists in each ML (ZINB regression model: B= 0.41 [95% CI 0.26, 0.66] p <0.001). 
Correlates of the regional variation of SPECT.  
The rate of SPECT per 100,000 people varied from 0 to 955/100,000 in 41 of 61 MLs where 
data were available for analysis (Figure 6).  
There was a 7.2 fold-variation after exclusion of the lowest rates of use (Appendix Table 2). 
The use of SPECT was positively correlated with percentage of women, percentage of people 
older than 65 years, and cardiovascular deaths (Table 3- 1).  
Cardiovascular disease was not correlated with testing; thus, multivariate analysis was 
performed using cardiovascular deaths as the indicator of burden of disease. Multivariable 
analysis showed that proportion of women and metro region were the only independent 
correlates of imaging use (Table 3- 2). 
 
 
Chapter 3. Appropriate use of cardiac imaging in Australia 
 
68 
 
Figure 3- 5 Rate of Stress echocardiography per 100,000 people (age-standardized) by Medicare Locals in Australia in 2012 
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Figure 3- 6 Rate of single-photon emission computed tomography per 100,000 people (age-standardized) by Medicare Locals in Australia in 2012 
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Discussion 
The results of this study demonstrated that there is an ongoing growth of cardiac imaging 
(transthoracic and transoesophageal echocardiography, stress echocardiography and single-
photon emission computed tomography) per 100,000 people in Australia.  
In addition, there is a substantial regional variation in the use of each of these modalities. As 
intense variations in practice are markers of potentially poor quality of care, this problem is 
worthy of attention.  
Growth of cardiovascular imaging.   
The sustainability of health systems has become an important point of interest in developed 
countries, due to increases in health expenditure, variations in practice, and proliferation in the 
provision of healthcare services.  
Although the age-adjusted mortality rates for cardiovascular disease have shown a continuous 
decline due to advances in prevention and treatment, the extent to which cardiovascular 
imaging has helped this improvement in outcomes is unclear 96. The latter is particularly a 
problem in relation to cardiac imaging 18, 89, 97; in the United States Medicare population, 
cardiac imaging reimbursements grew from US$1.6 billion to US$5.1 billion between 2000 
and 2006 18. At one stage, this increase was twice the average annual growth rate of all health 
care services 22, and in 2006, reimbursements paid for in-office cardiac imaging services 
amounted to 36% of the total Medicare part B payments 98. 
Subsequently, a number of efforts have been made to control this growth, including changes in 
reimbursement models, the use of pre-authorisation using Radiology Benefits managers, 
patient education and the development of Appropriate Use Criteria for Cardiac imaging (AUC) 
18, 99. These efforts have been reasonably effective in managing the growth as we can identify 
a trend towards lower expenditure on cardiac imaging in the USA 25, 67, which started to appear 
around 10 years ago; however there have been ongoing concerns about the appropriate use of 
testing as physician behaviour has become reliant upon the control provided by third parties 
rather than self-management 6, 85.  
In contrast to the reduction of cardiac imaging tests in the United States, the results of the 
present study show ongoing growth in Australia over the last decade, especially in 
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echocardiography rather than SPECT.  This difference in trend among the modalities may 
reflect the performance of SPECT by specialised (nuclear medicine) physicians and radiology 
practices in Australia, which reduces access to this technology, in comparison to 
echocardiography, which is widely accessible.  
Regional differences in imaging patterns.   
In addition to its growth, the variation in the use of all cardiac imaging deserves special 
attention. The extremities of the range of all tests were broad; even after exclusion of outliers 
there remained a 15 to 47--fold variation in the use of these tests among regions.   
Generally, greater regional use of testing was associated with the proportion with females, 
proximity to large cities, higher socioeconomic status and local concentration of physicians, 
but not with disease burden or deaths due to cardiovascular causes.  Indeed, the regional 
medical workforce appears to be the strongest independent correlate of echocardiography use.  
The most widely used cardiac imaging test was TTE, with a national rate of performance of 
3,106 per 100,000 people per year. This rate of TTE utilization is less than the USA, where it 
averages 13,360 per 100,000 Medicare enrollees (range 4,000 to 34,000) 24, and greater than 
the UK average of 2,100 per 100,000 weighted population (range 120 to 4,200 per 100,000) 89, 
100.   
Some differences in the source of these data make comparisons of raw numbers difficult – 
Australian data captures outpatient echocardiograms, US data mainly derives from persons >65 
years old, and UK data includes inpatient as well as outpatient echocardiograms. Interestingly, 
the rate of echocardiography has a 34 fold variation in the UK, and a 3.7 fold variation when 
the highest and lowest regions were excluded 89. In this study, the numbers of trans-
oesophageal and stress echocardiograms were too low to be meaningful in many areas, but the 
trends found were similar to the results of the use of TTE.  
Although SPECT data were also not obtainable in all regions, different trends emerged. The 
association of SPECT use with non-metropolitan regions may reflect lower access to 
alternative testing (including stress echocardiography) in these regions. Importantly, SPECT 
was correlated with older population and cardiovascular death. This may be consistent with the 
more specific use of this test with coronary artery disease, rather than undifferentiated 
symptoms. The association with regional areas and older populations might imply that SPECT 
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has a greater potential for improving health outcomes than the current use of echocardiography 
101. 
This study supports the association of cardiac imaging with the location a patient seeks care 24.  
Access to cardiac ultrasound is influenced by socioeconomic status, and strongly affected by 
the availability of doctors in the area, consistent with known associations between 
socioeconomic status, cardiovascular health and access to care 101, 102.  Indeed, the association 
of imaging with the number of doctors in the area was independent of distribution of patient 
gender, geography, burden of disease, and socioeconomic status.  
Although potentially influenced by the fact that the data are restricted to outpatient 
echocardiograms (and therefore less morbid disease than would be observed in hospitalised 
patients), the use of all modalities of cardiac ultrasound was negatively associated with 
cardiovascular disease burden and mortality. Although echocardiography can be used to 
investigate nonspecific symptoms that may actually be caused by non-cardiovascular disease 
(e.g. dyspnoea finally attributed to lung disease), or to screening for cardiovascular disease that 
never actually eventuates (e.g. screening for LV dysfunction in chemotherapy), it appears 
unlikely that these and similar scenarios could fully explain this lack of association. 
Geographical variations in health care practice may be explained by a number of reasons 88. 
Repetition of previously performed tests may account for increased numbers in regions where 
there are numerous referral centres (e.g. urban Sydney, Melbourne and Adelaide). While 
financial incentives for performance of the test in a fee-for-service environment (generally 
USA, Australia) may explain some variations in practice, the similar regional variation in 
testing in the UK (where there is no financial incentive for additional screening) suggested that 
this explanation might be overstated 89. More likely, variation in the rates of test utilisation 
reflect divergences in access to imaging and practice style 24.  
Limitations.  
This study has limitations that pertain to the use of administrative data. Access to details 
regarding disease burden, including differences among cardiovascular diseases and deaths due 
to cardiovascular causes, might help to distinguish tests performed for diagnosis, prognostic 
evaluation or follow-up.  Particularly in the outpatient setting, the negative association between 
test use and proportion of cardiac diseases and deaths may reflect testing earlier in the disease 
course – which may indeed be appropriate. Patients with late stage disease are likely to have a 
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clear diagnosis and prognosis, so that any further investigation may add limited value. Likewise, 
access to additional patient-level information regarding the ordering physician, test indications, 
and proportion of repeat studies may improve understanding of appropriate use.   
Finally, low utilisation in regional areas does not necessarily suggest that these patients are 
failing to have the imaging performed; a more likely scenario is these patients may attend a 
larger centre either by choice or because their disease requires them to visit a referral service.  
Conclusion  
The results of this study present evidence of growth and regional variation in the use of cardiac 
imaging in Australia, which is not completely accounted for by variations in demographics or 
disease burden.   
The international profile of geographic variation in imaging use is surprisingly consistent, 
implying regional variations in practice style and/or access to imaging. Given the absence of 
association with variations in disease burden or mortality, it appears likely that reduction in 
this variation would not generate patient harm and could provide economic savings.  
These observations suggest either under or over-utilization (or both), and implementation of an 
appropriate use process may generate convergence. 
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Chapter 4. Evidence status of the Appropriate Use Criteria 
The research contained within this chapter has been published as5: 
 Fonseca R, Negishi K and Marwick TH. What is the evidence status of Appropriate 
Use Criteria (AUC)? Insight from a matching exercise with the guidelines for 
echocardiography. Intern Med J. 2015;45:864-9. 
Preface 
In the previous chapter, growth in the use of cardiac imaging techniques within Australia, 
especially echocardiography, was demonstrated. Moreover, the findings indicate that the 
burden of disease does not explain the use of echocardiography. These results support the 
notion that there exists an inappropriate use of cardiac imaging in Australia.  
As it was explained in Chapter 1, the AUC were designed to achieve appropriate use of cardiac 
imaging, but the challenges and potential risks of using the criteria in the Australian practice 
have not been assessed.  
The following chapters, 4 to 7 (inclusive), aim to determine if the American AUC are in fact 
suitable to use in Australia in order to improve appropriate use of cardiac imaging particularly 
echocardiography, which, according to the findings in Chapter 3, needs an imminent 
intervention to ensure appropriate use among clinicians.  
Several issues must first be addressed to determine if the AUC are suitable to use in Australia. 
Amongst these issues, assessing the scientific evidence status is crucial, due to the Australian 
practice of relying heavily upon the American guidelines for the management and diagnosis of 
cardiovascular diseases, including the use of echocardiography. Any discordance between 
those guidelines and the AUC would result in confusion with the attending clinician.  
This chapter aims to determine the differences between the AUC and the published guidelines 
in order to understand possible challenges of the use of the appropriate use criteria.  
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Abstract 
There is interest in adopting the American Appropriate Use Criteria (AUC) for transthoracic 
echocardiography to Australian practice. We matched 90 of 98 criteria of the AUC (53 
“appropriate”, 12 sometimes appropriate, 25 rarely appropriate) to the guidelines, but 8 criteria 
lacked any possible match. Among the matched criteria, 76 (82%) indications were concordant 
with the guidelines. A stronger basis in scientific evidence would be desirable to settle these 
discrepancies before Australian adoption of AUC. 
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Introduction 
The growth of cardiac imaging has paralleled advances in the therapeutic options for 
cardiovascular disease and improvements in imaging technology 30. However, the cost of this 
growth has necessitated a reduction in the heterogeneity of practice and provision of high-
quality health services 22.  
The Appropriate Use Criteria (AUC)26 were developed in the USA to better align the expense 
and value of cardiac imaging 30. However, some have expressed concern that the selection of 
AUC on the basis of expert opinion using a modified Delphi process risks the provision of 
unscientific guidance 64 because their evidence base is insufficiently robust 103.  
In contrast, clinical guidelines have become a cornerstone of cardiology, optimising patient 
outcomes through facilitating clinical decision relating to the diagnosis, prevention or treatment 
of diseases or conditions 65.  These documents have classed recommendations according to the 
level of available scientific evidence 65, which has helped the calculation of risk and outcomes 
in clinical practice 104. 
The adoption of AUC to Australian practice has been proposed as a means of containing the 
growth of imaging. Currently, Australian practice of cardiology relies heavily on the published 
American and European guidelines in regards to diagnosis and management of cardiovascular 
illnesses. Consequently, any conflicting messages, between the published guidelines and the 
appropriate use criteria, result in difficulties for the attending physician.  
We hypothesised that the differing ways of formulating AUC and the guidelines might be 
responsible for discordances between these entities. Given the paucity of guidelines for 
transthoracic echocardiography in Australian literature, we were free to adopt both European 
and American guidelines so as to most exactly approximate the AUC.  
In order to elucidate the relation between the class of recommendation and the appropriateness 
designation for transthoracic echocardiography, we sought to find a match for each item of 
ACCF/ASE/AHA Appropriate Use Criteria from published cardiology guidelines. 
Methods 
We searched for the matched items for each of the 98 criteria for transthoracic 
echocardiography in the 2011 AUC in the following manner: When a specific indication 
contained in the AUC lacked a match in the 2003 Guidelines for the Clinical Application of 
Echocardiography 65, other guidelines were used, principally in those related to management 
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of heart failure 105, aortic disease 106, pulmonary hypertension 107, pulmonary embolism 108, 
cardiac devices 109, syncope 110, perioperative evaluation 111, 112, supraventricular arrhythmias 
113, and valvular diseases 114.  
We defined concordance if usually “appropriate” items (A) had Class I or IIa recommendation 
in the guidelines; “rarely appropriate” (RA) had Class III; or usually appropriate (UA) had 
Class IIb 30. 
Results and discussion 
Among the 98 AUC indications for the use of TTE, the majority (90 items, 92%) had a match 
in the different guidelines: 53 usually “appropriate”, 12 sometimes appropriate, 25 rarely 
appropriate. Four of the usually “appropriate” indications and the same number of rarely 
appropriate indications did not have a counterpart in the guidelines (8% of the indications of 
the AUC for TTE) (Figure 4- 1).  
 
Figure 4- 1 Appropriate Use Criteria indications with and without a counterpart in clinical 
guidelines  
 
Blue: with matching. Yellow: no counterpart. 
 
53, 
54%
12, 
12%
25, 
26%
4, 
4%
4, 
4%Appropriate items matched Uncertain items matched
Inappropriate items matched Appropriate items unmatched
Inappropriate items unmatched
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Among the 90 matched criteria, 76 (82%) indications were concordant with the guidelines, but 
there were 14 indications with discordance.  
Four indications categorised as “Usually Appropriate” in the AUC had Class III 
recommendations in the guidelines. They were on syncope without cardiovascular signs and 
symptoms, routine surveillance of mild valvular stenosis and prosthetic valve without 
suspected valve dysfunction, and monitoring for rejection in cardiac transplant recipients. 
Other two “appropriate” indications, on re-evaluation of known ascending aortic dilation or 
history of aortic dissection, where the concept was found in the guidelines, did not have any 
recommendation numbered and suggested limited use of TEE only to the root or those with 
Marfan syndrome (Table 4- 1).  
There were five (20%) discordances in “inappropriate” (“rarely appropriate”) indications (4 
Class I and 1 Class IIa in guidelines), concerning the use of echocardiography in screening for 
heart disease, reevaluation of pulmonary hypertension with no change in clinical status, routine 
surveillance of moderate or severe valvular stenosis without a change in clinical status or 
cardiac exam and diagnosis of endocarditis or pulmonary embolism (Table 4- 2). 
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Table 4- 1 Discrepancies between Usually Appropriate indications and guidelines 
AUC Table Item 
No 
AUC indication Appropriate 
Use score 
Guidelin
es* 
Recommendation Class 
1 TTE for 
General 
Evaluation of 
Cardiac 
Structure and 
Function 
9 Syncope when there are no other 
symptoms or signs of 
cardiovascular disease  
A 7 1 Syncope in a patient for whom there is no 
clinical suspicion of heart disease. 
III 
3 TTE for 
Evaluation of 
Valvular 
Function 
39 Routine surveillance (>3 y) of 
mild valvular stenosis without a 
change in clinical status or 
cardiac exam 
A 7 1 Routine re-evaluation of asymptomatic adult 
patients with mild aortic stenosis having 
stable physical signs and normal LV size and 
function.   
III 
1 Routine re-evaluation of asymptomatic 
patients with mild to moderate mitral stenosis 
and stable physical signs.  
III 
3 TTE for 
Evaluation of 
Valvular 
Function 
49 Routine surveillance (≥3 y after 
valve implantation) of prosthetic 
valve if no known or suspected 
valve dysfunction 
A 7 1 Routine re-evaluation of patients with valve 
replacements without suspicion of valvular 
dysfunction and unchanged clinical signs and 
symptoms. 
III 
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6 TTE for 
Evaluation of 
Hypertension, 
HF or 
Cardiomyopat
hy 
84 Monitoring for rejection in a 
cardiac transplant recipient 
A 7 2 Recommendations for the Non-Invasive 
Monitoring of Acute Heart Transplant 
Rejection: Class III: 2. The use of 
echocardiography as an alternative to EMB 
for rejection monitoring is not recommended. 
III  
5 TTE for 
Evaluation of 
Aortic 
Disease 
64 Re-evaluation of known 
ascending aortic dilation or 
history of aortic dissection to 
establish a baseline rate of 
expansion or when the rate of 
expansion is excessive.  
A 9 3 Because TTE does accurately visualise the 
aortic root, its primary role as an imaging 
method for serial follow-up is in patients with 
aortic disease limited to the root, particularly 
those with Marfan syndrome. TEE is 
preferred.  
N/A  
5 TTE for 
Evaluation of 
Aortic 
Disease 
65 Re-evaluation of known 
ascending aortic dilation or 
history of aortic dissection with a 
change in clinical status or 
cardiac exam or when findings 
may alter management or 
therapy 
A 9 3 Because TTE does accurately visualise the 
aortic root, its primary role as an imaging 
method for serial follow-up is in patients with 
aortic disease limited to the root, particularly 
those with Marfan syndrome. TEE is 
preferred.  
 N/A 
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Guidelines*: 1, ACC/AHA Guidelines for the Clinical Application of Echocardiography65; 2, The International Society of Heart and Lung 
Transplantation Guidelines for the care of heart transplant recipients112; 3, 2010 ACCF/AHA/AATS Guidelines for the Diagnosis and Management 
of Patients With Thoracic Aortic Disease106; and 4.  ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease 114
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Table 4- 2 Discrepancies between “Rarely Appropriate” indications (“Inappropriate”) and guidelines 
AUC Table Item 
No 
AUC indication Appropri
ate Use  
score 
Guideline
s* 
Recommendation Clas
s 
1 TTE for General 
Evaluation of Cardiac 
Structure and Function 
10 Initial evaluation of 
ventricular function (e.g., 
screening) with no symptoms 
or signs of cardiovascular 
disease 
I 2 1 Patients with a family history of genetically 
transmitted cardiovascular disease. 
I 
1 Patients with phenotypic features of Marfan 
syndrome or related connective tissue 
diseases. 
I 
1 First-degree relatives (parents, siblings, 
children) of patients with unexplained 
dilated cardiomyopathy in whom no 
aetiology has been identified.  
I 
1 TTE for General 
Evaluation of Cardiac 
Structure and Function 
16 Routine surveillance (<1 y) 
of known pulmonary 
hypertension without change 
in clinical status or cardiac 
exam 
I 3 1 Follow-up of pulmonary artery pressures in 
patients with pulmonary hypertension to 
evaluate response to treatment. 
I 
3 TTE for Evaluation of 
Valvular Function 
40 Routine surveillance (<1 y) 
of moderate or severe 
I 3 1 Re-evaluation of asymptomatic patients 
with severe stenosis.  
I 
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valvular stenosis without a 
change in clinical status or 
cardiac exam 
3 TTE for Evaluation of 
Valvular Function 
54 Transient bacteremia with a 
pathogen not typically 
associated with infective 
endocarditis and/or a 
documented 
nonendovascular source of 
infection 
I 3 4  Transthoracic echocardiography to detect 
valvular vegetations with or without 
positive blood culture is recommended for 
the diagnosis of infective endocarditis. 
I 
2 TTE for Cardiovascular 
Evaluation in an Acute 
Setting 
28 Suspected pulmonary 
embolism in order to 
establish diagnosis 
I 2 1 Pulmonary emboli and suspected clots in 
the right atrium or ventricle or main 
pulmonary artery branches 
IIa 
Guidelines*: 1, ACC/AHA Guidelines for the Clinical Application of Echocardiography65 and 4.  ACC/AHA 2006 Guidelines for the Management 
of Patients With Valvular Heart Disease 114. 
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Additionally, there were three “Sometimes Appropriate” indications (Uncertain) (25%) with 
Class I recommendations in guidelines. These inconsistencies were related to evaluation of 
critically ill patients, re-evaluation of known HF with a change in clinical status or cardiac 
exam with a clear precipitating change in medication or diet and routine surveillance (<1 year) 
of adult congenital heart disease following incomplete or palliative repair with residual 
structural or hemodynamic abnormality without a change in clinical status or cardiac exam 
(Table 4- 3). 
 
Discussion 
In this matching exercise, we found significant inconsistencies with published guidelines in 15% 
of the 98 AUC for transthoracic echocardiography - 1% without indications in guidelines and 
14% that contradict the guidelines.  
The incorporation of clinical evidence into guidelines is an esential pillar of clinical practice, 
although the proliferation of guidelines, their variable quality and sometimes contradictory 
messages, make it a struggle for clinicians to incorporate these documents into their clinical 
practice 115. Not all guidelines show a clear connection between evidence and 
recommendations65. Surprisingly – given the role of echocardiography as one of the most 
commonly used imaging techniques - the guidelines for the clinical application of 
echocardiography do not incorporate level of evidence65, 105. 
The Appropriate   UC for echocardiography have been developed to help clinicians to choose 
testing more appropriately and to improve quality of care and standardisation of medical 
practice 26.  
This study identified contradictions between AUC and guidelines, which are awkward and 
confusing, highlighting the shortcomings of a process whereby rating of appropriateness is 
based purely on expert opinion 64, 103. A stronger evidence base is needed in order to settle these 
discrepancies in future updates of the AUC.  
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Table 4- 3 Discrepancies between Sometimes Appropriate Indications and guidelines 
AUC Table Item 
No 
AUC indication Appr
opria
te 
Use  
score 
Guidelines* Recommendation Cl
ass 
2 TTE for 
Cardiovascular 
Evaluation in an 
Acute Setting 
20 Assessment of volume status in a 
critically ill patient  
U 5 1 The hemodynamically unstable patient. I 
6 TTE for Evaluation 
of Hypertension, HF 
or Cardiomyopathy 
72 Re-evaluation of known HF 
(systolic or diastolic) with a 
change in clinical status or 
cardiac exam with a clear 
precipitating change in 
medication or diet 
U 4 1 Re-evaluation of LV function in patients with 
established cardiomyopathy when there has been a 
documented change in clinical status or to guide 
medical therapy. 
I 
7 TTE for Adult 
Congenital Heart 
Disease 
97 Routine surveillance (<1 y) of 
adult congenital heart disease 
following incomplete or 
palliative repair + with residual 
U 5 1 Periodic echocardiography in patients with 
surgically repaired (or palliated) congenital heart 
disease with the following: change in clinical 
condition or clinical suspicion of residual defects, 
I 
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structural or hemodynamic 
abnormality + without a change 
in clinical status or cardiac exam 
obstruction of conduits and baffles, or LV or RV 
function that must be followed, or when there is a 
possibility of hemodynamic progression or a 
history of pulmonary hypertension 
Guidelines*: 1, ACC/AHA Guidelines for the Clinical Application of Echocardiography 65 
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Given the number of guidelines evaluating the use of echocardiography in different diseases 
and scenarios, our study results do not show all the possible relationships between the AUC 
criteria and the published guidelines.  
We showed the main differences between American AUC and American and European 
guidelines, but it is likely that more discrepancies would become apparent if additional 
guidelines were compared. The practice of echocardiography in Australia parallels, and is 
informed by, the practices of the American and European cardiology societies.  
It is imperative to develop a greater degree of internal consistency between guidelines and the 
AUC to facilitate widespread adoption of the AUC.  
Conclusion  
The appropriate use criteria for transthoracic echocardiography are not consistent with the 
guidelines for the use of echocardiography.  
The potential incorporation of an AUC process into Australian practice might still improve 
patient outcomes, reduce variation and contain costs, but should be informed by these 
limitations. 
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Chapter 5. Impact of Appropriate Use Criteria on clinicians’ behaviour 
 
The research contained within this chapter has been published as6: 
 Fonseca R, Negishi K, Otahal P and Marwick TH. Temporal changes in appropriateness 
of cardiac imaging. J Am Coll Cardiol. 2015;65:763-73. 
Preface 
In the previous chapter, a comparison between the AUC for echocardiography and clinical 
guidelines was assessed. The results showed that the AUC are not entirely concordant with the 
published cardiovascular guidelines, which if adopted as is would bring issues in the Australian 
clinical practice.  
In order to continue with the evaluation of the AUC to determine their suitability for use in 
Australia, this chapter aims to evaluate if the AUC are a tool that influences clinicians’ ordering 
behaviour. This will be done by assessing the changes of proportion of “appropriate” and 
inappropriate requests since the AUC were first launched.  
This chapter documents a systematic review of the published literature determining changes in 
the proportion of appropriate and inappropriate tests over time as an indicator of impact on 
clinicians’ requesting behaviour.  
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Abstract 
Appropriate use criteria (AUC) for cardiac imaging have been available for more than ten years. 
The extent to which improvements in appropriate use have been identified and reported are 
undefined. This study systematically reviewed published evidence to identify whether the 
promulgation of the AUC has led to an improvement in the proportion of appropriate cardiac 
imaging requests.  
Methods:  
Electronic databases were systematically searched for English-language papers related to AUC 
and cardiovascular imaging. We found 59 reports involving 103,567 tests that were published 
between 2000 and 2012. The rate of appropriate testing over time was analysed in a meta-
regression. 
Results:  
New AUC were associated with apparent improvement of appropriateness for  transthoracic 
echocardiography (TTE) (80% [95% confidence interval (CI): 0.75 to 0.84] in 2007 to 85% 
[95% CI: 0.81 to 0.89] in 2011), trans-oesophageal echocardiography (TEE) (89% [95% CI: 
0.81 to 0.94] in 2007 vs 95% [95% CI: 0.93 to 0.96] in 2011), and computed tomography 
angiography (CTA) (37% [95% CI: 0.21 to 0.55] in 2006 vs 55% [95% CI: 0.44 to 0.65] in 
2010), but not for stress echocardiography (SE) (53% [95% CI: 0.45 to 0.61] in 2008 vs 52% 
[95% CI: 0.42 to 0.61] in 2011) or single-photon emission computed tomography (SPECT) 
(72% [95% CI:  0.66 to 0.77] vs 68% [95% CI: 0.60 to0.74] in 2005 and 2009 respectively). 
Although there were no correlations between the proportion of appropriate TTEs and published 
year (p=0.36) for 2007 AUC, there was a positive correlation between proportion of 
appropriateness and the year of publication (p=0.01) for 2011 AUC. There was a significant 
decrease in the proportion of appropriateness over time using the 2007 TEE AUC (p=0.03) and 
2006 CTA AUC (p=0.02). There were no meaningful associations between appropriateness 
and publication year for stress echocardiography, CTA or SPECT.  
Conclusion: Rates of reported appropriate use in imaging show improvements for TTE and 
CTA but not for stress imaging and TEE.  The observed reductions in imaging studies are not 
matched by reported rates of appropriate use.  
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Introduction 
The Appropriate Use Criteria (AUC) were launched to reduce heterogeneity of practice and to 
improve health service quality. Subsequently, AUC have also been considered as a method of 
controlling resource utilisation and medical expenditures 31. This is specifically true in cardiac 
imaging, where at one stage; the growth in costs was double the average annual increase of all 
services 99. Cardiology imaging reimbursements increased from US $1.6 billion in 2000 to US 
$5.1 billion in 2006 18. However, after 2009, the volume of cardiac imaging has shown a 
decreasing trend 25, 67, 116.  
The initial AUC for single photon emission computed tomography (SPECT) were followed by 
AUC for cardiac magnetic resonance (CMR) and cardiac computed tomography (CCT), 
transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), and stress 
echocardiography (SE) 26, 32, 33, 117-119.  
It is unclear whether the publication of AUC was the reason for the reduction of cardiac 
imaging. Evaluations after educational campaigns have shown heterogeneous responses 120-122. 
When changes have been reported, some papers have shown a decline in the number of 
requests116, 120, 121, and most have shown an improvement in the proportion of tests coded as 
being appropriate 122.  
The goal of the current study was to demonstrate the impact if any, of AUC on the ordering 
behaviour of clinicians by examining reported rates of appropriateness over time. 
Methods 
Search strategy.  
We adhered to the protocol specified in the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) statement for reporting systematic reviews 123.  
Two reviewers (R.F and K.N) conducted a literature search of five online databases (Pubmed 
/ Medline, Embase, Web of Science, Scopus , and Cochrane) for published studies that 
estimated the proportion of appropriate tests using the AUC for cardiac imaging including TTE, 
TEE, SE, SPECT, CMR and CCT for all years from 2005 to 2014.  
Search keywords included the terms [“Cardiac” OR “Cardiovascular”] AND [“imaging” OR 
“echocardiography” OR “echocardiogram” OR “nuclear cardiology” OR “SPECT” OR 
“single-photon emission computed tomography” OR “single photon emission computed 
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tomography” OR “Positron emission tomography” OR “CCT” OR “cardiac computed 
tomography” OR “computed tomography” OR “CT” OR “CMR” OR “cardiac magnetic 
resonance” OR “magnetic resonance”] AND [“appropriate* use criteria” OR “AUC”]. Papers 
were limited to those published in English. References to publications and relevant articles 
were also searched for further reports.  
Inclusion criteria.  
Publications in peer-reviewed, English language journals evaluating the AUC in 
echocardiography (TTE, TEE, and SE), SPECT, CMR and CTA were included in this 
systematic review if they reported the following:  
 The Appropriate Use Criteria edition and type used; 
 The year of collection of the data; 
 The sample size of tests evaluated; 
 The proportion of appropriate studies and the proportion of uncertain (“maybe 
appropriate”) or inappropriate (“rarely appropriate”) tests; 
 The proportion of classified and/or unclassified tests. 
No restrictions were applied to the types of patients, the report’s country of origin or type of 
institution where the AUC were evaluated.  
 Outcomes.  
The primary outcome of this systematic review was to calculate the proportion of appropriate 
tests of the total sample (defined by the proportion of appropriate tests in the total sample of 
each study). The secondary outcome was to determine the proportion of appropriate tests of 
classifiable imaging studies. For both, our goal was to establish the relation between 
appropriateness with the median year of acquisition of the data and year of publication of the 
manuscript. We also sought to assess the trends in classified imaging studies over time for each 
of the AUC editions.  
Data extraction.  
Data were extracted by one review author (R.F.) and checked by a second reviewer (K.N.). 
Discrepancies between reviewers were resolved by consensus, or, if necessary, by a third 
author (T.H.M.).  
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Information on publication year, average of enrolment year, sample size, proportion of 
appropriate tests, gender, mean age, proportion of inpatient population and speciality of doctors 
who requested the tests was extracted independently from every eligible report.  
The goal of this extraction was to determine whether there was any relationship between 
appropriateness and these factors.  If a paper reported the effect of intervention in the same 
population but at two points in time, both data points were used in two different analyses.  
Because there were two editions of the AUC for each cardiac imaging test at the time of data 
extraction, the analysis was performed in 10 groups: 2007 and 2011 TTE, 2007 and 2011 TEE, 
2008 and 2011 SE, 2005 and 2009 SPECT, and 2006 and 2010 CCA.   
Statistical analysis.  
Meta-analysis was performed using a logit transformation to calculate the weighted summary 
proportion under a random-effects model (DerSimonian-Laird estimator). We assumed that 
effect sizes differed between studies due to variances in the characteristics of participants, 
dissimilarities between hospitals and regions, or protocols for using cardiac imaging in diverse 
scenarios, among others. A random effect model was used because the variation in observed 
effects were not only due to sampling error. 
 Ten pooled analyses were conducted separately: one for each cardiac imaging and edition of 
AUC used (TTE 2007, TTE 2011, TEE 2007, TEE 2011, SE 2008, SE 2011, SPECT 2005, 
SPECT 2009, CTA 2006 and CTA 2010).  
Reports were included in more than one analysis if the study evaluated more than one cardiac 
imaging technique or a different edition of AUC. Heterogeneity between the included studies 
was assessed using Cochrane’s Q (reported with a chi-square value and p-value) and was 
quantified with the I2 statistic.   
Possible sources of heterogeneity were investigated further by meta-regression analysis. The 
characteristics selected for this study included age, gender, hospitalisation status, specialisation 
of the physician who referred for testing, year of publication and the average year of enrolment 
of data.  
Meta-regressions were performed on the (non-linear) logit scale; to show the effect of each 
study characteristic, we back-transformed the model coefficient at the mean of each 
characteristic. For those characteristics that were proportion data (inpatients, male, specialists) 
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we have shown the coefficient per 0.1 unit (or 10%) increase in proportion rather than the 
standard per 1-unit increase.  Publication bias was examined by plotting a funnel plot and was 
quantified by Egger’s test.  
All statistical analyses were performed with R software version 3.1.0 with the following 
packages: “meta”, “metaphor”, and “boot”79. 
Results 
Literature search process.  
The initial search of the five online databases used in this work identified a total of 5,323 
original papers (Figure 5- 1). Exclusion of 5,264 after reviewing of the title, abstract or both, 
left 59 possible articles suitable for the present systematic review.  
Some studies were used more than once if they had data for different cardiac imaging or the 
same imaging but different AUC edition. Of the studies included, 15 studies were used for the 
TTE 2007 AUC analysis; 10 studies for TTE 2011 AUC, 5 studies for TEE 2007 AUC, 3 
studies for TEE 2011 AUC, 6 for SE 2008 AUC, 8 for SE 2011 AUC, 11 for SPECT 2005 
AUC, 11 for SPECT 2009 AUC, 9 for CTA 2006 AUC, and 7 for CTA 2010 AUC analysis.  
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Figure 5- 1 . Schematic diagram of literature search and selection procedure for articles 
included in the systematic review 
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Characteristics of original reports.  
The majority of reports (53%) were retrospective in design (Appendix Table 4). An individual 
different to the ordering physician did the appropriateness scoring by using medical records, 
data and requests of tests in nearly 90% of studies. Among these studies in which reviewers 
scored appropriateness, 58% had the score reviewed only for unclassified tests or disagreement 
between reviewers.  
Physicians evaluated appropriateness in 51% of the studies, nurses or sonographers were 
reviewers in 15%, and the occupation of the reviewer was undefined in 34%. The weighted 
average of appropriate tests for physicians was 40% of the total sample, compared to 65% for 
nurses and 71% for sonographers. 
In the vast majority of the studies, there were no reports about the agreement between reviewers. 
In those papers in which reviewer agreement was reported, the agreement (kappa) between 
physician reviewers varied between 0.31 and 0.84.  This range exceeded that for nurses (0.56 
to 0.74) and sonographers (0.67 and 0.84).   
The observations were based on the request at the point-of-service in 86%.  Most (73%) were 
performed in an academic setting, with 13.6% in a community setting and 13.6% in both 
environments.  
Table 5- 1 and Table 5- 2 present the studies included for each of the analyses.
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Table 5- 1 Overview of studies included for the TTE and TEE analysis    
Study Test AUC 
Editio
n 
Publ 
Yea
r 
Enrolme
nt year 
n App 
test
s 
App 
(%) 
Classifie
d 
Studies 
Previo
us echo 
(%) 
Inpa
tient 
(%) 
Age 
(y) 
Wome
n 
Cardiac 
Specialist
% 
Ward59 TTE* 2007 2008 2007 155
3 
122
8 
0.79 1385 0.36 0.48 58.8±16.9 0.53 0.48 
Willens60 TTE 2007 2009 2008 625 481 0.77 526 _ 0.17 _ _ 0.22 
Dharmarajan
46  
TTE 2007 2009 2003 58 51 0.88 58 _ _ 29.0±6.0 1.00 0.19 
Kirkpatrick49 TTE 2007 2009 2007 368 206 0.56 237 0.78 0.00 55.0±17.0 0.51 0.61 
Martin51 TTE 2007 2009 2008 274 237 0.86 268 _ 1.00 _ 0.50 0.38 
Bhave 45 TTE 2007 2010 2009 258 199 0.77 221 0.35 _ 59.0±18.0 0.53 0.55 
Rao56 TTE 2007 2010 2008 772 533 0.69 716 _ 0.00 _ _ 1.00 
Aggarwal38 TTE 2007 2010 2007 329 278 0.84 299 _ 0.44 63.0±15.0 0.42 0.57 
Gathak47 TTE 2007 2011 2009 431 364 0.84 394 _ _ _ _ _ 
Rahimi155 TTE 2007 2011 2000 177 143 0.81 164 0.37 0.00 53.0±17.0 0.27 0.37 
Rahimi255 TTE 2007 2011 2008 348 251 0.72 296 0.54 0.00 58.0±17.0 0.48 0.37 
Parikh53 TTE 2007 2012 2010 384 333 0.87 336 0.31 0.68 64.0±16.0 0.45 0.51 
Bhatia 42 TTE 2007 2012 2011 450 288 0.64 347 0.69 0.33 70.6±14.7 0.50 0.38 
Alqarqaz39 TTE 2007 2012 2009 170 131 0.77 147 _ _ _ _ 0.40 
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Silverman58 TTE 2007 2012 2009 485 442 0.91 485 _ _ _ 0.50 _ 
Bailey40 TTE 2007 2013 2008 108
0 
933 0.86 945 _ 1.00 71.2±15.0 _ 0.10 
Willens61 TTE 2011 2011 2008 625 479 0.77 617 _ 0.17 _ _ 0.22 
Parikh53 TTE 2011 2012 2010 384 354 0.92 363 0.31 0.68 64.0±16.0 0.45 0.51 
Bhatia142 TTE 2011 2012 2011 450 313 0.69 441 0.69 0.33 70.6±14.7 0.50 0.38 
Patil54 TTE 2011 2012 2010 182
0 
149
3 
0.82 1812 _ 0.47 _ _ _ 
Alqarqaz39 TTE 2011 2012 2009 170 131 0.77 170 _ _ _ _ 0.40 
Ballo41  TTE 2011 2012 2010 931 739 0.79 920 _ _ 72.8±14.4 0.46 0.49 
Mansour50  TTE 2011 2012 2007 155
3 
125
3 
0.81 1525 _ 0.49 59.0±17.0 0.52 0.50 
Bailey 40 TTE 2011 2013 2008 108
0 
104
2 
0.96 1080 _ 1.00 71.2±15.0 _ 0.10 
Matulevicius35 TTE 2011 2013 2011 535 491 0.92 535 _ 0.57 _ 0.59 0.31 
Bhatia2120  TTE 2011 2013 2011 131
8 
110
5 
0.84 1312 _ _ 63.0 0.46 _ 
Bhatia3120 TTE 2011 2013 2012 345 312 0.90 337 _ _ 61.0 0.42 _ 
Rao57 TEE † 2007 2009 2006 123
5 
115
6 
0.94 1235 _ _ 61.0 _ _ 
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Aggarwal38 TEE 2007 2010 2007 200 191 0.95 194 _ 0.50 63.0±15.0 0.42 0.57 
Ogbara52  TEE 2007 2011 2011 389 321 0.82 389 _ _ _ _ _ 
Bhatia43  TEE 2007 2012 2011 202 156 0.77 166 _ 0.76 63.0±14.0 0.20 0.73 
Mansour50  TEE 2007 2012 2007 405 358 0.88 368 _ 0.72 59.0±17.0 0.52 0.50 
Bhatia43  TEE 2011 2012 2011 202 190 0.94 199 _ 0.76 63.0±14.0 0.20 0.73 
Grewal48 TEE 2011 2012 2008 671 639 0.95 659 _ _ 66.0±13.0 0.33 _ 
Mansour 50 TEE 2011 2012 2007 405 382 0.94 404 _ 0.72 59.0±17.0 0.52 0.50 
*TTE: Transthoracic Echocardiography 
†TEE: Trans-oesophageal Echocardiography 
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Table 5- 2 Overview of studies included for the SE, SPECT and CCT analysis 
Study Imagin
g test 
AU
C 
Edit
ion 
Publ 
Year 
Enrol
ment 
year 
n App 
tests 
App 
(%) 
Classifi
ed 
Studies 
Previo
us echo 
(%) 
Inpati
ent 
(%) 
Age (y) Wom
en 
Cardiac 
Speciali
st% 
McCully124 SE* 2008 2009 2005 298 159 0.53 241 _ _ 66.0±13.0 0.48 _ 
Mansour125  SE 2008 2010 2008 289 180 0.62 253 _ 0.07 59.0±18.0 0.49 0.45 
Bhatia44  SE 2008 2013 2011 252 104 0.41 126 0.15 _ 58.1±12.2 0.42 0.50 
Willens121 SE 2008 2013 2008 209 104 0.50 189 _ 0.00 56.1±13.8 0.53 0.52 
Lin126 SE 2008 2013 2010 111 50 0.45 92 _ _ 51.4 0.54 _ 
Schmitz63  SE 2008 2013 2010 300 194 0.65 226 _ _ _ _ 
 
Mansour50  SE 2011 2012 2008 289 165 0.57 281 _ 0.07 59.0±17.0 0.52 0.50 
Cortigiani127  SE 2011 2012 2003 1552 984 0.63 1552 _ 0.00 _ _ _ 
Bhatia44  SE 2011 2013 2011 252 105 0.42 221 0.15 _ 58.1±12.2 0.42 0.50 
Bhattacharyya 62 SE 2011 2013 2011 100 49 0.49 100 _ _ _ _ _ 
Willens1121 SE 2011 2013 2008 209 100 0.48 207 _ 0.00 56.1±13.8 0.53 0.52 
Willens2121 SE 2011 2013 2011 209 82 0.39 200 _ 0.00 56.3±14.7 0.53 0.53 
Willens3121 SE 2011 2013 2001 111 48 0.43 107 _ 0.00 57.7±13.3 0.50 1.00 
Schmitz63  SE 2011 2013 2010 300 300 1.00 300 _ _ _ _ 
 
Gibbons1128 SPECT 2005 2008 2005 284 182 0.64 253 _ _ 67.0±11.0 0.37 _ 
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Mehta129 SPECT 2005 2008 2006 1209 940 0.78 1173 _ _ _ 0.55 0.69 
Hendel 130 SPECT 2005 2010 2007 6351 4192 0.66 5906 _ _ 65.7±11.8 0.41 0.75 
Gibbons2131 SPECT 2005 2010 2006 284 188 0.66 241 _ _ 68.0±11.0 0.33 _ 
Carryer132  SPECT 2005 2010 2005 281 179 0.64 250 _ _ 67.0±11.0 0.37 _ 
Gupta133 SPECT 2005 2011 2009 314 263 0.84 314 _ _ 62.0±14.0 0.48 0.62 
Gibbons3122 SPECT 2005 2011 2008 273 164 0.60 232 _ _ 65.0±13.0 0.33 _ 
Gholamrezanezhad13
4 
SPECT 2005 2011 2009 291 211 0.72 279 _ _ 55.3±10.3 0.57 _ 
Druz 135 SPECT 2005 2011 2007 585 370 0.63 570 _ 0.48 63.5±13.1 0.45 0.44 
Soine1136 SPECT 2005 2012 2007 1377 950 0.69 1377 _ _ 58.4±13.4 0.52 _ 
Soine2136 SPECT 2005 2012 2007 1445 1286 0.89 1445 _ _ 60.8±10.6 0.09 _ 
Carryer132  SPECT 2009 2010 2005 281 168 0.60 281 _ _ 67.0±11.0 0.37 _ 
Koh137 SPECT 2009 2011 2009 1623 1331 0.82 1574 _ _ 61.0±11.0 0.39 0.93 
Gholamrezanezhad13
4 
SPECT 2009 2011 2009 291 219 0.75 283 _ _ 55.3±10.3 0.57 _ 
Nelson1138 SPECT 2009 2012 2009 150 101 0.67 148 _ 0.12 61.0±10.0 0.01 _ 
Nelson2138 SPECT 2009 2012 2009 150 111 0.74 150 _ _ 65.0±12.0 0.43 0.47 
Koh139 SPECT 2009 2012 2009 176 106 0.60 176 _ _ 61.0±11.0 0.41 _ 
Lin126 SPECT 2009 2013 2010 338 178 0.53 312 _ _ 57.3 0.34 1.00 
Winchester140 SPECT 2009 2013 2011 332 259 0.78 328 _ _ _ 0.04 _ 
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 Doukky141  SPECT 2009 2013 2009 1511 779 0.52 1491 _ _ 59.0±13.0 0.43 _ 
Moralidis142 SPECT 2009 2013 2011 3032 2208 0.73 3008 _ _ 66.0±11.0 0.41 _ 
Aldweib143  SPECT 2009 2013 2006 1199 740 0.62 1194 0.36 _ 63.8±12.5 0.44 _ 
Ayyad 1144 CCT ‡ 2006 2009 2006 763 530 0.69 715 _ _ 57.2±13.6 0.35 _ 
Ayyad 2144 CCT 2006 2009 2007 646 507 0.78 623 _ _ 58.1±13.3 0.35 _ 
Miller145 CCT 2006 2010 2007 251 69 0.27 136 _ _ _ _ _ 
Murphy146 CCT 2006 2010 2008 267 126 0.47 189 0.69 _ 56.2±14.0 0.36 0.82 
El Sibai 147 CCT 2006 2011 2009 100 8 0.08 100 _ 0.19 53.0±13.0 0.17 0.77 
Chinnaiyan148 CCT 2006 2012 2009 25387 5053 0.20 12853 _ 0.27 57.0 0.46 0.21 
Rich149 CCT 2006 2012 2011 1216 503 0.41 1069 _ 0.31 57.5±15.7 0.47 _ 
Mazimba150 CCT 2006 2012 2007 243 36 0.15 243 _ _ 59.2±12.3 0.55 _ 
Wasfy151 CCT 2006 2012 2008 267 119 0.45 189 0.51 _ 56.2±14.0 0.36 _ 
El Sibai 147 CCT 2010 2011 2009 100 38 0.38 100 _ 0.19 53.0±13.0 0.17 0.77 
Chinnaiyan148 CCT 2010 2012 2009 25387 18266 0.72 22442 _ 0.27 57.0 0.46 0.21 
Rich149 CCT 2010 2012 2011 1216 863 0.71 1159 _ 0.31 57.5±15.7 0.47 _ 
Mazimba150 CCT 2010 2012 2007 243 119 0.49 243 _ _ 59.2±12.3 0.55 _ 
Wasfy151 CCT 2010 2012 2008 267 157 0.59 231 0.51 _ 56.2±14 0.36 _ 
Lin126 CCT 2010 2013 2010 23 13 0.56 18 _ _ 50.3 0.39 _ 
Cullen 152 CCT 2010 2013 2007 251 85 0.34 212 _ _ _ _ _ 
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*SE: Stress Echocardiography 
†SPECT: Single-photon emission computed tomography 
‡CCT: Cardiac Computed Tomography 
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Publication bias.  
Funnel plots were made for each of the pooled analyses (Figure 5- 2). There was evidence for 
publication bias for stress echocardiography 2011 (p=0.01) and CTA 2010 (p=0.02).  
However, bias was not identified for TTE 2007 (p=0.24), TTE 2011 (p=0.10), TEE 2007 
(p=0.99), TEE 2011 (p=0.39), SE 2008 (p=0.65), SPECT 2005 (p=0.35), SPECT 2009 
(p=0.93), CTA 2006 (p=0.08).  
Figure 5- 2 Publication bias for Stress echocardiography (2011 AUC edition) and Cardiac 
computed tomography (2010 AUC edition)  
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Temporal changes in appropriate use.  
The overall findings of this study are that new versions of AUC were associated with apparent 
improvement of appropriateness for transthoracic (TTE) and transesophageal 
echocardiography (TEE), and computed tomography angiography (CTA), but not for stress 
echocardiography (SE) or single photon emission computed tomography (SPECT) (Figure 5- 
3).  
The only modality showing a correlation between the proportion of appropriate testing and the 
published year was for TTE using the 2011 guidelines. 
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Figure 5- 3 Reported Appropriate Use in Papers Applying Different Versions of Appropriate 
Use Criteria 
 
Each line represents a summary of overall estimates calculated from random effect models of 
the proportion of appropriate tests. Individual Forest plots are provided in the online figures. 
TTE: Transthoracic echocardiography; TTE: Trans-oesophageal echocardiography, SE: Stress 
echocardiography, CCT: Cardiac computed tomography, SPECT: Single-photon emission 
computed tomography. 
(Y axis: AUC edition, X axis: Overall estimates of appropriate use (95% CI)). 
 
 
 
Chapter 5. Impact of Appropriate Use Criteria on clinicians’ behaviour 
 
106 
 
Transthoracic echocardiography (2007 AUC edition).  
Of the 15 studies in which the of AUC for TTE was evaluated using the 2007 edition, one 
study55 was presented twice because it analysed two different samples for TTE at two different 
of points of time (Table 5- 1, Figure 5- 4). Thus, there are 16 different rows (n=7,762 TTE) 
analysed for 15 different studies published between 2008 and 2013, with a range of enrolment 
between 2000 and 2011.  
The pooled proportion of appropriateness of the total sample was 0.80 [95% CI, 0.75 to 0.84], 
with substantial heterogeneity among the estimates [I2= 95.4%, p<0.0001]. The weighted 
average of appropriate tests among classifiable studies was 0.91 [95% CI: 0.87 to 0.93] (Table 
5- 3).  
We explored heterogeneity using the following factors: publication year, gender, proportion of 
inpatients and proportion ordered by cardiologists. In univariable meta-regression, there were 
no significant associations of the proportion of appropriate tests with publication year (p=0.36) 
(Table 5- 4).  
In addition, there were no significant relations between appropriateness and gender, type of 
patient, or cardiologist who ordered the test. However, there was a positive association between 
the proportion of appropriate testing and the proportion of inpatients (p=0.0006) (Table 5- 3). 
The proportion of classifiable studies did not show a significant improvement over time (Table 
5- 3).  
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Figure 5- 4 Appropriateness of Transthoracic Echocardiography using the 2007 (up) and 2011 
(down) AUC edition 
 
Studies were ordered by increasing publication year. The overall estimate was calculated from 
random effect model. 
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Table 5- 3 Proportion of appropriate tests and their association with the publication year in the total sample (first columns) and among classifiable 
studies (2nd group of columns).  The 3rd group of columns examines the association between the proportion of classifiable tests and publication 
years. 
 Total sample Classified studies % Classified studies of Total sample 
 %Appropriate Pub 
year* 
p %Appropriate Pub year* p %Classified Pub year* p 
TTE 2007 0.80 [0.75;0.84] 0.09 0.36 0.91 [0.87;0.93] 0.26 0.06 0.89 [0.85;0.92] -0.02 0.87 
TTE 2011 0.85 [0.81;0.89] 0.73 0.01 0.87 [0.83;0.90] 0.69 0.07 0.99 [0.98;0.99] 0.67 0.24 
TEE 2007 0.89 [0.81;0.94] -0.43 0.03 0.95 [0.89;0.97] -0.01 0.98 0.97 [0.91;0.99] -1.54 0.03 
TEE 2011 0.95 [0.93;0.96] − − 0.96 [0.94;0.97] − − 0.99 [0.97;0.99] − − 
SE 2008 0.53 [0.45;0.61] -0.07 0.46 0.71 [0.60;0.80] 0.05 0.80 0.80 [0.67;0.89] -0.12 0.57 
SE 2011 0.52 [0.42;0.61] -0.04 0.97 0.53 [0.44;0.61] -1.42 0.35 0.98 [0.95;0.99] -1.42 0.35 
SPECT 
2005 
0.72 [0.66;0.77] 0.10 0.40 0.76 [0.71;0.80] 0.04 0.70 0.95 [0.92;0.97] 0.84 0.05 
SPECT 
2009 
0.68 [0.60;0.74] -0.12 0.42 0.69 [0.71;0.76] -0.13 0.42 0.99 [0.97;0.99] -0.01 0.99 
CCT 2006 0.37 [0.21;0.55] -0.59 0.02 0.48 [0.35;0.62] -0.57 0.05 0.87 [0.74;0.94] -0.09 0.87 
CCT 2010 0.55 [0.44;0.65] -0.06 0.89 0.61 [0.47;0.74] 0.16 0.76 0.90 [0.85;0.94] -1.41 0.03 
*Regression coefficient (slope). Values in brackets are 95% confidence intervals. Abbreviations as in Tables 1 and 2.  
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Table 5- 4 Meta- regression of the associations of the proportion of appropriate tests. 
  Publication year* p Male* p Cardiologists* p Inpatient* p Age* p 
TTE 2007 0.09 0.36 -0.62 0.64 -1.03 0.10 1.10 <0.01 -0.01 0.67 
TTE 2011 0.73 0.01 -0.02 1.00 -2.59 0.22 3.04 <0.01 0.00 0.99 
TEE 2007 -0.43 0.03 -3.42 0.42 -4.81 0.42 -6.34 0.01 -0.01 0.97 
TEE 2011 − − 0.16 0.88 0.16 0.88 0.16 0.88 0.03 0.51 
SE 2008 -0.07 0.46 -1.63 0.68 -8.87 0.24 − − 0.03 0.46 
SE 2011 -0.04 0.97 -2.03 0.56 -0.32 0.69 4.71 0.51 0.13 0.25 
SPECT 2005 0.10 0.40 1.18 0.64 0.96 0.71 − − -0.01 0.16 
SPECT 2009 -0.12 0.42 0.39 0.69 -0.76 0.75 − − 0.01 0.77 
CCT 2006 -0.59 0.02 -0.02 1.00 0.49 0.89 17.53 <0.01 0.28 0.28 
CCT 2010 -0.06 0.89 -2.42 0.19 − − 11.69 0.02 0.01 0.45 
*Regression Coefficient (Slope). Abbreviations as in tables 1 and 2.  
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Transthoracic echocardiography (2011 AUC edition).  
Ten studies using the 2011 edition of the AUC for TTE were analysed (n=9,211). Because one 
study, 120 was divided into two, there were 11 studies included in this analysis. The weighted 
proportion of appropriate tests was 0.85 with substantial heterogeneity among the estimates 
[95% CI, 0.81 to 0.89, I2= 96.2%, p<0.0001] (Figure 5- 4).  
In this group, a significant positive association was found between appropriateness and year of 
publication (p=0.01), as well as a strong positive association between inpatient status and 
appropriateness in the total sample (p<0.0001) (Table 5- 4).  There were no improvements in 
the proportion of appropriate tests among classifiable studies over time (Table 5- 3).  
Trans-oesophageal echocardiography.  
There were five studies based on the TEE 2007 AUC (n=2,431) published between 2009 and 
2012 (Figure 5- 5). The weighted proportion of appropriate tests was 0.89 with substantial 
heterogeneity among estimates [95% CI, 0.81 to 0.94, I2= 94.8%, p<0.0001]. In the overall 
sample, there were negative associations between appropriateness, publication year (p=0.03), 
and inpatients (p=0.007) (Table 5- 4).  
There were no significant associations between appropriateness and gender, ordering physician, 
or age. There was an apparent correlation between the proportion of classified studies and 
publication year (Table 5- 3).  
Three studies used TEE 2011 AUC, which including 1,278 tests. There was no association with 
time, gender, specialists or type of patients.  
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Figure 5- 5 Appropriateness of TEE using the 2007 (up) and 2011 (down) AUC edition 
 
Studies were ordered by increasing publication year. The overall estimate was calculated from 
random effect model. 
 
Stress echocardiography.  
The 2008 AUC were used in six studies (n=1,459) published between 2009 and 2013, with 
enrollment data between 2005 and 2011. The pooled appropriate testing proportion using the 
2008 AUC for SE was 0.53 with significant heterogeneity between estimates [95% CI: 0.45 to 
0.61; I2= 88.3%, p<0.0001] (Figure 5- 6).There were no significant associations between the 
proportion of appropriateness and publication year, gender, or specialists for either all imaging 
studies or classifiable studies (Table 5- 3 and Table 5- 4).  
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Figure 5- 6 Appropriateness of SE using the 2008 (up) and 2011 (down) AUC edition 
 
Studies were ordered by increasing publication year. The overall estimate was calculated from 
random effect model. 
 
In regards to the analysis of the AUC 2011 for SE, one study121 was divided into three. Thus, 
eight studies with a total of 3,022 tests were included (Figure 5- 6).  The average 
appropriateness was 0.52 [95% CI: 0.42 to 0.61; I2= 93.7% p< 0.0001]. No significant 
associations between appropriateness and publication year, gender, or specialists were found 
(Table 5- 4) either among all studies or classifiable studies (Table 5- 3).  
SPECT.   
Ten studies used the 2005 AUC version for SPECT, with one study136 divided in two resulting 
in 11 studies (n=12,694 tests). The weighted proportion of appropriate tests was 0.72 [95% CI: 
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0.66 to 0.77; I2= 97.2%, p<0.0001] (Figure 5- 7). No significant associations between 
appropriateness and publication year, gender, or specialists were found (Table 5- 4).  
Using the 2009 AUC edition for SPECT, ten studies were found (n=9,083 tests), with one study  
divided in two. The weighted proportion of appropriate tests was 0.68 [95% CI: 0.60 to 0.74; 
I2= 97.8%, p <0.0001]. No significant associations between appropriateness and publication 
year, gender, or specialists were found.  
CTA.   
Eight studies (n=29,140) were found evaluating the 2006 AUC for CTA, with one paper 144 
divided in two. The average of appropriateness was 0.37 [95% CI: 0.21 to 0.55; I2 = 99.6%, 
p<0.0001] (Figure 5- 8). A drop in the proportion of appropriate tests in relation to the year of 
publication of the paper was found (p=0.02) (Table 5- 4). No significant associations between 
appropriateness and gender, or specialists were identified.  However, a strong positive 
association between the proportion of appropriateness and hospitalised patients (inpatients) 
was found (p <0.0001).  
For the evaluation of the 2010 AUC for CTA, seven studies included 27,487 tests (Figure 5- 
8).  The weighted proportion of appropriate tests was 0.55 [95% CI: 0.44 to 0.65, I2= 97.8% 
p<0.0001]. Only a significant association between appropriateness and inpatient tests was 
found (p=0.0206) (Table 5- 4). There was a significant diminution of classified studies in 
relation to publication year (Table 5- 3). 
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Figure 5- 7 Appropriateness of SPECT using the 2005 (up) and 2009 (down) AUC edition 
 
Studies were ordered by increasing publication year. The overall estimate was calculated from 
random effect model. 
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Figure 5- 8 Appropriateness of CCT using the 2006 (up) and 2010 (down) AUC edition  
 
Studies were ordered by increasing publication year. The overall estimate was calculated from 
random effect model. 
 
“Rarely appropriate” (inappropriate) and “maybe appropriate” (uncertain) tests.  
Table 5- 5 and Table 5- 6 present the proportion of “rarely appropriate” (inappropriate) and 
“maybe appropriate” (uncertain) tests, respectively, and their association with the publication 
year in the total sample and among classifiable imaging studies.  
There was a significant diminution of ‘rarely appropriate tests’ in the 2007 TEE AUC with 
time. However, no such improvement was noted with the new AUC edition. There was no 
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impact of the AUC in ‘rarely appropriate tests’ for other cardiac imaging modalities. Between 
the old and new editions, “rarely appropriate” stress echocardiography studies increased from 
18% to 27%, SPECT from 11% to 20%, and CTA from 17% to 21%. 
TEE 2007 showed a decrease in the ‘maybe appropriate tests’ through time (beta=-0.84, 
p=0.04). CTA 2006 showed an increase in the proportion of ‘maybe appropriate tests’ of 
classified imaging studies but not of the total sample, over time (beta=0.31, p=0.01).  No other 
improvements in the ‘maybe appropriate tests’ were found for the remaining modalities. 
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Table 5- 5 Meta-regression of proportion of “Rarely appropriate” tests (Inappropriate) of total sample and classified studies as dependent variables 
 
 Total Sample Classified Studies 
% “Rarely appropriate” Pub year* p value % “Rarely appropriate” Pub year* p value 
TTE 2007 0.08 [0.06;0.11] -0.25 0.06 0.09 [0.07;0.13] -0.26 0.06 
TTE 2011 0.09 [0.06;0.12] -0.63 0.09 0.09 [0.07;0.12] -0.64 0.08 
TEE 2007 0.01 [0.01;0.03] -0.45 0.00 0.01 [0.01;0.03] -0.43 0.00 
TEE 2011 0.02 [0.02;0.04] − − 0.03 [0.02;0.04] − − 
SE 2008 0.18 [0.11;0.27] -0.03 0.91 0.23 [0.16;0.32] 0.02 0.92 
SE 2011 0.27 [0.22;0.33] 0.10 0.83 0.28 [0.22;0.35] 0.02 0.97 
SPECT 2005 0.11 [0.09;0.14] -0.13 0.28 0.12 [0.10;0.14] -0.15 0.21 
SPECT 2009 0.20 [0.14;0.28] 0.05 0.81 0.20 [0.14;0.28] 0.05 0.78 
CCT 2006 0.17 [0.12;0.23] 0.40 0.09 0.21 [0.13;0.33] 0.45 0.05 
CCT 2010 0.21 [0.11;0.37] -0.55 0.43 0.23 [0.12;0.39] -0.40 0.56 
Values in brackets are 95% confidence intervals. *Regression coefficient (slope). Abbreviations as in Tables 1 and 2.  
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Table 5- 6 Meta-regression of proportion of “May be appropriate” (uncertain) tests of total sample and classified studies as dependent variables. 
 Total Sample Classified Studies 
 % May be appropriate Publication year* p value % May be appropriate Publication year* p value 
TTE 2007 − − − − − − 
TTE 2011 0.04 [0.03;0.06] -0.84 0.05 0.04 [0.03;0.06] -0.84 0.04 
TEE 2007 − − − − − − 
TEE 2011 0.01 [0.00;0.03] − − 0.01 [0.00;0.03] − − 
SE 2008 0.06 [0.03;0.09] -0.28 0.26 0.08 [0.05;0.12] -0.22 0.31 
SE 2011 0.15 [0.09;0.24] 0.02 0.98 0.16 [0.10;0.24] 0.07 0.95 
SPECT 2005 0.11 [0.09;0.14] 0.09 0.35 0.12 [0.10;0.15] 0.07 0.50 
SPECT 2009 0.08 [0.05;0.13] 0.06 0.81 0.09 [0.05;0.14] 0.07 0.80 
CCT 2006 0.19 [0.12;0.29] 0.26 0.17 0.24 [0.18;0.31] 0.31 0.01 
CCT 2010 0.11 [0.08;0.16] 0.12 0.78 0.12 [0.09;0.17] 0.24 0.59 
Values in brackets are 95% confidence intervals. *Regression coefficient (slope). Abbreviations as in Tables 1 and 2 
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Discussion 
This comprehensive assessment of the published literature evaluating AUC for different 
cardiac imaging techniques from 103,567 tests grouped in 10 different cardiac imaging 
outcomes. Meta-regression was used to assess the temporal trend of appropriateness, based on 
the year of publication. In contrast to studies comparing the behaviour of specific groups of 
physicians over time, the results are an indication of “real-world” practice at sites publishing 
their appropriate use data.   
There are five significant findings; first, the improvement of appropriate use from the original 
to the revised versions may merely reflect an easier classification of patients and a change in 
attribution of the proportion of appropriate testing rather than a change in practice.  Second, 
this study showed a temporal improvement in percent appropriateness for TTE, TEE and CTA, 
but no evidence of a change in the number and proportion of appropriate testing for other 
modalities.  Overall rates of appropriate use for CTA and SE remain low, and those for SPECT 
only modest. This implies a disconnection between clinical practice and AUC that warrants 
better understanding.  Third, this limited change has not matched the reduction of imaging tests 
over the last five years, suggesting that physician use of AUC in the ordering process may not 
have played a significant role in this decrease. However, an indirect role (though AUC 
influence on the decisions of Radiology Benefit Managers (RBM)) cannot be excluded. Fourth, 
the proportion of appropriate use presented here may well be shown in its best light in these 
retrospective and largely unblinded evaluations, which for the most part were performed by 
physicians able to identify appropriate indications, even if this was not the primary reason for 
the test. Moreover, the studies were mainly made at the point of service of academic medical 
institutions. There was substantial variation between observers, in particular between 
physicians. Finally, although there was some evidence of publication bias for SE 2011 and 
CTA 2010, bias was not identified for the majority of scenarios. 
Understanding temporal variations in appropriate use.  
The observed heterogeneity of the proportion of appropriate testing among studies might be 
expected on the basis of a wide variety of participant characteristics, study designs, types of 
hospital and regions in the published data. However, the unique aspect of this study is its 
examination of the temporal variation in the proportion of appropriate testing. This is difficult 
to measure in a specific study as ordering physicians may not behave as they do in daily life.  
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The drivers of test ordering are complex, and the persistent rate of approximately 80% for TTE 
(and less for other modalities) perhaps testifies to a variety of influences that are not disease-
specific and include factors individual to the patient, including those related to other 
comorbidities and situational considerations.  
These features may drive the request for testing in a situation when the test is considered “rarely 
appropriate”. In addition, clinical practice guidelines may be discordant with AUC.  Finally, 
the adjudication of appropriate testing is often inconsistent because appropriate and rarely 
appropriate reasons for testing may co-exist in the same patient. The implication is that the 
ordering physician may choose an existing appropriate indication rather than the real clinical 
issue. This change in indication is especially likely to happen when the proportion of 
inappropriate (or rarely appropriate) tests is reviewed as part of the accreditation process 66. 
In this respect, the increment of “rarely” appropriate tests from the first to the second versions 
of stress echocardiography, SPECT, and CTA, was a surprising finding of this meta-analysis. 
Interestingly, none of these tests showed a gradation of “rarely appropriate” use within the time 
frame of each edition; therefore, this finding likely reflects the change in criteria rather than a 
change in practice.  
Alternative approaches to reducing cost.  
The use of AUC as a process to reduce costs by trying to maintain appropriate testing neglects 
the fact that testing labeled as “sometimes” and “rarely” appropriate is very appropriate in some 
situations. Indeed, this is a shortcoming of the widespread use of Radiology Benefit Managers 
(RBM) as a tool to control the use of cardiac imaging: they are inflexible to situational 
demands121. The application of AUC at point-of-care, for example using electronic tools that 
help physicians to choose “appropriately” has produced similar results to the RBM, but has the 
same limitation. 45 
Although the nuances of particular clinical scenarios make the AUC problematic for 
controlling testing, they are potentially valuable as a yardstick for education. The evidence 
regarding the value of educational campaigns is currently contradictory 120-122. In the 
interpretation of responses to AUC campaigns, it should be kept in mind that knowledge of 
AUC is but one component of test selection, which is also influenced by the characteristics of 
health professionals, features of practice settings, incentives, linkage of AUC performance with 
accreditation or licensing bodies, patient factors, compatibility with existing practice and 
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beliefs, and perceived quality of the guidelines.153 Moreover, repetition requirements for an 
educational campaign to have a sustained effect are unclear. 
In jurisdictions where the laboratory is responsible for appropriate use, a strategy of laboratory-
based audit is needed for the thousands of cardiac imaging requests which are submitted to the 
laboratory every year. The use of AUC to facilitate audit is more likely to be effective than its 
application to individual test requests. Tests that are most likely to be of “maybe” or “rare” 
appropriateness include those requested in younger patients, those with previous tests, those 
who are outpatients or tests that are re-evaluations in asymptomatic patients or without changes 
in clinical status.59 These situations might be used as markers of potential inappropriate use in 
individual patients. 
Study limitations.  
This study has sought to link reported percent appropriateness rates with the reduction of 
imaging over time, but there are some potential problems. First, most cardiovascular imaging 
is performed in the community practice environment, while most AUC studies have been 
reported in academic medical centres.  
Nonetheless, the broad discussion of AUC over the last decade might be expected to influence 
all environments, and a practice-specific variation of some tests and not others seems unlikely. 
Second, it is unclear whether changes in percent appropriateness reflect better test selection 
rather than observer-expectancy effect, or coding of indications to satisfy AUC. 
Conclusions 
Improvements in the percent appropriateness rate of TTE seem to correlate with the temporal 
reduction in imaging. However, methodological problems in this literature – including possible 
publication bias and retrospective assignment of AUC ratings in most studies by individual(s) 
affiliated with the institution where the study was performed – may compromise confidence in 
this observation. Moreover, these changes are not uniform, with no association between the 
rate of appropriateness and date of publication for SPECT, TEE, CT and SE. It is possible that 
the reduction of imaging tests is unrelated to AUC.  
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Chapter 6. Impact of Appropriate Use Criteria on Survival 
The research contained within this chapter has been published as7: 
 Fonseca R, Otahal P, Galligan J, Neilson S, Huynh Q, Saito M, Negishi K and Marwick 
TH. Association of Survival Time with Transthoracic Echocardiography in Stable 
Patients with Heart Failure: Is Routine Follow-Up Ever Appropriate? International 
Journal of Cardiology. 2016. 
Preface 
As it was discussed in the introductory chapter, the achievement of appropriate use of cardiac 
imaging has become a crucial battle in an attempt to control imaging use and health expenditure 
growth. The AUC were designed to achieve these aims. Australia is no stranger to this problem; 
it was demonstrated that growth in imaging use has affected Australia over the last decade but 
most importantly, it seems the imaging use, especially echocardiography, is not properly 
controlled 4.  
The interest in using the AUC has become a current topic of discussion in Australia. However, 
as it has been shown in chapters 3 and 4, there are inconsistencies between the guidelines and 
AUC which may challenge our physicians and moreover, it seems that, despite all the focus on 
the use of AUC, these have not achieved the goal of changing the ordering behaviour in doctors, 
demonstrated by a lack of significant increase in the proportion of “appropriate” testing and 
the consequential decrease in “inappropriate” screening5, 6.  
Once more, it has been evidenced that the use of transthoracic echocardiography is one of the 
most challenging in the medical practice: there has been an increase in the proportion of 
“appropriate” tests over time due to a decrease in the proportion of “uncertain” tests. However, 
the proportion of “inappropriate” tests has not changed6.  
In this chapter, we sought to determine if the AUC have an impact on health outcomes. In the 
AUC for echocardiography, most of the inappropriate scenarios are defined by timing of 
follow-up testing and absence or change of symptoms or signs of cardiac disease 
(asymptomatic or stable patients)26 and there are some indications that are uncertain due to a 
lack of scientific evidence.  
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For this reason, we have chosen to analyse the impact of the criteria on heart failure survival 
and readmission and to provide scientific evidence to the AUC. Heart failure is one of the most 
expensive syndromes for any health system due to the poor quality of life, high prevalence and 
incidence, and costly care154, 155.  In Australia, the cost of chronic heart failure has been 
estimated at more than $ 1 billion per year156, and the increase in readmissions and mortality 
have increased during the last decade157. This burden on the health care system can be improved 
by reducing the time to and rates of readmission and death through the appropriate use of 
cardiac imaging. 
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Abstract 
Background. The appropriateness of repeat transthoracic echocardiography (TTE) for stable 
heart failure (HF) is based on timing of the follow-up examination, but this lacks scientific 
support. We sought the association of routine follow-up TTE on survival and readmission in 
stable HF.  
Methods. Patients with HF were selected from consecutive HF admissions from 2008-2012. 
Groups were divided into: no follow-up TTE; routine <1 year with no change in status 
("inappropriate"), ≥1year follow-up with no change in status ("uncertain") and TTE due to 
change in clinical status (“appropriate”). Survival analysis was performed for the combined 
endpoint of HF readmission and death, and a separate analysis was performed for HF 
readmission, with death as a competing risk.  
Results. Of 550 HF patients, 141 had a follow-up TTE, including 41 (29%) within 1 year. The 
event-free time was 1.10 years [95% CI: 0.69, 1.49] for no TTE, 2.61 years [95% CI: 1.08, 
3.04] for the “inappropriate” group, 2.45 years [95% CI: 1.37, 5.78] for the “uncertain” group, 
and 0.09 years [95% CI: 0.02, 1.80] for the “appropriate” group (p<0.001 between all groups; 
p=0.16 between “inappropriate”, “uncertain” and “appropriate” test groups; p=0.06 between 
“inappropriate” and “uncertain” groups). HF readmission was not associated with follow-up 
TTE timing. There were no differences in the cumulative incidence for death between groups. 
There were no differences in change in management in “inappropriate” and “uncertain” tests.  
Conclusion: The distinction of appropriateness of routine repeat TTE in stable HF patients, 
based on testing <1 or ≥1 year after index admission appears unjustified. 
Keywords: appropriate use, heart failure, echocardiography  
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Introduction 
The Appropriate Use Criteria (AUC) for transthoracic echocardiography (TTE) were designed 
to facilitate selection of the most appropriate testing for individual clinical situations, in the 
context of rational use, standardization of clinical practice, and delivery of high-quality care 78. 
However, there have been concerns that the determination of AUC on the basis of expert 
opinion carries the risk of non-scientific guidance 5, 64, 103. This is particularly problematic when 
the only distinction between an “appropriate” and an “inappropriate” (also called “rarely 
appropriate”) TTE is the time of routine follow-up evaluation or the symptom status of the 
patient 78.  
Recent studies have questioned the relationship between appropriateness assessment and the 
clinical impact of testing 35, 158.  Although there is no a perfect way to determine clinical impact 
of a TTE, its benefits have been measured by the change in management and surprisingly, an 
average of one third of appropriate TTE have led to a change in management, with no 
differences between “appropriate” or “inappropriate” TTE 35.  
Heart failure (HF) is one of the most expensive and highly prevalent cardiovascular conditions. 
The evidence regarding follow-up and clinical benefit of the routine use of TTE in stable 
patients with HF is sparse 78. Additionally, there have not been studies of the association 
between survival in HF and appropriate use status. Therefore, we sought to assess the 
association between survival and time to HF readmission and appropriate use in HF patients 
with no change in clinical status or cardiac exam.  
The main objectives of this study were to assess:  
1) Association of routine follow-up tests with survival and HF readmission in stable HF,  
2) Differences in outcome between tests performed with <1 year follow-up (inappropriate, or 
“rarely appropriate”), with ≥1 year follow-up (uncertain appropriateness), “appropriate” TTE 
(those performed in response to a change in status or exam) or no follow-up TTE,  
3) Associations of changes in management after TTE on survival and HF readmission time in 
each described AUC group,  
4) Role of routine follow-up TTE in stable HF patients, more specifically “uncertain” tests 
compared to “inappropriate” tests.  
Chapter 6. Impact of Appropriate Use Criteria on Survival 
 
126 
 
Methods 
Study design and inclusion criteria.  
This cohort analysis analysed event-free survival, cause-specific hazard, and cumulative 
incidence involving the subsequent outcomes (HF readmission or death) of HF patients. The 
study included available data of all patients hospitalised for an initial heart failure admission at 
a tertiary referral hospital between 1st July 2008 and 30 June 2012.  
Patients were included if they were ≥18 years old and had a diagnosis of HF at discharge and 
had a TTE before or during their first HF admission. Patients were excluded if they were <18 
years old or did not have a TTE previously or during the HF admission.  
A routine follow-up TTE was defined as a TTE performed for a periodic evaluation in a patient 
with no change in clinical status or cardiac exam within a year (inappropriate) or after a year 
(uncertain appropriateness).   “Appropriate” TTE in these HF patients were defined as being 
due to a change in clinical status or cardiac exam. “Change in clinical status” was defined as 
any change in the stability of the condition determined by a new onset or worsening of signs 
or symptoms of left-sided failure, right-sided failure or biventricular failure or apparition of 
new symptoms or signs such as chest pain, shock, hypotension, syncope, arrhythmia, murmur, 
or peripheral embolic event.  
“Change in cardiac exam” corresponded to any change in observation, palpation or auscultation 
during cardiac exam. “Stable HF” was defined as a patient with HF with no visible progression 
of the disease, determined by no change in symptoms or signs of left or right-sided failure or 
biventricular failure.   
Change in management.  
Change in management was determined as any change of care occurred in response to the 
follow-up TTE. These changes included changes in medications (beta-blockers, angiotensin-
converting-enzyme inhibitor/angiotensin-II receptor blockers, diuretics, inotropes, 
anticoagulants, and mineralocorticoid antagonists), referral to another subspecialty, surgery or 
invasive procedures, cardioversion, or new diagnostic testing or change/cancellation of the 
initially planned management. A complete review of the electronic medical record (EMR) was 
performed for each TTE. Due to the possible permutations, “change in management” was not 
studied in detail and it was analysed as a binary variable (yes/no).   
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Clinical characteristics.  
General characteristics and baseline comorbidities were identified from the EMR. These 
variables (Appendix Table 5) included demographics, systolic blood pressure, functional status 
(New York Heart Association Functional Classification, NYHA), medications, and laboratory 
findings (creatinine (µmol/L), left ventricular ejection fraction (LVEF, %), medical history and 
comorbid disease. Risk of death was determined for each patient using the Meta-Analysis 
Global Group in Chronic Heart Failure (MAGGIC) HF risk calculator 159.  
Follow-up TTE.  
Four groups were defined, in accordance with routine follow-up time described in the AUC:  
 “Appropriate”: patients with follow-up TTE due to a change in clinical status or cardiac 
exam,  
 “Inappropriate”: routine follow-up <1 year (defined as rarely-appropriate by the AUC), 
 “Uncertain”: routine follow-up ≥1 year  78 ,  
 No-TTE: patients with no follow-up TTE.  
 
The starting time was defined as the day of discharge.   
Outcomes and end points.  
The primary outcomes were the combined endpoint of HF readmission or death from any cause 
and HF readmission and death separately. HF readmission was defined as any subsequent 
hospital admission for which the primary diagnosis was recorded as HF; time to HF 
readmission was determined from the date of discharge of first hospital admission for HF to 
the day of the readmission for HF. Time to death was recorded as the time between the date of 
hospital discharge until the date of death. Participants who were free of events (HF readmission 
or death) were censored when follow-up time ended.  
Statistical analysis.  
This survival analysis comprised event-free survival, cause-specific hazard, and cumulative 
incidence. All statistical analyses were performed using R software 35. Continuous variables 
are reported as mean (SD). Categorical variables are expressed as proportions. Non-normally 
distributed continuous variables are expressed as median and interquartile range (IQR).  
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Baseline differences between all groups were detected using ANOVA for normally distributed 
continuous variables and the nonparametric Kruskal-Wallis rank sum test for non-normally 
distributed continuous variables. A t-test was used to compare variables between the two 
groups and the Mann-Whitney U test was used for non-normally distributed variables. The 
Fisher’s exact test was used for categorical variables with less than 5 observations, and a chi-
squared test for other similar variables.  
For the event-free survival, the analysis was focused on event-free status, plotted with the 
Kaplan-Meier curves. Cox proportional hazard regression was used to assess the event-free 
survival for a combined endpoint (HF readmission or death).  Models were assessed by testing 
the proportional hazards assumption and by examining Schoenfeld residuals plots.  
For the competing risk analysis, HF readmission was defined as the main outcome and death 
as the competing event.  In both analyses follow-up TTE was treated as a time-varying 
covariate; with patients contributing to the risk-set in the No-TTE group until the date of their 
follow-up, upon which these patients switched to contribute to the risk-set in either the 
“appropriate”, “inappropriate” or “uncertain” groups (whichever was applicable). 
Multivariable analysis were performed using a purposeful selection of covariates 160.  
The study was performed on available administrative data of all patients hospitalised for initial 
heart failure admission at a tertiary hospital between 1st July 2008 and 30 June 2012. On the 
basis of 75% of the patients having no follow-up TTE, and an anticipated 1 year survival free 
of readmission and death in this group, the study had an 80% power at an alpha of 0.05 to 
identify a difference in outcome with non-TTE and TTE groups of 302 and 101, respectively 
161.  
Results 
Study population.  
The study population comprised 550 (69%) of 799 patients with a first Heart Failure admission, 
identified from July 2008 to June 2012, who had TTE prior to or during admission. Of the 141 
in this group who had a TTE after discharge and before HF readmission, 60 had a routine 
(“inappropriate” or “uncertain”) follow-up TTE, performed for a periodic evaluation with no 
change in clinical status or cardiac exam, and 81 patients had an “appropriate” second TTE due 
to change in clinical status or cardiac exam.  
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The 60 patients who had a routine follow-up TTE were divided in two groups according to 
AUC: 41 patients undertaking routine follow-up in <1 year (“inappropriate”) and 19 with ≥1-
year routine follow-up (“uncertain” by the AUC). The remaining 409 patients had no follow-
up TTE (Figure 6- 1).  
Figure 6- 1 Flow chart of the study 
 
 
The general characteristics of population are shown in Appendix Table 5.  In general, patients 
with no follow-up TTE were older than the other groups, and were also more likely to have 
higher levels of creatinine, greater risk of death at 1 and 3 years (measured by the MAGGIC 
score) and more likely to have NYHA class 3 and 4 HF.  There were no differences between 
people with “inappropriate” and “uncertain” tests, except for a higher proportion of history of 
myocardial infarction in the “uncertain” TTE group (58% vs 27%, p=0.04) (Table 6- 1).  
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Table 6- 1 Baseline characteristics between no follow-up TTE and follow-up TTE groups 
(“inappropriate”, “uncertain” and “appropriate” groups).   
  No TTE TTE p 
n 409 141 
 
age (median [IQR]) 79 [70, 84] 74 [66, 79] <0.01 
Gender male, n (%) 222 (54.3) 85 (60.3) 0.25 
Body mass index, median [IQR] 26 [23, 30] 27 [24, 32] 0.01 
Systolic blood pressure in mmHG, median 
[IQR] 
120 [105, 135] 120 [110, 
136] 
0.31 
Creatinine levels in µ/L, median [IQR] 112 [86, 148] 96 [74, 120] <0.01 
Left ventricular ejection fraction %, median 
[IQR] 
0.45 [0.32, 0.60] 0.45 [0.35, 
0.58] 
0.69 
MAGGIC score, median [IQR]) 28 [23, 33] 24 [20, 28] <0.01 
Risk of death 1 year, median [IQR] 0.21 [0.13, 0.32] 0.15 [0.10, 
0.21] 
<0.01 
Risk of death 3 years, median [IQR] 0.46 [0.32, 0.63] 0.34 [0.25, 
0.46] 
<0.01 
Betablockers, n (%) 225 (55.0) 90 (63.8) 0.08 
Diuretics, n (%) 369 (90.2) 122 (86.5) 0.29 
Mineralocorticoids, n (%) 124 (30.3) 49 (34.8) 0.38 
Angiotensin-converting-enzyme inhibitor/ 
angiotensin-II receptor blockers, n (%) 
304 (74.3) 106 (75.2) 0.93 
Calcium antagonists, n (%) 82 (20.0) 24 (17.0) 0.51 
Antiarrhythmics, n (%) 44 (10.8) 17 (12.1) 0.79 
Digoxin, n (%) 84 (20.5) 27 (19.1) 0.82 
Statins, n (%) 210 (51.3) 74 (52.5) 0.89 
Hypertension, n (%) 292 (71.4) 101 (71.6) 1.00 
Dyslipidaemia, n (%) 194 (47.4) 77 (54.6) 0.17 
History of angina, n (%) 119 (29.1) 55 (39.0) 0.04 
History of atrial fibrillation, n (%) 203 (49.6) 75 (53.2) 0.53 
Arrhythmia, n (%) 68 (16.6) 26 (18.4) 0.72 
Cardiomyopathy, n (%) 153 (37.4) 48 (34.0) 0.54 
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Dilated cardiomyopathy, n (%) 115 (28.1) 38 (27.0) 0.88 
Hypertrophic cardiomyopathy, n (%) 25 (6.1) 8 (5.7) 1.00 
Restrictive cardiomyopathy, n (%) 13 (3.2) 2 (1.4) 0.38 
Deep vein thrombosis, n (%) 20 (4.9) 5 (3.5) 0.67 
Angioplasty, n (%) 78 (19.1) 33 (23.4) 0.33 
Myocardial infarction, n (%) 178 (43.5) 52 (36.9) 0.20 
Cerebrovascular disease, n (%) 93 (22.7) 31 (22.0) 0.95 
Renal disease, n (%) 106 (25.9) 31 (22.0) 0.41 
Valvular disease, n (%) 152 (37.2) 51 (36.2) 0.91 
Cardiac catheterisation, n (%) 53 (13.0) 19 (13.5) 0.99 
Diabetes mellitus, n (%) 166 (40.6) 53 (37.6) 0.60 
Chronic obstructive pulmonary disease, n (%) 167 (40.8) 61 (43.3) 0.69 
NYHA class, n (%) 
  
<0.01 
1 78 (19.1) 36 (25.5) 
 
2 111 (27.1) 49 (34.8) 
 
3 142 (34.7) 48 (34.0) 
 
4 78 (19.1) 8 (5.7) 
 
NHYA class 3 and 4, n (%) 220 (53.8) 56 (39.7) 0.01 
Active change in management after follow-up 
TTE (%) 
_ 30 (21.3) _ 
 
Abbreviations: TTE: transthoracic echocardiography; p: p value (significant values <0.05); 
IQR: Inter quartile range; mmHg: millimeters of mercury; µ/L: micromoles per litre; NYHA: 
New York Heart Association heart failure classification. 
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In general, patients with “inappropriate” tests were younger, had more favourable levels of 
creatinine, had worse ejection fraction and less history of hypertension, dyslipidaemia, and 
angina. No differences were found in clinical status, risk of death and HF readmission or 
mortality.  
The “uncertain” test group was similar to the “appropriate” test group except in history of 
cardiovascular disease, which was higher in the “appropriate” test group. No differences were 
found in proportion of outcomes between these groups.  
Event free survival analysis.  
The median follow-up time was 1.02 years (range 0.003, 6.48) and the median time for follow-
up TTE was 0.57 years (range 0.01, 5.00). There was a statistically significant difference 
between the proportions of patients with HF readmission between the groups (Table 6- 2). 
There were no significant differences in mortality between groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. Impact of Appropriate Use Criteria on Survival 
 
133 
 
Table 6- 2  Outcomes in no follow-up TTE and follow-up TTE groups (Inappropriate, 
“uncertain” and “appropriate” groups). 
  HF readmission, n 
(%) 
Death, n (%) HF/death, n 
(%) 
TTE 28 (19.9) 63 (44.7) 91 (64.5) 
No TTE 166 (40.6) 170 (41.6) 336 (82.2) 
p (TTE vs none) <0.01 0.58 <0.01 
Inappropriate 10 (24.4) 17 (41.5) 27 (65.9) 
Uncertain 1 (5.3) 8 (42.1) 9 (47.4) 
Appropriate 17 (21.0) 38 (46.9) 55 (67.9) 
p (all groups) <0.01 0.85 <0.01 
p (inappropriate, uncertain 
and appropriate groups) 
0.21 0.82 0.24 
p (inappropriate and 
uncertain groups) 
0.15 1 0.28 
p (inappropriate and 
appropriate groups) 
0.84 0.71 0.98 
p (uncertain and appropriate 
groups)  
0.18 0.9 0.16 
 
Abbreviations: HF=heart failure, TTE=transthoracic echocardiography. 
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Figure 6- 2 shows the survival function for HF readmission and death as combined outcome in 
each of the TTE groups. The estimated median survival time was 1.10 years [95%CI: 0.69, 
1.49] for the no TTE group, 2.61 years [95% CI: 1.08, 3.04] for the “inappropriate” test group, 
2.45 years [95% CI: 1.37, 5.78] for the “uncertain” test group, and 0.09 years [95% CI: 0.02, 
1.80] for the “appropriate” test group (log rank test 23.1, p<0.001 between all groups; log rank 
test 3.7, p=0.16 between “inappropriate”, “uncertain” and “appropriate” test groups, and log 
rank test 3.5, p=0.06 for “inappropriate” and “uncertain” groups).  
 
Figure 6- 2 Survival function for HF readmission and mortality as combined outcome in 
patients with HF after discharge from first HF admission. 
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Estimations of the average effect of risk factors on the overall survival (HF readmission and 
death as composite outcome) are shown inTable 6- 3. In the univariable hazards models, the 
event rate among older people, people with higher MAGGIC score (therefore higher risk of 
death), myocardial infarction, renal disease and NYHA class 3 and 4 was higher than people 
without these features. People with higher body mass index had a lower event rate than people 
with lower BMI (Table 6- 3).  
Although there was a possible increase in the risk of having HF readmission or death in the 
“appropriate” TTE group (HR 1.50 [95% CI: 0.95, 2.39], p=0.08) compared to the 
“inappropriate” group and a similar trend in the “uncertain” group (HR 1.36 [95% CI: 0.63, 
2.94], p=0.43) vs the “inappropriate” group, there were no significant differences between 
groups compared to “inappropriate” tests group as the reference.  
The results for the adjusted model show HF readmission to be associated with renal disease 
and higher HF classification (Table 6- 3). Interestingly there were no differences between TTE 
groups. Routine follow-up TTE time (<1 year and ≥1 year, or “inappropriate” and “uncertain” 
respectively), did not show differences in outcome between both groups.  
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Table 6- 3 Estimations of the average effect of risk factors on the overall survival (combined 
endpoint) 
  Univariable Cox Model Multivariable Cox 
Model 
  HR (95% CI) p HR (95% CI) p 
Inappropriate Ref _ Ref _ 
Uncertain 1.36 (0.63 - 2.94) 0.43 1.33 (0.61 - 2.86) 0.47 
Appropriate 1.50 (0.95 - 2.39) 0.08 1.56 (0.98 - 2.48) 0.06 
No TTE 0.93 (0.62 - 1.39) 0.72 0.92 (0.62 - 1.38) 0.70 
Age 1.02 (1.01 - 1.02) <0.01 
  
Gender male 1.16 (0.96 - 1.40) 0.14 
  
Body mass index 0.98 (0.96 - 1.00) 0.01 
  
Systolic blood pressure in mmHG 1.00 (0.99 - 1.00) 0.10 
  
Creatinine levels in µ/L 1.00 (1.00 - 1.00) 0.07 
  
Left ventricular ejection 
fraction % 
0.87 (0.44 - 1.70) 0.68 
  
MAGGIC score 1.06 (1.04 - 1.07) <0.01 
  
Risk of death 1 year 20.65 (9.66 - 
44.16) 
<0.01 
  
Risk of death 3 years 6.98 (4.19 - 
11.62) 
<0.01 
  
Betablockers use 0.84 (0.70 - 1.02) 0.08 
  
Diuretics use 0.96 (0.71 - 1.30) 0.81 
  
Mineralocorticoids 1.09 (0.89 - 1.33) 0.42 
  
Angiotensin-converting-enzyme 
inhibitor/ angiotensin-II receptor 
blockers 
0.82 (0.67 - 1.02) 0.08 
  
Calcium antagonists 0.94 (0.74 - 1.19) 0.59 
  
Antiarrhythmics 1.09 (0.81 - 1.47) 0.57 
  
Digoxin 1.01 (0.80 - 1.28) 0.91 
  
Statins 1.03 (0.85 - 1.24) 0.77 
  
Hypertension 1.05 (0.85 - 1.29) 0.66 
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Dyslipidaemia 1.09 (0.90 - 1.31) 0.40 
  
History of angina 0.96 (0.78 - 1.18) 0.68 
  
History of atrial fibrillation 1.09 (0.90 - 1.32) 0.37 
  
Arrhythmia 1.04 (0.81 - 1.32) 0.78 
  
Cardiomyopathy 0.99 (0.81 - 1.21) 0.92 
  
Dilated cardiomyopathy 0.96 (0.78 - 1.19) 0.72 
  
Hypertrophic cardiomyopathy 1.13 (0.77 - 1.65) 0.54 
  
Restrictive cardiomyopathy 0.94 (0.52 - 1.71) 0.84 
  
Deep vein thrombosis 1.19 (0.75 - 1.88) 0.47 
  
Angioplasty 0.87 (0.68 - 1.11) 0.27 
  
Myocardial infarction 1.27 (1.05 - 1.54) 0.02 
  
Cerebrovascular disease 1.10 (0.88 - 1.38) 0.38 
  
Renal disease 1.45 (1.17 - 1.80) <0.01 1.47 (1.18 - 1.82) <0.01 
Valvular disease 1.19 (0.98 - 1.45) 0.08 
  
Cardiac catheterisation 0.98 (0.73 - 1.31) 0.88 
  
Diabetes mellitus 0.90 (0.74 - 1.09) 0.28 
  
Chronic obstructive pulmonary 
disease 
1.11 (0.92 - 1.35) 0.27 
  
NHYA class 3 and 4 1.62 (1.33 - 1.96) <0.01 1.69 (1.40 - 2.06) <0.01 
Active change in management 
after follow-up TTE  
0.79 (0.54 - 1.17) 0.24 
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Analysis of heart failure readmission in the presence of mortality as the competing event.  
The univariable and multivariable subdistribution hazard ratios of risk factors are shown 
inTable 6- 4, with timing of routine follow-up TTE shown as a time-dependent variable. The 
univariable model showed no statistical differences in the risk of HF readmission between the 
different TTE groups in the presence of death as a competing risk. The MAGGIC score, history 
of renal disease, coronary disease (as evidenced by use of statins, and cardiac catheterization), 
lower ejection fraction and NYHA class 3 and 4, were all associated with HF readmission.  
The use of statins, history of renal disease, cardiac catheterization and higher NYHA class were 
the independent predictors of HF readmission (Table 6- 4). Interestingly, there were no 
differences between TTE groups. No statistically significant differences were found between 
TTE groups for death as the endpoint in the presence as HF readmission as the competing event 
(Table 6- 4).  
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Table 6- 4 Competing risk models for HF readmission in the presence of death as the competing event (univariable/multivariable HF), and for 
death in the presence of HF readmission as the competing risk (univariable/multivariable mortality).   
Heart Failure Mortality 
 Univariate 
 
Multivariate 
 
Univariate 
 
Multivariate 
 
 HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Inappropriate Ref _ Ref _ Ref _ Ref _ 
Uncertain 0.20 (0.03 - 1.46) 0.11 0.17 (0.02 - 1.25) 0.08 0.92 (0.44 - 1.91) 0.83 0.84 (0.43 - 1.67) 0.62 
Appropriate 0.85 (0.40 - 1.77) 0.66 0.71 (0.33 - 1.51) 0.37 1.13 (0.66 - 1.92) 0.66 1.20 (0.70 - 2.09) 0.51 
No TTE 1.65 (0.90 – 3.00) 0.10 1.43 (0.77 - 2.63) 0.26 1.01 (0.63 - 1.60) 0.97 0.87 (0.53 - 1.42) 0.58 
Age 1.00 (0.99 - 1.01) 0.92 
  
1.03 (1.01 - 1.04) <0.01 1.02 (1.01 - 1.04) <0.01 
Gender male 1.20 (0.90 - 1.59) 0.22 
  
1.05 (0.81 - 1.36) 0.71 
  
Body mass index 1.00 (0.98 - 1.02) 0.85 
  
0.97 (0.94 - 0.99) <0.01 
  
Systolic blood pressure in 
mmHG 
0.99 (0.99 – 1.00) 0.08 
  
1.00 (0.99 - 1.01) 0.94 
  
Creatinine levels in µ/L _ _ 
  
1.00 (1.00 – 1.00) 0.15 
  
Left ventricular ejection 
fraction % 
0.35 (0.13 - 0.96) 0.04 
  
2.58 (1.04 - 6.41) 0.04 
  
MAGGIC score 1.02 (1.00 - 1.04) 0.03 
  
1.06 (1.04 - 1.08) <0.01 
  
Risk of death 1 year 3.54 (1.16 - 10.8) 0.03 
  
18.60 (6.47 - 53.60) <0.01 
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Risk of death 3 years 2.31 (1.12 - 4.78) 0.02 
  
7.60 (3.79 - 15.20) <0.01 
  
Betablockers use 1.05 (0.79 - 1.40) 0.73 
  
0.68 (0.53 - 0.88) <0.01 
  
Diuretics use 1.71 (0.99 - 2.96) 0.05 
  
0.66 (0.46 - 0.95) 0.02 
  
Mineralocorticoids 1.14 (0.85 - 1.53) 0.39 
  
0.97 (0.74 - 1.27) 0.81 
  
Angiotensin-converting-
enzyme inhibitor/ 
angiotensin-II receptor 
blockers 
1.21 (0.86 - 1.70) 0.28 
  
0.66 (0.50 - 0.86) <0.01 0.68 (0.52 - 0.89) <0.01 
Calcium-antagonists 1.27 (0.91 - 1.77) 0.16 
  
0.81 (0.58 - 1.12) 0.20 
  
Antiarrhythmics 1.00 (0.63 - 1.57) 0.99 
  
1.18 (0.81 - 1.73) 0.39 
  
Digoxin 1.10 (0.79 - 1.55) 0.57 
  
0.97 (0.71 - 1.33) 0.87 
  
Statins 1.50 (1.12 – 2.00) 0.01 1.41 (1.04 - 1.90) 0.03 0.67 (0.52 - 0.87) <0.01 
  
Hypertension 1.16 (0.84 - 1.61) 0.36 
  
0.92 (0.70 - 1.21) 0.55 
  
Dyslipidemia 1.27 (0.96 - 1.68) 0.10 
  
0.85 (0.66 - 1.09) 0.20 
  
History of angina 1.17 (0.88 - 1.56) 0.29 
  
0.71 (0.53 - 0.94) 0.02 0.62 (0.46 - 0.83) <0.01 
History of atrial fibrillation 0.99 (0.75 - 1.32) 0.97 
  
1.17 (0.90 - 1.5) 0.24 
  
Arrhythmia 0.77 (0.51 - 1.14) 0.19 
  
1.36 (1.01 - 1.82) 0.04 1.46 (1.07 - 1.98) 0.02 
Cardiomyopathy 1.05 (0.79 - 1.41) 0.73 
  
1.00 (0.77 - 1.29) 0.99 
  
Dilated cardiomyopathy 1.16 (0.85 - 1.58) 0.36 
  
0.87 (0.66 - 1.15) 0.33 
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Hypertrophic 
cardiomyopathy 
0.71 (0.37 - 1.39) 0.32 
  
1.50 (0.94 - 2.38) 0.09 
  
Restrictive cardiomyopathy 1.00 (0.43 - 2.29) 0.99 
  
1.07 (0.47 - 2.41) 0.88 
  
Deep vein thrombosis 0.94 (0.47 - 1.90) 0.87 
  
1.23 (0.64 - 2.36) 0.53 
  
Angioplasty 0.99 (0.7 0- 1.39) 0.94 
  
0.74 (0.53 - 1.05) 0.09 
  
Myocardial infarction 1.23 (0.93 - 1.63) 0.15 
  
1.07 (0.82 - 1.38) 0.63 1.35 (1.02 - 1.79) 0.04 
Cerebrovascular disease 0.96 (0.68 - 1.36) 0.83 
  
1.24 (0.93 - 1.65) 0.15 
  
Renal disease 1.82 (1.35 - 2.44) <0.01 1.76 (1.31 - 2.37) <0.01 0.88 (0.65 - 1.20) 0.42 
  
Valvular disease 1.32 (0.99 - 1.75) 0.06 
  
1.01 (0.78 - 1.31) 0.93 
  
Cardiac catheterisation 1.75 (1.23 - 2.50) <0.01 1.68 (1.18 - 2.41) <0.01 0.39 (0.22 - 0.67) <0.01 0.40 (0.23 - 0.71) <0.01 
Diabetes mellitus 1.04 (0.78 - 1.38) 0.79 
  
0.84 (0.65 - 1.09) 0.20 
  
Chronic obstructive 
pulmonary disease 
1.07 (0.81 - 1.42) 0.65 
  
1.10 (0.85 - 1.42) 0.46 
  
NHYA class 3 and 4 1.34 (1.01 - 1.77) 0.04 1.42 (1.06 - 1.90) 0.02 1.51 (1.17 - 1.95) <0.01 1.34 (1.04 - 1.74) 0.02 
Active change in 
management after follow-up 
TTE  
0.81 (0.50 - 1.31) 0.39 
  
0.80 (0.43 - 1.50) 0.49 
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Cumulative incidence function for HF readmission and mortality.   
Cumulative incidence curves for HF readmission and mortality for all TTE groups are shown 
in Figure 6- 3. The curves for HF readmission (p<0.01) but not mortality (p=0.61) showed 
differences between groups.   
 
Figure 6- 3 Cumulative incidence curves for HF readmission and death between TTE groups 
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Impact of change in management after follow-up TTE.  
Table 6- 5 shows the competing risk regression for TTE groups and its active change in 
management derived.  No statistically significant differences were found between groups of 
TTE on HF readmission or mortality neither a statistically significant impact of active change 
in management (HR for readmission after change in management in the presence of death as 
the competing event: 1.17 (95% CI: 0.5, 2.75), p=0.72) (Table 6- 5).  
 
 
Table 6- 5 Impact of active change in management after TTE on HF readmission in the presence 
of death as the competing event  
 Multivariable HF 
readmission 
Multivariable mortality 
 HR (95% CI) p HR (95% CI) p 
Inappropriate Ref _ Ref _ 
Uncertain 0.20 (0.03 - 1.44) 0.11 0.86 (0.39 - 1.89) 0.71 
Appropriate 0.82 (0.38 - 1.78) 0.61 1.00 (0.62 - 1.98) 0.74 
Active change in management 1.17 (0.50 - 2.75) 0.72 0.70 (0.37 - 1.32) 0.27 
 
 
 
Discussion 
To our knowledge, this is the first study that analyses survival time and HF readmission time 
of “appropriate”, “inappropriate” and “uncertain” TTE in HF patients and makes a comparison 
between those tests, to understand the association of AUC status and outcome.  
The results of this study support the perception that “inappropriate” tests (routine follow-up 
TTE <1 year) do not provide value to the time of survival or event-free time, even in the 
presence of active change in management. Moreover, these results also suggest that routine 
follow-up of stable HF patients after >1 year (“uncertain” tests) does not improve the composite 
of survival and HF readmission time, compared with follow-up <1 year (“inappropriate”). Even 
when HF readmission time is analysed in the presence of death as a competing risk, the timing 
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of routine follow-up TTE did not influence the outcome. The use of echocardiography 
according to the time expressed by the AUC, did not impact time to readmission and death.  
Transthoracic echocardiography in Heart Failure. 
TTE is relevant in evaluating patients with HF to clarify prognosis, evolution of disease and to 
determine optimal medical therapy 162. The AUC propose that follow-up TTE in stable patients 
with HF after an interval of <1 year is inappropriate, but the expert panel could not reach a 
consensus in the setting of follow-up for >1 year. Interestingly, although previous evidence 
shows that TTE improves outcomes in HF patients (compared to no use of TTE), our results 
do not show an impact of echocardiography on free-event time or survival time. The results of 
the present study suggest that, although there is an increase in risk of HF readmission when 
there is no routine follow-up TTE, the routine evaluation with TTE in stable HF patients does 
not have a specific impact in risk of death or time to death.  
AUC and change in management.  
One of the most important roles of cardiac imaging is to guide practitioners and specialists to 
improve health outcomes. This aim is achieved by choosing the correct treatment for the patient. 
A change in management after a follow-up TTE should be the result of a detailed analysis of 
the patient’s situation and should seek to improve pre-existing conditions. Recent data 
regarding downstream testing have challenged the concept of “inappropriateness” by 
contextualising it in relation to clinical impact 35. These analyses, which showed that “rarely 
appropriate” tests may impact the management of patients, are confirmed by our study, 
showing that 24% of “rarely appropriate” TTE led to an active change in management. 
However, changes in patient management were not associated with a tangible improvement in 
survival time.  Nonetheless, it is hard to measure the clinical impact of an echocardiogram; 
medical decisions are complex, and other variables readily confound the effects attributable to 
imaging.  
The need of “rarely appropriate” testing.  
Although the AUC have been used for several years and the appropriateness of cardiac imaging 
has been a major budgetary issue 163, 164, the rate of “inappropriate” testing has not reached zero 
6, 35, 165. Although various strategies have been used to decrease the ‘rarely appropriate’ 
(“inappropriate”) tests, such as educational campaigns, feedback, audits, point of order 
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software and decision supports and radiology benefit managers, the results have not been 
uniform 99, 120, 166, 167.  
The presence of “inappropriate” tests in different hospitals, communities and environments, 
raise the prospect of some value in these tests 35, 59, 75. The concept of “inappropriateness” 
subjectively used by the AUC determines that such tests are a waste of resources that put the 
patients in more risk than benefit, as these patients are likely to have less pathology than those 
who have “appropriate” TTEs. The results of this study add another perspective: although it 
has previously been proven that “inappropriate” tests have led to a change in management, we 
cannot separate the close relationship between change in management and improvement in 
survival and event-free time. More research should be done to understand the change in 
management in a stable HF patient after an “inappropriate” test with no impact in survival.  
Limitations.  
These analyses have inherent limitations. First, there may be been situations where patients 
attended other institutions which are not part of the information system used by our hospital 
system. However, it is uncommon for patients to move between public and private systems 
from one admission to the next.  
Second, although “inappropriate” tests led to a change in management, our study did not 
evaluate other factors such as improvement in quality of life that could be the drivers of the 
change of treatment after testing. Nonetheless, our study found that the change in treatment for 
stable HF after “inappropriate” or “uncertain” testing did not have an impact in survival time 
or free-event time between groups.  
Third, the role of type B natriuretic peptide in guiding therapy is controversial, and this assay 
was performed mainly in symptomatic patients. Statistical methods for dealing with missing 
BNP data were not performed because these were not missing at random. Nonetheless, various 
biomarker approaches for assessment of volume status – including bioimpedance vector 
analysis 168 - may offer an important adjunct or alternative to echocardiography.  
Finally, a multidisciplinary approach is clearly critical in the management of patients with heart 
failure 169. However, to the extent that surveillance echocardiography is used in making 
judgments about HF management, the evidence here suggests that this has limited benefit.  
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Conclusion  
Among patients with stable heart failure who underwent routine follow-up TTE, the timing of 
this test (or indeed its performance) did not influence survival or HF readmission time. These 
findings suggest that the distinction of appropriateness of routine repeat TTE in stable HF, 
based on the timing of testing after index admission, appears unjustified.
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Chapter 7. Understanding Cardiac Imaging Decision-Making: Appropriate Use 
Determinants 
 
Preface 
The previous chapters have demonstrated a need to improve the appropriate use of imaging in 
Australia in order to impact health costs and patient care.  
In consideration of using the AUC in Australia in support of the above, inconsistencies between 
guidelines and criteria have been identified, as well as the limited impact that the introduction 
of AUC has had on ordering behaviour and health outcomes. 
To better understand why behaviours and outcomes have not been affected following the 
publication of AUC, the following study was completed in an attempt to determine a 
relationship between appropriate use and decision-making. 
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Abstract 
Background: The Appropriateness Criteria (AUC) for Echocardiography were designed to 
facilitate doctors’ decision-making, to reduce variability, and to achieve appropriate use. 
However, there is little evidence that the AUC have had a sustained impact on clinician’s 
ordering behaviour. This study explores the professional, systemic, policy and patient-related 
factors that contribute to current echocardiography ordering behaviour, with a focus on the 
appropriate use of echocardiography. 
Methods: Semi-structured face-to-face interviews with cardiologists and non-cardiologists 
who had requested echocardiograms at a tertiary hospital were conducted. The interview guide 
included hypothetical clinical scenarios to better understand doctors’ decision-making in 
ordering echocardiograms and the actions they could take when receiving test reports. The 
methods of analysis were a combination of thematic and discourse analysis.  
Results: 17 clinicians were interviewed, 10 of them were cardiologists. The primary reason for 
requesting an echocardiogram was a medical reason. However, other factors influenced 
decisions. Three main categories emerged from the interviews: personal factors, systemic 
factors, and follow-up of guidelines and protocols. Personal factors included training 
experience, attitude towards workload, the perception of risks, relationship with colleagues, 
patients’ expectations, and management of uncertainty. Systemic factors involved the 
availability of services and patients’ information.  
Conclusion: The idea of appropriate use is a subjective concept, which is related to the need 
of performing a test which is hard to capture in AUC. This difference in concepts plus the 
variety of factors that influence decision-making makes the AUC ill-equipped to achieve 
appropriate use of echocardiography. The drivers of inappropriate testing are not entirely 
controlled by AUC. 
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Introduction 
In Australia, data have shown a consistent increase in the use of echocardiography during the 
last decade. The marked geographical differences in its use support the perception that the 
utilisation of cardiac imaging is not necessarily illness-related and its use should be framed 
under the premises of the appropriate use 4. In the United States of America, cardiovascular 
imaging procedures are commonly listed within the first 200 Medicare expenditures, 
echocardiography being the most used cardiac imaging test 18.  
Guidelines for the use of cardiac ultrasound, including the Appropriate Use Criteria (AUC) for 
Echocardiography, have been developed to help clinicians to achieve proper use to control 
overuse of imaging services and to improve patient care 26, 65. Despite the AUC, it has been 
estimated that 5 to 25% of cardiac imaging examinations are still being performed for 
“inappropriate” indications 6, 170.  
There have been several strategies in the USA promoting and enforcing the systemic use of the 
Appropriate Use Criteria to effect a decrease in the percentage of “inappropriate” tests 120-122, 
170-173. Such approaches include educational interventions, clinician audit and feedback, use of 
radiology benefits management companies and pre-authorisation processes, and use of 
software at the point of request 99, 120-122, 170-173. However, the impact that those interventions 
have had on clinicians’ ordering behaviour to adhere to the Appropriate Use Criteria has been 
questioned. Although there has been a decline in cardiac imaging in the USA in the last decade, 
it has not applied to all imaging techniques 25, 67 . Moreover, studies suggest that there has been 
limited impact on the improvement of resource utilisation and appropriateness over time 6, 121.  
To address the issues associated with decisions around the appropriate use of echocardiography, 
it is, therefore, necessary to examine the factors that lead a doctor to choose when to perform 
a cardiac test and most importantly, to explore the aspects that influence doctors to order an 
echocardiogram that is “inappropriate”. Because requesting echocardiograms is not exclusive 
to cardiologists 6, 174, the need for addressing those factors in other specialities is mandatory.  
This chapter is a qualitative study aimed at understanding reasons for ordering imaging tests 
and factors contributing to doctors (cardiologists and non-cardiologists), prescribing 
inappropriate echocardiograms. The process of decision making regarding cardiac imaging, 
particularly echocardiography, is explored, including the impact of available resources, 
consideration of potential benefits, harms and other factors influencing decision making.  
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Understanding these factors may assist in the development of more effective recommendations 
and educational campaigns to reduce the incidence of, and ultimately avoid, inappropriate 
testing. 
 
Methodology 
Study design 
We conducted a qualitative research study using individual face-to-face semi-structured 
interviews that included doctors (cardiologists and non-cardiologists) who had ordered an 
echocardiogram during the past year at the Royal Hobart Hospital (RHH). The RHH is 
Tasmania’s largest hospital and primary referral centre.  The Tasmanian Ethics Committee 
approved this study. 
Participants were selected and interviewed between April and September 2016. We guided the 
interviews by a set of open-ended questions developed through literature review and expert 
consultation. Doctors were asked to provide some general information about themselves and 
the characteristics of their practice. The interview guide included hypothetical clinical 
scenarios to understand better doctors’ decision-making on ordering echocardiograms and the 
actions they could take when receiving test reports. The cases included “appropriate” and 
“inappropriate” indications according to the Appropriate Use Criteria for Echocardiography26. 
Additionally, the scenarios included a patient with an “inappropriate” echocardiogram with 
incidental findings to uncover concerns, perspectives, and actions about receiving unexpected 
abnormal results.  Interviews focused on the factors that influence the decision of clinicians to 
order an echocardiogram, including the role patient expectations play in the decision-making 
process. We also examined their awareness of Appropriate Use Criteria, how discussions about 
performing an echocardiogram were initiated with patients, and what they understood their role 
was in avoiding inappropriate requests. The process of decision making about cardiac imaging 
was explored, including the impact of available resources, consideration of potential benefits 
and harms and other factors required for decision making. Interview questions and clinical 
scenarios are provided in Appendix 6- 1 and Appendix 6- 2. 
The methods of analysis were a combination of thematic and discourse analysis175-177. The 
thematic analysis allowed the identification of common factors that shape the experience of 
healthcare professionals and their patients. Discourse analysis focused on the structural and 
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cultural factors that shape individual experiences, factors that may not always be at the 
forefront of interviewees’ awareness. 
Data collection 
Potential participants were contacted by telephone, email, and in person, and asked if they were 
interested in being involved in the study.  Cardiologists were chosen from the Cardiology 
Department and non-cardiologists from the General Medicine Department. These two 
departments originate the vast majority of echocardiogram requests at the hospital. An 
approach document describing the study and inviting them to participate in this research 
(Appendix 6- 3 and Appendix 6- 4), were sent to the clinicians (Cardiologists, Cardiac 
Surgeons, General Medicine Specialists, Pneumologists, Nephrologists, Neurologists, 
Gastroenterologists, Geriatricians, Registrars for each speciality, and Interns). For doctors who 
chose to be interviewed, a written informed consent was completed prior to the meeting 
(Appendix 6- 5).  
Physicians were interviewed in person. The interviews were designed to last between 25 and 
30 minutes. All participants gave verbal and written consent. No reward was given after the 
interviews.  
The face-to-face interviews were entirely recorded and transcribed verbatim.  
Each participant was identified by a unique numerical code (individual ID code). Recordings, 
transcriptions and interviewees details were stored electronically using the individual ID code 
for each participant. Consent forms were stored separately. All information was used and 
presented in a deidentified manner.  
Data analysis 
Thematic codes were established using two ways: a priori (found by literature review and 
interview guide) and through the reading of the transcripts. Each code was clearly defined to 
assure accuracy. One researcher (RF with less than a year in qualitative research) coded all 
interviews using Excel®. Coding was closely supervised by a qualitative researcher-author (KJ 
with more than 5 years of qualitative research). Discrepancies in coding were resolved by 
consensus.  
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Results 
General characteristics of participants 
Twenty-seven clinicians were invited to participate (Table 7- 1). Seventeen physicians (63% 
of the invitees) participated in the study and divided into two separate groups: “cardiologists” 
and “non-cardiologists”. The rate of participation was higher in the “cardiologists” group (77% 
vs. 50% in non-cardiologists).  
The “cardiology group” (or cardiologists) was formed by cardiac specialists, cardiac surgeons, 
and registrars of such specialities. Ten of the participants were included in the “cardiology 
group”. The “non-cardiologists’ group” included: physicians who were not cardiac related 
specialists or cardiac related registrars and interns. Seven of all participants were included in 
the “non-cardiology group”. These physicians were General Medicine Specialists, 
Neurologists, Geriatricians, and interns (doctors who had been practising within the first year 
after finishing medical school). In total, fifteen of the clinicians in the group were specialists 
or speciality registrars; all of them had been practising for five (or more) years since graduating 
from medical school. The other two physicians were interns. 
Table 7- 1 . Rate of response to invitation to participate in the study 
 Contacted Participated % 
Cardiologist (<5 years of medical experience) 0 0 - 
Cardiologist (5-10 years of medical experience) 6 5 83% 
Cardiologist >10 years of medical experience 7 5 71% 
Non-cardiologist <5 years of medical experience 2 2 100% 
Non-cardiologist 5-10 years fo medical experience 6 2 33% 
Non-cardiologist >10 years fo medical experience 6 3 50% 
Total 27 17 63% 
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Gender diversity was skewed towards males in the cardiology group due to there being no 
female cardiologists currently working in the hospital. Cardiologists were represented by the 
highest proportion of specialists having practiced for more than a decade (4 out of 10 vs. 2 out 
of 7 in the non-cardiology group).  
There was a marked difference in the number of echocardiography requests per month between 
groups as expected (Table 7- 2).  
Table 7- 2. Characteristics of participating clinicians (n=17) 
  Cardiologist Non-cardiologist 
n 10 7 
Age years median (range) 38 (29 – 70) 36 (26 – 41) 
Gender, Male (%) 10 (100.0) 4 (57.1) 
Years since Medical School , median (range) 10 (5 – 48) 8 (0.9 – 15) 
Cardiology patients per month (mean (sd)) 189 (128) 49 (48) 
Echocardiography requests per month, median (range) 20 (8 – 100) 
 
4 (1 – 20) 
 
Quotes 
Summative testimonials for the main themes were supported by quotations. Quotations were 
represented as “NC” or “C” if the participant was in the “Non-cardiologist” or in the 
“Cardiologist” group respectively. Identification of clinicians was avoided by dividing them 
according to their years of clinical practice: less than 5 years of clinical practice, between 5 and 
10 years of clinical practice, and more than 10 years of clinical practice. Years of experience 
as specialists was not chosen to characterise those groups because some of the interviewees 
were not specialists (registrars in speciality training or interns).  
 Clinical reasoning process and Appropriate use concept.  
All of the participants reported that the primary motive for ordering an echocardiogram was a 
medical reason, either to improve existing comorbidities or to avoid cardiac-related morbidity 
in the future. This medical reason involves not purely objective clinical assessment (i.e. 
symptoms or signs, age, body characteristics of the patient), but also factored a consideration 
of the patients’ quality of life:   
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“If you have a 90-year-old patient with dementia who’s had a stroke, where the care is going 
to be palliative, in that situation you would never order an echo as you know it’s not going to 
be useful.” (NC5, more than ten years of clinical practice). 
Towards those aims, all participants reported that an echocardiogram was a valuable test 
regardless its limitations. Despite overall positive influence that echocardiography has in their 
practice, they were aware of the impact that overuse of health services has on the health system 
and the health budget. All the interviewees agreed that an appropriate use of health services, 
and in this case, appropriate use of echocardiography, is necessary.  
When the participants defined “appropriate use”, they indicated that an “appropriate” 
echocardiogram is a test that helps them to make a diagnosis and to plan further treatment. This 
understanding was not the result of knowledge or awareness of the Appropriate Use Criteria 
for Echocardiography.  Non-cardiologists expressed that they did not know about the existence 
of the Appropriate Use Criteria for Echocardiography, and, although all cardiologists said they 
were aware of the AUC, four cardiologists acknowledged they had read the Criteria, and one 
cardiologist stated that he tries to use it in the everyday practice. The interviewees used the 
terms “useful” and “necessary” rather than “appropriate” (or “inappropriate”) when discussing 
the value of echocardiograms.  
However, the concept of “appropriateness” is a personal understanding of the conditions of the 
patient and circumstances that involves the doctor-patient encounter, that leads doctors to order 
or perform an echocardiogram. They believe that this “subjectiveness” can lead to 
misinterpretations:  
“It is easy for other people to misunderstand a test as inappropriate when retrospective 
evaluations are done; they won't have the full context of the assessment that the doctors did at 
that moment.” (C1, 5-10 years of clinical experience).  
Factors that influence clinical reasoning and echocardiography ordering.  
Coding of transcripts identified that there were three major categories of factors that influenced 
physicians for requesting “appropriate” echocardiograms: (a) “Personal” factors,  (b) 
“Systemic” factors and (c) “Guidelines and protocols” (Figure 7- 1).  
Within these three major categories, some themes emerged and were collapsed in the following 
nine themes: 
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(a) Personal factors included: 
 Training and medical experience,  
 Attitude towards workload 
 Perception of risks and harms,  
 Relationship with colleagues,  
 Patient’s expectations,  
 Management of uncertainty.  
(b) Systemic factors included  
 availability of services 
 availability of patient’s medical information 
(c) Guidelines and protocols included the follow-up of guidelines, rules and protocols.  
 
 
Figure 7- 1 Factors that influence clinical reasoning and echocardiography ordering. 
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Personal factors.  
Training and medical experience 
Doctors develop expertise, competence and medical discernment through years of practice, 
academic and practical training, and previous case experience.  
Participants commonly reported that the improvement of their skills and development of 
expertise were the most important elements leading to ordering an echocardiogram, impacting 
their rationale and rationalisation for requesting exams. Senior cardiologists indicated that 
these skills help them to understand when to perform an echocardiogram and in what sort of 
patients. Doctors with fewer years of practice noted that the time for follow-up is a challenge. 
“You develop a technique that I call ‘the pattern recognition’. You understand the natural 
cause of disease and the point in time at which you have to make a decision to do something 
different; it is based upon clinical assessment, not upon an echocardiogram” (C7, more than 
10 years of clinical practice). 
However, doctors with more years of medical practice indicated that, although they welcomed 
the improvement in echo techniques and availability of exams, differences in the training 
process of new doctors was a possible cause of overuse and “inappropriate” use of 
echocardiography: 
“There is less emphasis on clinical examination nowadays than it used to be in the past. 
Nowadays we hear murmurs, and we try to quantify their severity which leads straight to 
ordering an echo to get the actual accurate quantity of information. However, this can result 
in overuse of imaging.” (C8, more than 10 years of medical practice).   
Along with the change in the training process and the broad availability of echocardiography, 
came a challenge that doctors, particularly cardiologists, stated: a better understanding of the 
technical issues of echocardiography and the scope and limitations of the test when evaluating 
cardiac diseases: 
 “I think there is a bit of a misconception amongst non-cardiologist; They do not understand 
what information we get from an echo, they do not know that we cannot actually explain 
everything from an echo. They are always obsessed with the ejection fraction, but other 
information and findings are of concern.”(C2, 5-10 years of medical practice). 
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It is common for a junior physician to defer to a senior consultant or specialist in respect to 
ordering tests due to a lack of clinical experience. Additionally, non-cardiologists follow the 
suggestions of the cardiac specialists because they recognise the experience and specialised 
skills and knowledge.  
Attitude towards workload 
Some doctors acknowledged that the ordering behaviour can be impacted by their workload or 
mood, resulting in an increase of “unnecessary” requests: 
“Sometimes it is just laziness. If you are very busy on the ward and it is too hard to decide 
whether it is entirely necessary or not, it is just easy to get one, and if it is unnecessary, no one 
usually says anything, but if they wanted it and it is not there, then it becomes an issue.” (C4, 
5-10 years of medical practice). 
“Some days patients want tests that I feel are not necessary but I want to avoid discussions or 
I’m tired and I will order tests anyway as I can't be bothered trying to change the patient's 
expectations”. (NC3, more than 10 years of medical practice)     
Perception of risks and harms 
The doctor’s understanding about limited hazards, harms, and possible misdiagnosis does not 
impact ordering patterns for echocardiograms. Although all doctors noted the possibility of 
risks, harms, and/or misdiagnosis with transthoracic echocardiography, it was considered safe 
to perform because it does not involve radiation or invasiveness. Clinicians confirm that risks 
increase when contrast is used, but this does not impact their decisions to request tests. All of 
them stated that they usually order echocardiograms because there is a problem they want to 
solve, and therefore, some sorts of findings are “expected”. Of note is the lack of concern 
regarding the risk of malpractice when considering requesting tests in the Australian 
environment.  
Relationship with colleagues 
Cardiologist,  particularly, may request exams if peers believe it is necessary, even when their 
thoughts differ. This attitude decreases the risk of bad relationships with colleagues:   
“When I was a trainee, I used to require echoes because I received orders from superiors who 
had the medical-legal responsibility. However, being a more senior doctor,  I don’t worry 
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about ‘getting in trouble’ if I don’t order an echo, but it is just to keep the clinical process 
running smoothly.” (C1, 5-10 years of medical experience).  
 “If an experienced cardiology colleague says we should do another echo, I would not feel 
strong enough to say no. I think to myself ‘what a waste of time’, but I would not say it. You 
know, people have different views, sometimes they are wrong, but they might think ‘I am not’.” 
(C7, more than 10 years of medical practice).   
Patient’s expectations 
All doctors with more than 5 years of medical practice, stated they feel an expectation is placed 
on them by patients, that a test should be done, especially in an ambulatory setting, and believe 
that skills gained through years of clinical practice have given them the ability to manage these 
effectively. 
These physicians believe three main reasons increase the probability of patients to have 
expectations: the available information predominantly on the internet, the level of a patient’s 
private insurance cover, and the need to be referred to a cardiac specialist. Cardiologists are 
more likely to request echocardiograms in the latter scenario.  
Apart from a patient's expectation, the anxiety of some patients may lead to an 
echocardiography request. In this situation, the test is seen as a way to  assuage the patient and 
avoid new consultations in the future: 
“Patients want reassurance with a test, and I think it helps in the long run because chances 
are it will be normal, and it will help them realise that or at least reassure them that what they 
are feeling, ‘the funny pains’, are not related to pathology. It can reduce the anxiety and 
prevent representations to the hospital, helping to keep them from coming in with chest pains 
so it may be appropriate for that purpose.” (C4, 5-10 years of medical practice). 
Uncertainty 
Despite the experience that doctors gain during their years of practice,  uncertainty plays a 
significant role in the decision-making process, even in very experienced specialists:  
“I am worried if they don’t have a full assessment and I miss something that it is going on with 
their heart that is not apparent because ECGs and clinical examinations are not very 
precise.”(C9, more than 10 years of medical practice).  
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“There is a variation in how we manage uncertainty and anxiety. Some doctors manage that 
uncertainty better than others. I have seen consultants who are very anxious not understanding 
what is happening to the patient, and they request more tests.” (NC3, more than 10 years of 
medical practice) 
This management of anxiety and uncertainty may be caused by previous clinical case 
experience, and it increases the chance of “inappropriate” requests: 
“There might be a bias to a situation where they missed an important finding, when they were 
a junior doctor, so they always do scans because they are worried that something might happen 
like years ago.” (NC3, more than 10 years of medical practice) 
Systemic factors  
Availability of services 
All respondents noted that the ease of access to echocardiography can impact decisions to order 
tests. Barriers, such as distance to the point of service or requirements needed to enable patients 
to move freely also affect the ordering of tests (e.g. a patient in a wheelchair). However, the 
availability of specialised transport services can assist to address these barriers.  
In the hospital, the waiting time until the test can be conducted was an important consideration 
for non-cardiologists because of the pressure they have to discharge patients.  
Cardiologists identified that the private setting increases the likelihood of ordering 
echocardiograms because the echocardiogram is more accessible regarding waiting time and 
there are economic incentives for both, hospital/practices and specialists that report the exams.  
Availability of patient’s medical information 
One of the issues that the clinicians postulated was that the system does not readily provide 
them with all the mandatory information for a patient’s consultation; the poor availability of 
previous echocardiogram results can create the environment for duplicate examinations, even 
though the earlier test may have been done a short time prior.  
Protocols and guidelines 
Although doctors stated that guidelines and protocols are useful to standardise practice and to 
improve health outcomes, participants also reported that they usually do not follow those 
documents closely. In some cases, the use of guidelines and protocols impact the ordering of 
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echocardiography negatively; cardiologists commented that in some scenarios, the guidelines 
and health policies make them request echoes, although they consider them redundant:  
“There are situations where I’ve ordered an echo when I otherwise would not have, because 
guidelines mandated. In patients with pulmonary hypertension, you’re required to do six-
monthly echoes despite, at least in my experience, I don’t find much use of those echoes. (C1, 
5-10 years of medical practice). 
Another physician reported that “suspicion of endocarditis” leads to ordering echocardiograms 
because they need to do it before requesting a transoesophageal echocardiogram which is a 
better test for the purpose. However, they cannot order a transoesophageal echocardiogram 
without a transthoracic echocardiogram previously. 
 
Discussion 
In this study, we examined factors leading doctors to order transthoracic echocardiograms and 
their relationship with the appropriate use of echocardiography. To our knowledge, this is the 
first study that intends to elucidate the thoughts and experiences of doctors when they are 
requesting cardiac ultrasounds to better understand the decision-making process around the 
appropriate use and cardiac imaging value.  
The findings highlight how a variety of elements influence the decision of requesting 
echocardiograms in clinical practice, but most importantly, that “appropriate” use is a 
subjective evaluation targeting the judgements and choices the physician has to address in 
medical practice, rather than the result of pressures aiming to control overuse of services and 
sustainability of the heatlh system after following the criteria for appropriate use of 
echocardiography.  
During the interviews, it was initially found that all doctors believed they required cardiac 
ultrasounds “appropriately” due to medical reasons as primary causes. However, the medical 
motivation was not undoubtedly a factor for “appropriate” use of echocardiography; other 
stimuli influenced the clinicians in some circumstances, which would lead to tests that do not 
have value for them, resulting in an measurable overuse and “inappropriate” use of resources. 
This is a significant challenge to solve when the quality of life, most commonly in the elderly 
or people with multiple co-morbidities or sequelae, is assessed, or when clinicians have no 
clarity of when to re-assess the patient’s case (e.g. timing for follow-up). 
Chapter 7. Understanding Cardiac Imaging Decision-Making: Appropriate Use Determinants 
 
161 
 
One of the most remarkable findings of this study is that there is a dissimilarity between the 
concept of appropriateness within the Appropriate Use Criteria 26 and that held by doctors. For 
the Appropriate Use Criteria, the “negative consequences” of the test which include procedural 
risks, false negatives (or false positives), or misdiagnosis, are the pillar for the definition of 
“appropriate” use of transthoracic cardiac ultrasound. While the risk of undesirable 
consequences or the possibility of diagnosis errors with “inappropriate” tests were certain 
drivers for the development of the AUC 26,  the clinicians in the current investigation stated 
that, while these risks might be acknowledged, are not the primary driver for not ordering an 
examination. The concept of “appropriate use” is influenced by the “necessity” of the test, 
which is in fact, the main reason for requesting an echocardiogram to lessen the uncertainties 
that they are facing with the patient. Moreover, despite awareness about the close relationship 
between health expenditure and use of medical services, this reason was not the motive for 
“appropriate” use of echocardiography either. Economic reasons come to play a significant role 
only when the patient is not covered by health insurance or needed to pay copayments178. 
The “necessity” and “appropriateness” of a test are comparable according to the interviewed 
physicians. The most valuable, and therefore, appropriate test for them, is a test which is needed 
to make decisions or to impact in some way, the care that the patient is receiving. The most 
significant factors influencing doctors to order “valuable” and “appropriate” tests are their 
experience and medical expertise. Doctors with more years of experience, more training, or 
with particular previous medical experiences, believe that they understand the diseases and can 
better rationalise the use of health resources, including echocardiograms. This situation is 
enhanced with better understanding of the limitations of the echocardiography technique, 
which is more common among cardiologists and related specialities. However, it is critical to 
take into account that the management of uncertainty178, 179 is an independent factor, that is not 
completely mitigated with more years of experience or training. There were differences 
between management of uncertainty even within the most experienced cardiac specialists.  
Professional experience helps doctors to manage patients’ expectations. However, there are 
some situations where the patient’s expectations play a vital role in the decision of requesting 
exams. In this environment, accepting patient’s expectations, although contrary to physicians' 
desires, is not always seen as a negative factor, because it may help to improve the doctor-
patient relationship and most importantly, to impact positively patient’s treatment by 
decreasing patient’s anxiety, which usually interferes with better outcomes. In addition, 
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requesting echocardiograms to decrease patients’ anxiety, is thought to decrease the chance of 
patient re-visits to hospitals and clinics. For these physicians, reducing patients' anxiety can be 
one of the most “appropriate” echocardiography indications. Interestingly, although 
professional experience helps doctors to interact better with other clinicians and colleagues, 
requesting an echocardiogram because a colleague with similar experience, or superior, has 
requested it, it is usually not seen as “appropriate”. In this scenario, doctors order the exams to 
avoid any sort of future controversies among clinicians, but the echocardiogram is still seen as 
“inappropriate”. 
Other sorts of factors were discussed during the interviews which impact the decision to request 
echocardiograms. Easy access to an exam is an important factor. Barriers to easy access (e.g 
long waiting lists due to few echocardiography laboratories) may result in the underuse or 
constrained ordering of tests as has been described180. However, the decision-making process 
when there are barriers to test access, results in a more “appropriate” use of resources: the tests 
are requested if there is a real need. This was mainly identified among non-cardiologists whose 
work is predominantly with inpatients. Long waiting periods to perfrom echocardiograms in 
hospital were a significant consideration, because it is ideal for patients to be discharged once 
they are stabilised and the management for the outpatient setting organised. In the outpatient 
setting, these barriers can be avoided if the patient has a private insurance. Moreover to easy 
access, the private setting may lead to more testing because of the existence of some economic 
incentives (for the specialist who interprets the results or the echo laboratory), a situation that 
has been found as a cause of overtesting by other authors 178. 
However, easy access to testing when a patient has a private insurance is not the only reason 
for requesting “inappropriate” echocardiograms related to the availability of resources. Doctors 
expressed that lack of availability of previous results are an important cause of re-testing. 
Medical practices do not share the same digital record system and commonly, when tests are 
performed, the results are not immediately available. Generally, the quality of the tests is not a 
problem: doctors trust the professionals who perform echocardiograms and the physicians who 
interpret the exam. However, quality may be an issue when patients have echocardiography 
results from other echocardiography laboratories. 
Other factors such as following guidelines and protocols, encourage doctors to request tests 
which, sometimes, are not seen as appropriate because the management plan is usually 
scheduled before the results of the test. This is particularly common in patients with pulmonary 
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hypertension, who have a follow-up echocardiogram every six months to maintain eligibility 
for treatment as a part of prescribing policy, or patients with suspected endocarditis who need 
a transthoracic echocardiogram to access to a transoesophageal exam.  
How to improve appropriate use  
The subjectiveness of the concept of appropriate use among clinicians and the variety of factors 
that influence their decision-making, do not favour the use of the appropriateness criteria as 
the way to accomplish appropriate use of echocardiography. Appropriate use of cardiac 
imaging is a hard objective to achieve, which involves not only doctors but also patients and 
policy makers.  
Academic training in cardiovascular diseases and echocardiography, health economics, and 
educational campaigns in general, including feedback and audit processes, would help 
physicians to understand the natural development of diseases and to find the appropriate time 
to follow-up a patient, and therefore, to order a test when it is necessary. These approaches may 
be enhanced by the use of software at the point of request (to give information to doctors about 
the benefits and harms of performing tests), and availability of staff at the echo-laboratory 
laboratory to pick up possible inappropriate situations, including screening imaging requests. 
Moreover, patients may play a vital role in the proper use of echocardiography by actively 
interacting with the physician through shared decision-making and health literacy. These 
approaches would certainly help physicians in their management decisions, including 
management of uncertainty.  
Policy makers and governments have an important role in the appropriate use process. 
Imbalance between access to healthcare between public and private settings, financial 
incentives, and systems of payment influence directly the decision making of doctors, resulting 
in inappropriate use of resources.  Interaction between all these actors and across all levels of 
care impact the quality of care and appropriate use of resources.  
Strengths and limitations 
Although we achieved saturation, as with any other qualitative study, there are limitations with 
the present study and the results are not applicable to all medical environments. The purpose 
of this study was to investigate the challenges that doctors face when ordering tests to 
understand how to achieve appropriate use. Potential limitations of this research are its small 
size, and the restricted response to participate in the study particularly in the “non-cardiology” 
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group. Since the participants were recruited from one hospital setting, this could be considered 
a limitation in terms of transferability. However, to limit the potential weakness of the design 
of the study, the clinicians interviewed during this investigation varied in terms of clinical 
expertise and experience in the inpatient and outpatient settings, and the use of hypoteical 
clinical scenarios included inpatient and ambulatory patients, allow the understanding of more 
factors that influence professionals when requesting echocardiograms.  
To decrease the possible bias, an experienced researcher was included in the analysis of codes 
and the grouping of those into themes, and the final allocation to themes was attained by 
consensus among all investigators. 
Conclusion 
Thhis research found that the drivers of inappropriate testing are not all controlable by AUC. 
The results suggest a mistmatch between the clinical reasoning process of physicians and the 
AUC for echocardiography.     
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Chapter 8. Identification of inappropriate echocardiogram requests at the point-of-
service 
The research contained within this chapter has been published as8, 181: 
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Echocardiograms in the Echocardiography Laboratory. Journal of the American 
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 Fonseca R, Pathan F and Marwick TH. Development and validation of a screening tool 
for the identification of inappropriate transthoracic echocardiograms. BMJ Open. 
2016;6:e012702.* 
 
*Drs Fonseca and Pathan should be regarded as joint first authors.  
 
Preface 
The chapters 4 to 7 have analysed several potential issues in the adoption of the AUC in 
Australian practice. These problems include differences between guidelines and criteria, no 
clear impact on clinicians’ requesting behaviour, unjustified definition of inappropriate 
indications based on follow-up time in patients with heart failure, and some disparity between 
the clinical reasoning process of doctors and the AUC. The problems may cause limited 
acceptance of the AUC for use in Australian practice. Irrespective of these challenges, it is 
evident, as demonstrated in chapter 2, there is a need to introduce a method or methods to 
ensure appropriate use in this country, most importantly in echocardiography use.   
The majority of strategies that have been implemented in an attempt to achieve appropriate use 
of imaging overseas have primarily been focused on the restriction of labelled inappropriate 
requests at the point-of-care (or point of request). The AUC model adopted in the USA aims to 
avoid the “inappropriate” test ordering through a system of cancellation once a test has been 
identified/labelled as inappropriate. However, new studies have shown that some tests currently 
labelled as inappropriate have in fact led to a change in management due to new important 
findings35-37, 75. Additionally, the possibility exists that requesting doctors choose “appropriate” 
indications instead of the patients’ presenting problem in order to be seen as to adhere to the 
criteria (thus avoiding audits and penalties), making the development of a strategy aiming to 
determine potential inappropriate echo requests in a transparent way and avoid risks of 
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cancelling a labelled inappropriate test (due to potential of missing important cardiac findings) 
necessary. 
For these reasons, this and the following chapter aim to explore and develop strategies to 
mitigate these issues. Chapter 8 seeks to determine the characteristics of scenarios labelled as 
“inappropriate” and to compile them in an easy-to-use questionnaire at the echo laboratory 
(point of service) to identify possible inappropriate requests. In addition to this strategy, chapter 
8 gives us a safe approach in order to avoid inappropriate tests without the risk of missing 
important cardiac findings through the use of hand-held echocardiography.  
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Abstract 
Objective:  
We sought whether simple clinical markers could be used in a questionnaire for recognition of 
inappropriate (or Rarely Appropriate, RA) tests at point-of-service. Most applications of 
Appropriateness Criteria (AC) for transthoracic echocardiogram (TTE) have been at the point 
of order, but a simple means of identifying RA tests in an audit process would be of value.  
Design, setting and participants:  
The study was performed in two major hospitals in Tasmania. Two reviewers created a 
questionnaire based on 4 questions most commonly associated with RA (suspected 
endocarditis with no positive blood cultures or new murmur, lack of cardiovascular symptoms 
or no change in clinical status or cardiac exam, routine surveillance and previous TTE within 
a year) in a derivation cohort of 814 patients. This was prospectively applied to 499 TTEs to 
calculate sensitivity and specificity for prediction of RA, and validated in external group 
(n=880).  
Results:  
Of 499 prospective TTEs, the questionnaire selected 18% requests as being potentially RA. As 
7.4% were actually RA (kappa 89%), the sensitivity and specificity of the questionnaire were 
84% and 87% respectively. In the external validation cohort, the model found 11% requests 
needed to be screened for appropriateness with a sensitivity and specificity of 80% and 95%.   
Conclusion:  
A questionnaire based on 4 questions detects a high proportion of RA TTE, and could be used 
for audit. 
Strengths and limitations:  
 Four binary questions encapsulate characteristics of rarely appropriate tests according 
to the Appropriate Use criteria for Echocardiography. 
 The questionnaire, applied to the transthoracic echocardiogram requests, selected 
around 1 in 5 requests as being potentially rarely appropriate. 
 Two or more affirmative answers had a high sensitivity and specificity to discriminate 
Rarely Appropriate tests.  
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 It is a feasible tool, which can be used at the point of service to screen for inappropriate 
tests with a low impact on the workflow.  
 The use of this approach requires review of medical records to adjudicate 
appropriateness when inadequate information is provided on the request form. 
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Introduction 
Investigations constitute an important component of resource utilization and waste in medicine. 
The Appropriateness Criteria (AC) for transthoracic echocardiography (TTE) 26 have become 
widely adopted in the United States, and seek to control resource utilisation, reduce variability 
of practice, and to improve decision making and patient care 28.   
Evaluations of appropriate use have exposed potential targets for improvement.120, 182, but 
despite attempts to decrease rarely appropriate (RA) testing at the point of order, there is limited 
evidence of a decline in the number of tests, 2, 183-186 and in some cases, results are contradictory 
120, 128. AC are probably not responsible for the reduction in imaging over the last decade85; the 
trend of appropriate and RA tests has not improved during this time 6.  
This lack of clear improvement in the rate of RA tests 6 contrasts with the heightened level of 
awareness on RA test use 28, 66, 183. A recent review noted that guidelines for quality in 
cardiovascular imaging advocate implementation of appropriateness criteria, though there are 
limited effective methods to reduce the rate of inappropriate testing. They contend that part of 
the complexity of implementing appropriateness criteria may be unfamiliarity with the 
classification and the time required to review each imaging request with the guidelines187. 
Various processes have been devised to police RA requests by screening at point-of-order, for 
example, based on use of radiology benefit managers or software integrated with the ordering 
process.121, 126, 130. An alternative approach might be laboratory-based 2, but matching patient 
details against >100 AC is impractical and inefficient. In this study, we sought to determine 
whether a simple point-of-service-questionnaire (PSQ) based on the most common RA 
characteristics according to the 2011 AC for TTE 26, 59 could facilitate recognition of these tests 
in the echocardiography laboratory.  
Methods 
We sought to develop the “point of service questionnaire” (PSQ) and then perform a diagnostic 
accuracy analysis 188. The model was developed in three steps (Figure 8- 1). Eligible requests 
were selected from two separate hospitals and at the times specified in steps 1 to 3. TTE 
requests were excluded for analysis if the patient was <18 years old, or if classification was not 
possible because of insufficient clinical documentation. 
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Figure 8- 1 Design of study 
 
 
The study design pertained to appropriate selection of tests already ordered by the patient’s 
physician. We elected not to discuss the uncertainties about appropriate use with these patients. 
Nonetheless, we have discussed appropriate use with patient representatives in meetings about 
medical expenditure in Australia. Because of the co-payments associated with outpatient 
echocardiography in this country, this is perceived as a very important topic. 
Our target condition was to determine “inappropriate” (also known as “Rarely Appropriate”, 
RA) TTE requests at the point of service as adjudged by the reference standard with the 
“Appropriateness Criteria for echocardiography (AC)”26. We developed then assessed the 
index test (PSQ)-  
We compared the accuracy of our index PSQ model with the reference AC standard by 
evaluating sensitivity, specificity, positive and negative predictive value for each of the 
responses as well for each of the possible cut points: one affirmative answer vs two affirmative 
answers vs three affirmative answers. 
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Derivation of model:  
The most common causes of inappropriate tests described by the 2011 AC for TTE were 
identified from a retrospective group of 814 TTE requests, at a teaching hospital. After this 
analysis, four questions, which summarise those characteristics, were identified. The “Point of 
Service Questionnaire (PSQ)” comprised binary questions based on the characteristics of RA 
tests in our derivation cohort and also accounted for published characteristics seen in the 
choosing wisely programme 187 and published research.59.   
Internal validation:  
We then tested these questions in an internal validation cohort to ascertain their ability to 
identify RA requests as judged against the gold standard (AC code for a specific request). The 
four most common characteristics for RA tests (PSQ) were applied prospectively to all the 
requests (n= 499) for a TTE at the same tertiary referral hospital, between March and May 
2015. 
External validation:  
The PSQ was applied to a cohort of 880 requests at a regional referral hospital between May-
August 2015.  
Patient demographic information, inpatient/outpatient distribution, referring physician 
(cardiologist or not) and the indication for the study were determined from the request form. 
Investigators reviewed the digital medical record to capture any additional information, 
especially when confronted with inadequate information. The time required to access 
additional information was recorded whenever such an action was necessary and the result was 
averaged for all such requests. 
For each of the steps a general physician (RF) and a cardiologist (FP) independently recorded 
the results for each of the questions in the PSQ. Appropriateness of requests was scored by the 
same observers, independently of the PSQ evaluation, using the 2011 AC 26. Each study was 
scored as appropriate, rarely appropriate (previously described as “inappropriate”), or maybe 
appropriate (previously “uncertain”). If the main indication was not listed in the AC, 
investigators were asked to select “Not classifiable”.28. When there was disagreement, a 
consensus between reviewers was reached. If no consensus was attained, a third investigator 
(TM) reviewed the data and determined AC score. This AC score served as the “Gold Standard” 
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by which the PSQ was assessed. Where a repeat study was performed to guide management 
(e.g. repeat TTE to evaluate reverse remodelling after 3-6 months of medical therapy) despite 
2 affirmative responses this request was classified as appropriate as per the AC guidelines on 
studies, which are used to guide management. 
Sensitivity, specificity, positive likelihood ratio, and odds ratio were used to define the PSQ 
accuracy for the prediction of RA requests using R software79. The above parameters were 
analysed for each affirmative response and cumulatively. During individual analysis, a single 
affirmative response (question 1, 2, 3 or 4) was compared to “no affirmative responses”. For 
the assessment of the cumulative affirmative responses, comparison was made to both “no 
affirmative responses" and to “no or one affirmative response”.  
Inter-observer variability in the scoring process to determine level of appropriateness was 
defined using kappa statistics.  
Results 
Predictors of RA tests were sought in a group of 814 patients among whom 9% were RA. Our 
results revealed the RA requests corresponded with indications where there were no new 
symptoms or no change in clinical status or cardiac exam (indications 35, 53, 10, 8 of the AC) 
and indications for routine surveillance (indications 88,11,13,40, 28). We sought to distill the 
underlying markers of an inappropriate request using “routine studies” and the “absence of a 
change in clinical status or new symptoms” which accounted for 88% of RA requests. 
Furthermore, 28% of RA tests had a TTE within the previous year. Additionally, there was a 
specific clinical situation that accounted for the 26% of inappropriate tests (Indication 53: 
Transient fever without evidence of bactermia or new murmur). 
We identified four features associated with RA tests: evaluation in the absence of 
symptoms/signs of cardiac disease or no change in clinical status, routine surveillance, 
existence of a previous TTE within the year of the new TTE request and suspected endocarditis 
with no positive blood cultures or new murmur. (Table 8- 1) 
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Table 8- 1 . Rarely appropriate (“inappropriate”) tests found in derivation group 
AC Item Count Proportion Routine 
surveillance 
Lack of change 
in clinical 
status/Evaluation 
of symptoms 
without other 
symptoms/signs 
of cardiac 
disease 
35 Initial evaluation when there are no other 
symptoms or signs of valvular or 
structural heart disease 
25 0.36 No Yes 
53 Transient fever without evidence of 
bacteraemia or a new murmur 
18 0.26 No Yes 
10 Initial evaluation of ventricular function 
(e.g., screening) with no symptoms or 
signs of cardiovascular disease 
6 0.09 No Yes 
28 Suspected pulmonary embolism in order 
to establish diagnosis 
4 0.06 No No 
54 Transient bacteraemia with a pathogen 
not typically associated with infective 
endocarditis and/or a documented 
nonendovascular source of infection 
4 0.06 No No 
88 Routine surveillance (<1 y) of known 
cardiomyopathy without a change in 
clinical status or cardiac exam 
3 0.04 Yes Yes 
8 Light-headedness/presyncope when there 
are no other symptoms or signs of 
cardiovascular disease 
2 0.03 No Yes 
11 Routine surveillance of ventricular 
function with known CAD and no change 
in clinical status or cardiac exam 
2 0.03 Yes Yes 
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13 Routine perioperative evaluation of 
ventricular function with no symptoms or 
signs of cardiovascular disease 
2 0.03 Yes Yes 
40 Routine surveillance (<1 y) of moderate 
or severe valvular stenosis without a 
change in clinical status or cardiac exam 
2 0.03 Yes Yes 
38 Routine surveillance (<3 y) of mild 
valvular stenosis without a change in 
clinical status or cardiac exam 
1 0.01 Yes Yes 
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Based on the above, we developed a PSQ composed of four binary questions:  
Q1: Was the scan requested in the absence of new cardiovascular symptoms, or change in 
clinical status or cardiac examination?  Note that it requires symptoms to be cardiovascular 
(this would include transient ischemic attacks, strokes). Pre-existing symptoms or signs such 
as a long-standing murmur or dyspnoea, which has been evaluated and have not changed would 
score as a “yes” response. Therefore, a “yes response” (affirmative response) to question 1, 
means the patient does not have any new cardiovascular sign or symptom, or in those with pre-
existing cardiovascular illness, there has not been a worsening of their clinical status.  
Q2: Is this a routine surveillance scan? This captures tests being considered for a “periodic” 
evaluation since a certain period of time has elapsed. The test is not being ordered due to the 
anticipation of changing clinical decision making or guiding therapy.  
Q3: Has there been a previous TTE within the last year?  
Q4: Is the test requested for suspected endocarditis with no positive blood cultures or new 
murmur? 
The PSQ was applied to 501 studies in the internal validation cohort at a tertiary referral 
hospital and to 881 TTE requests at a regional hospital (external validation cohort). Two 
requests within the internal validation cohort and one request in the external validation cohort 
were not classifiable as it was not possible to collect information to answer the questionnaire. 
The final analysis was made in 499 TTE requests in the internal validation and 880 TTE 
requests in the external validation groups respectively.  
Table 8- 2 shows study characteristics and appropriateness classification by group. The internal 
and external validation cohorts are well matched. However, the former group had a lower 
proportion of outpatients.  
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Table 8- 2 Study characteristics and appropriateness classification according to groups 
  PSQ Derivation 
cohort (n=814) 
Internal 
validation 
cohort 
(n=499) 
External 
validation 
cohort 
(n=880) 
p value  
Age years (Median [IQR]) 65.00 [52.00, 
76.00] 
67 [55, 76] 70 [58, 80] <0.01 
Male, n (%) 444 (54.6) 256 (51.3) 449 (51.0) 0.96 
Outpatient, n (%) 573 (70.4) 289 (57.9) 661 (75.1) <0.01 
Referred by cardiologists, n 
(%) 
348 (42.8) 253 (50.7) 686 (78.0) <0.01 
Appropriateness score 
   
 
Appropriate, n (%) 707 (86.9) 431 (86.4) 774 (88.0) <0.01 
RA appropriate, n (%) 68 (8.4) 37 (7.4) 75 (8.5)  
May be appropriate, n (%) 13 (1.6) 18 (3.6) 7 (0.8)  
Unclassifiable, n (%) 26 (3.2) 13 (2.6) 24 (2.7)  
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The 10 most common RA indications in the internal validation group are described in Table 8- 
3. Inter-rater agreement for scoring between both reviewers was high (kappa=89%). 
 
Table 8- 3 Ten most common rarely appropriate indications in prospective internal validation 
cohort 
Indication  # Proportion 
 
88 
Routine surveillance (<1 y) of known cardiomyopathy without a change in 
clinical status or cardiac exam 
7 0.19 
 
10 
Initial evaluation of ventricular function (e.g., screening) with no 
symptoms or signs of cardiovascular disease 
5 0.14 
 
53 
Transient fever without evidence of bacteraemia or a new murmur 4 0.11 
60 Routine surveillance of known small pericardial effusion with no change 
in clinical status 
3 0.08 
 
35 
Initial evaluation when there are no other symptoms or signs of valvular or 
structural heart disease 
2 0.05 
 
 
36 
Re-evaluation in a patient without valvular disease on prior 
echocardiogram and no change in clinical status or cardiac exam 
2 0.05 
 
 
40 
Routine surveillance (<1 y) of moderate or severe valvular stenosis without 
a change in clinical status or cardiac exam 
2 0.05 
 
48 
Routine surveillance (<3 y after valve implantation) of prosthetic valve if 
no known or suspected valve dysfunction 
2 0.05 
 
74 
Routine surveillance (<1 y) of HF (systolic or diastolic) when there is no 
change in clinical status or cardiac exam 
2 0.05 
79 Routine surveillance (<1 y) of implanted device without a change in 
clinical status or cardiac exam 
2 0.05 
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When question 1 (no change in symptoms/no change in clinical status/no change in cardiac 
exam) was answered affirmatively, it had a higher OR, greater positive predictive value and 
positive likelihood ratio to pick up possible RA tests when compared independently to other 
questions. This was driven by examination of asymptomatic or stable patients (Appendix Table 
6).  
In the internal validation cohort, 18% of the tests had ≥2 affirmative answers (two “yes” 
responses). A PSQ with ≥ 2 affirmative responses had an Odds Ratio (OR) 33.96 [13.61, 84.78], 
sensitivity 0.84 [0.68, 0.94] and specificity of 0.87 [0.83, 0.90] for inappropriate requests. 
In the external validation group (n=880), ≥2 affirmative answers were 11% of total requests; it 
had a sensitivity of 80%, specificity of 95% and OR 83.01 (Table 8- 4).  
 
Table 8- 4 Diagnostic tests of the Point of Service Questionnaire for RA requests 
 
Sensitivi
ty 
Estimate 
[lower-
upper] 
Specifici
ty 
Estimate 
[lower-
upper] 
Odds ratio 
Estimate 
[lower-
upper] 
Positive 
predictiv
e value 
Estimate 
[lower-
upper] 
Negative 
predictiv
e value 
Positive 
likelihood 
ratio 
Estimate 
[lower-
upper] 
Negative 
likelihoo
d ratio 
Estimate 
[lower-
upper] 
Prospec
tive 
cohort 
0.84[0.68
,0.94] 
0.87[0.83
,0.90] 
33.96[13.6
1,84.78] 
0.34[0.24
,0.44] 
0.98[0.97
,1.00] 
6.34[4.83,8
.34] 
0.19[0.09
,0.39] 
Externa
l 
retrosp
ective 
validati
on 
cohort 
0.80[0.69
,0.88] 
0.95[0.84
,0.97] 
83.3[43.13,
159.83] 
0.62[0.51
,0.72] 
0.98[0.97
,0.99] 
17.41[12.4
6,24.32] 
0.21[0.13
,0.33] 
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The PSQ with ≥2 affirmative responses identified 84%, and 80% of the inappropriate tests in 
the internal and external validation cohorts respectively.  
Around 20% of the TTE requests provided inadequate information and it was necessary to 
check the digital medical records (Table 8- 5). 
 
Table 8- 5 Differences in time when medical record (DMR) needed to be checked. 
  Internal validation cohort External validation cohort 
  yes no yes no 
Needed DMR 95 (0.19) 404 (0.81) 168 (0.19) 712 (0.81) 
Seconds 
(median 
[IQR]) 
120 [62, 120] 18 [14, 21] 80 [63, 98] 12 [9, 20] 
 
 
Discussion: 
The approach proposed in this study has been to encapsulate the essence of the RA tests into 
four binary questions which can be used rapidly to screen for these inappropriate requests. The 
questions which we have utilised are consistent with published literature with the choosing 
wisely programme identifying “Routine studies” and “no change in signs or symptoms” as 
unnecessary repeat testing187. Similarly, other authors identified that 54% of inappropriate 
requests had a TTE within the last year59. Although only 28% of the inappropriate studies in 
the derivation cohort had a TTE within the previous year, we included this question to improve 
the strength of our model. Finally given the high prevalence of inappropriate endocarditis 
requests (26% in our derivation cohort), it was included as the final question in our model.  
The primary finding of this study is that the application of the PSQ is feasible, and it identifies 
a high proportion of inappropriate tests without the need to review all the TTE requests against 
the AC. An affirmative response to any of the questions increases the likelihood of a test being 
deemed “Rarely Appropriate”, and when two (or more) of the questions were answered 
affirmatively, the chance of determining a test as inappropriate increased more than 33 times. 
The results were consistent in the different cohorts and scenarios (inpatients/outpatients, test 
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referred by cardiologists/non-cardiologists).  We propose a PSQ based method for screening 
appropriateness (Figure 8- 2).  
Using this model less than 1/5 of TTE requests would need to be audited against the AUC 
thereby minimising interruption of work flow. Nevertheless, occasional requests such as 
asymptomatic severe mitral regurgitation surveillance within 1 years (AC indication 45 
Uncertain) or repeat echocardiography for a heart failure patient on optimal medical therapy 
without a change in signs on symptoms to guide therapy (AUC indication 73: Appropriate) 
could still be performed despite 2 affirmative responses. 
The use of radiology benefit management companies (RBM) is still an important pole in the 
process of performance of cardiac imaging although one of the aims of the AC was to reduce 
the need of those companies.189 Prior authorization and claim denials continue to be the top 
challenges of the process.190  The results of this study show that the use of the questionnaire 
provides a transparent solution, which can be implemented with minimal delay at point-of-
service, thereby minimising the need for RBMs or other middlemen.  
Several attempts have been made to improve appropriateness at the point-of-order and care, 
implementing software to control the request of inappropriate tests.45, 126, 184 However, the use 
of those tools at the point-of-order are susceptible to indication drift: for example, the real 
indication for testing may be RA but inactive problems are appropriate. Perhaps for this reason, 
the AC literature has shown little or no improvement in requesting behaviour.126, 184.  
Our proposed method could be used to facilitate appropriate use audits (simplifying to 4 
questions from >200 AUC, which is useful where these data are not available in electronic 
format), or added to the current appropriate use process at the point-of-service. At that level, 
the proposed approach provides a simple screening tool to flag possibly inappropriate tests at 
the time of scheduling. 
In our study, the prevalence of RA tests varied between 7 and 9%. These values fall on the 
lower end of the prevalence distribution of RA tests documented in various studies.6, 35, 42, 45, 49, 
59, 120  
A comprehensive plan detailing the management of inappropriate requests found at the point 
of service is lacking. At the very least, a clear and effective communication strategy needs to 
be in place to inform a discussion before a “rarely appropriate” test is scheduled.  
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This questionnaire should act as a prompt to refer to the AC rather than an absolute assessment 
of appropriateness. Education has resulted in increased awareness of the AC without a 
significant change in clinical practice.6 It is intuitive to entrust point-of-care policing regarding 
the appropriateness of an investigation to those with the greatest experience. However, such a 
policy may result in interruption of workflow, delays and a greater burden on already busy 
echocardiography units.  
Our results show that the use of 4 simple binary questions identifies RA tests with a high 
sensitivity and specificity. The questionnaire identifies potential RA requests which can then 
be confirmed by reference to the AC (Available online, in-print or as a mobile phone 
applications) or by discussing the case with a Cardiologist at the echocardiographic laboratory 
or with the referring physician.  
The use of the questionnaire may face some challenges. Firstly, the need to review medical 
records to adjudicate appropriateness when inadequate information was provided on request 
forms is a potential limitation. However, corroboration of clinical history is a common clinical 
practice in all imaging units as it is mandatory to establish the question being asked of an 
investigation and is essential to implementing a Bayesian approach to reporting. This raises a 
second issue, which is quality control of echocardiography requests. We identified 20% of 
requests as inadequate requiring further corroboration of clinical history. This result was 
similar to recently published data, which found in a review of 1303 requests that 26.2% were 
inadequate to determine adherence to AC.191 The study concluded that the top three reasons for 
inadequacy was failure to report change in clinical status or cardiac exam, date of prior 
echocardiogram and type and severity of valvular lesion. Though the last 2 would be easily 
accessible in any echocardiographic laboratory (assuming the previous studies were performed 
within that laboratory), the first failure is critical in determining appropriateness. Clearly, it 
follows that access to electronic medical records is a necessary and essential component of an 
echocardiographic laboratory’s workflow.  
Secondly, the possible difference in referral patterns between hospitals and private labs, may 
impact on the positive predictive value of our questionnaire. The Private/ Public divide varies 
tremendously across countries and to date has not been assessed in regards to compliance with 
AC. Though our criteria address the issue of awareness and simplicity perhaps, the greatest 
challenge facing an overburdened medical infrastructure is the systemic dependence of 
investigations.  
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Furthermore, although our rate of inappropriate use is lower than reported in other institutions, 
and could be seen as a limitation, we overcame this issue by performing an analysis of over 
800 requests in the derivation process. We also validated this questionnaire in over 1200 
patients (internal and external validation cohorts). 
Finally, previous researchers have sought to differentiate the appropriateness of a study from 
its clinical utility arguing a RA test does not necessarily mean a clinically useless one nor does 
an appropriate request always correspond with a useful one.35, 59 Parker Ward, demonstrated 
that 17% of inappropriate tests had “new important TTE abnormalities” and Matulevicius,  
showed that 21.7 % of Rarely Appropriate tests led to an active change in management. Thus, 
identification of inappropriate tests is a step on the path to improving quality and 
appropriateness in cardiovascular imaging; decision-making has to be informed by individual 
characteristics.  
How we handle inappropriate requests will ultimately have financial and clinical implications. 
The proportion of inappropriateness is between 7% and 23%.6, 187  Our study shows an 
inappropriate rate of 7.4% to 8.5%. Experience from elsewhere in Australia has demonstrated 
the inappropriate rate of 20%.192  In 2015, the total Medicare reimbursement for transthoracic 
echocardiography was approximately AUD$186.0 million.76 Assuming a rate of inappropriate 
echocardiography between 7% and 20%, the cost to the Australian health system of 
inappropriate transthoracic echocardiography would be between AUD$13.0 - 37.2 million. The 
healthcare costs are clearly proportionate to the use of transthoracic echocardiography and 
prevalence of appropriate use. 
A mandatory AC score (Appropriate or otherwise) or point-of-service score tied to funding 
would enhance compliance with AC and enable continuous auditing of resource utilisation. 
There are > 100 categories of appropriateness and the incremental workflow issues are 
prohibitive. We proposed an alternative approach where response to the PSQ serves as a less 
cumbersome beacon of appropriateness. 
Conclusion  
We have demonstrated that >2 affirmative answers at a simple PSQ detect a high proportion of 
RA tests. This approach can be used as a red flag for inappropriate examinations and a prompt 
to further discussion about the suitability for testing in individual patients. We propose this 
PSQ can be a quality control tool that captures the majority of inappropriate use, in the absence 
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of the infrastructure that supports AC in North America, and a simple marker for departmental 
and regional audits. 
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Figure 8- 2 Comparison between AC model and PSQ model. 
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Chapter 9. Usefulness of Hand-held echocardiography in inappropriate tests 
 
The research contained within this chapter has been published as9: 
 Pathan F, Fonseca R and Marwick TH. Usefulness of Hand-Held Ultrasonography as a 
Gatekeeper to Standard Echocardiography for "Rarely Appropriate" Echocardiography 
Requests. Am J Cardiol. 2016;118:1588-1592.* 
*Drs Pathan and Fonseca should be regarded as joint first authors. 
Preface 
The previous chapter presented a strategy to identify inappropriate requests at the point of 
service using an easy questionnaire, which can be responded to with no impact on the workflow 
of the site. The point-of-service questionnaire is a “red flag” to inappropriate tests, which, 
instead of being cancelled, should be analysed in a deeper way to determine the need of the 
test. However, the needs of clinicians leading to test orders, as exemplified in Chapter 6, in 
chapter 7, this chapter aims to determine if the use of hand-held echocardiography could help 
clinicians by providing the information they need to make informed decisions.At the same time, 
the approach could avoid the performance of inappropriate tests at the echo laboratory, 
impacting the workload of the service and expenditure.  
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Abstract 
Adoption of Appropriate Use Criteria (AUC) has not had a major impact on the frequency of 
“rarely appropriate” tests, with the rarely appropriate tests rate remaining at ~20% in most 
institutions. We sought whether access to Hand-Held Ultrasound (HHU) could be an alternative 
means of reducing “rarely appropriate” requests. We compared two approaches to rarely 
appropriate requests; “standard echocardiography” (SE) as requested (control) and Hand-Held 
Ultrasound as a gatekeeper (HHU).  
Methods and results 
Patients were followed up for 6 months and assessed for endpoints including time until scan, 
repeat echocardiography/ cost of either strategy, new major pathology and change in 
management.  The most common rarely appropriate requests in both groups were assessment 
of infective endocarditis without positive blood cultures and precordial murmur evaluation in 
absence of any other symptoms or signs of cardiovascular disease.  
 The groups had comparable age, gender, requesting physician, and inpatient vs. outpatient 
distribution. HHU led to a 59% reduction in rarely appropriate requests requiring SE. HHU 
significantly reduced time to decision for inpatients (0 [IQR: 0,1] vs 2 days [IQR: 1,4], p<0.001) 
and total cost of echocardiography ($109±86 vs $181±37, p<0.001). New major pathology was 
identified in 29% and 23% of HHU and SE respectively.  
There was no difference with respect to change in management.  
Conclusion. 
HHU can be an effective gatekeeper to SE for rarely appropriate echocardiograms, reducing 
time to echocardiography and cost while satisfying the referring physician and avoiding repeat 
requests for SE. HHU provides a safety net, which identifies potential important findings in 
rarely appropriate requests. 
Keywords: Handheld ultrasonography, Appropriate Use  
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Introduction 
The availability and safety profile of echocardiography have contributed to overutilization of 
this technique, with echocardiography being a significant contributor to the growth of Medicare 
reimbursements to cardiologists from USD 1.6 to 5.4 billion between 2000 and 2006 18. The 
Appropriate Use Criteria (AUC) and educational initiatives have been components of efforts 
to restrain inappropriate use and costly care 26, 193.  
Despite a decrease in reimbursements by 33% for echocardiography between 2006 and 2010173, 
there is limited evidence to suggest that there is a decline in the rate of inappropriate 
echocardiography 6. Indeed, interventions targeting education and the use of point of order 
applications have been applied with varying degrees of success 120, 184.  
A problem with the AUC process is that restriction of tests may be contrary to the guidelines5 
and risks missing significant pathology. Parker Ward demonstrated that 17% of inappropriate 
studies have “new important transthoracic echocardiography (TTE) abnormalities” 59; 22% of 
rarely appropriate tests resulted in an active change in management35.  
In the context of these observations, it is hard to enforce an overarching prohibition on rarely 
appropriate requests. Although previously unconnected, hand-held ultrasonography (HHU) has 
developed over a similar timeline to the AUC. Validation studies against standard TTE (SE), 
show high levels of agreement for morphology, functional and valvular assessment (kappa 0.90 
to 0.99) 194. Comparisons of HHU to physical examination have demonstrated the superiority 
of the former and its cost-effectiveness 195.  
We hypothesised that HHU could be applied as a gatekeeper to SE for rarely appropriate 
examinations and that such a strategy would: Reduce numbers of SE performed and cost, 
identify relevant pathology which would have been missed if the rarely appropriate tests were 
cancelled and facilitate decision making and patient management. 
Methods 
This was a case-control study designed to compare a Hand-Held Ultrasonography based 
approach to rarely appropriate tests to the current SE based system. It was performed across 
two hospitals and included both inpatients and outpatients. Rarely appropriate requests were 
identified using the AUC26. If the clinical history was inadequate to ascertain appropriateness, 
medical records were consulted. The process of cancelling “rarely appropriate” requests is not 
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systematic and is dependent on inpatient and outpatient waiting lists. We performed HHU on 
requests, which were destined to be cancelled.  
The study was performed between March 2015 and December 2015.  All rarely appropriate 
requests during this period were assessed for eligibility. Requests were excluded from analysis 
if deemed “appropriate” following review of medical records or if tests were mandated by 
guidelines. Requests beyond the scope of HHU were also excluded. The resulting cohort of 
HHU cases was case matched 2:1 to a cohort of rarely appropriate requests which had 
undergone SE between 2013 and 2015. 
 Eligible patients with rarely appropriate requests received a cardiology consultation and HHU 
examination performed by a cardiologist (Figure 9- 1).  
If the consult suggested the request was appropriate, then a SE was conducted and these patients 
were excluded. The study was approved by the Tasmanian Human Research Ethics Committee. 
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Figure 9- 1 Study design 
 
AUC= Appropriate Use Criteria, RA= Rarely Appropriate, SE= Standard Echocardiographic 
examination 
 
HHU was performed using the GE Vscan V1.2 handheld device (GE Health Care, Milwaukee, 
WI). The HHU study protocol involved 2D grey scale and colour Doppler images across all 
standardised echocardiographic (Figure 9- 2). Linear or area measurements were made as 
appropriate. Spectral Doppler data was not obtained as this characteristic is not available on 
the HHU. The severity of disease was approximated using 2D signs of severity (e.g. leaflet 
excursion, chamber dilatation), size, and duration of the colour jet / proximal convergence zone.  
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Figure 9- 2 Hand-held ultrasound protocol  
 
1,2) Parasternal long and short axis views including short axis sweep for left ventricular 
function and regional wall motion assessment.  
3,4,5) Apical views as illustrated and 5 chamber for aortic valve assessment.  
6) Subcostal- long axis and inferior vena cava view  
7) Aortic Arch view. Colour Doppler applied to all views.
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All HHU examinations were limited to < 10 minutes’ duration. Results of the HHU study were 
communicated to the treating team, documented in clinical notes or provided as a short report 
for outpatients.  
Eligible patients went on to have a formal SE if the HHU suggested a full study was warranted: 
Non-diagnostic HHU, Any HHU abnormality in patients without a previous echocardiogram 
and any new changes in patients with a previous examination. 
The HHU cohort was case-matched to a cohort of patients with rarely appropriate tests, who 
underwent the reference SE. The SE examination was performed on 3 machines: GE Vivid 9 
(GE Health Care, Milwaukee, WI), Phillips IE33 (Philips Medical Systems, Andover, 
Massachusetts) and Acuson SC2000 (Siemens, North Rhine-Westphalia, Germany). All SE 
were performed over 45- 60 minutes by an experienced sonographer, and interpreted by a 
cardiologist.   
Patients in both HHU and SE arms were followed up for 6 months and evaluated for the 
endpoints of: repeat TTE, the cost of care, time to scan, the length of stay (inpatients), new 
major TTE abnormality/ incidental findings and change in management. The cost of additional 
scans was incorporated into each arm.  
The cost of SE was standardised to $230 pre-examination as per the Australian Medicare 
benefits schedule91. The cost of the hand-held device is $6000 USD - assuming a depreciation 
of $750/ year and its use in 100 rarely appropriate requests per year, the cost per scan of the 
device would be $7.50 per rarely appropriate scan. We added to this the cost of storage of 
images, 15 minutes’ time for the cardiologist to perform consultation, echocardiography and 
generate a report to arrive at an estimated cost of $38 USD per scan. This approach is consistent 
with previous attempts to itemise a cost for HHU accounting for geographical variations (Table 
9- 1)194-202.  
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Table 9- 1 Cost benefit studies of hand held ultrasonography vs standard echocardiography. a 
Author Year Country Device HHU 
Cost 
Operator 
Cost 
Total HHU Cost 
(Device+Operator) 
Total StdE Cost 
Vourvouri 2003 Netherlands SonoHeart $5 $116b $121 $213 
Greaves 2005 UK OptiGo NR NR $8 $128 
Galasko 2006 UK OptiGo NR NR $65- $50 $258 
Trambaiolo 2007 Italy OptiGo $14 $26 $40 $122 
Gianstefani 2013 UK VScan $1 $33c $34 $137 
Kitada 2013 Japan VScan $2 NR $2 $88 
Khan 2014 USA VScan NR NR NR $800 
Mehta 2014 USA VScan $8 $11 $19 $1511d 
Kini 2015 USA VScan $9 $0- 23 $9- 32 $73 
Pathan 2016 Australia VScan $8 $30 $38 $173 
NR= Not Reported 
a.) All costs converted to US dollars based on conversion rate at time of publication, b.) Including Cardiology Consult, c.) £25 + 8 (Operator + 
Hospital costs), d.) $162 (Professional charge) + $1349 (Facility charge) 
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Major pathology was defined as 59: moderate or greater (left ventricular dysfunction, valvular 
regurgitation/ stenosis, pulmonary hypertension, diastolic dysfunction); a regional wall motion 
abnormality; right ventricular dysfunction and moderate or greater pericardial effusion, 
thrombus or vegetation.  
Changes in management were characterised as an active change in care including medication 
changes, subspecialty consultation, surgery or invasive procedures, diagnostic testing, change 
in the level of care, cancellation of initially planned procedure or intervention.   
Continuation of care: no escalation or de-escalation of current care, following direct 
communication about TTE results to patients and documentation by providers in the medical 
record. 
No change in care: no change in therapy or documentation of reassurance about TTE findings 
after TTE was performed, or the next step in management was already documented and the 
plan in place in place before the TTE result or results were not accessed, acknowledged or 
noted in further correspondence or discharge summaries.  
The statistical analysis was performed using R version 3.2.2 software.79 Baseline 
characteristics and outcomes were compared for the HHU and SE groups. Categorical variables 
and outcomes were compared using a chi-square test and continuous variables using the 
Student’s t-test with a p <0.05 considered statistically significant. 
Results 
A total of 872 Echocardiography request forms were audited for appropriateness. Based on the 
AUC, 93 (10.6%) requests were deemed inappropriate. Routine follow-up of pulmonary 
hypertension, which is mandated by guidelines, was responsible for 37 of these requests, which 
were then excluded. Of the remaining 56 requests, 15 were excluded due to: Inability to answer 
clinical question with HHU (3 requests), appropriate following cardiology consultation (2) and 
unable to attend an appointment for echocardiography (10). The 41 remaining cases included 
in the analysis were case matched 2:1 with a retrospective cohort. 
A total of 123 (41 HHU, 82 SE) patients in whom rarely appropriate tests were requested, were 
included in this study. There were no significant differences in the clinical or the request 
characteristics of the two groups (Table 9- 2).  
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A cardiologist was the requesting physician in 24% of the HHU and 32% of SE examinations 
(p=0.53). The remaining requests in each arm were ordered by a combination of medical and 
surgical physicians.  
“Rarely appropriate” studies for infective endocarditis, routine follow-up for heart failure and 
evaluation of a precordial murmur or ventricular function in the absence of cardiovascular signs 
and symptoms were the most common requests in both arms. 
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Table 9- 2 Patient and Request Characteristics at Baseline 
Patient Characteristics HHU (n= 
41) 
SE (n= 82) p 
Age (median [IQR]) 
(years) 
62 [52, 73] 61 [48, 72] 0.60 
Male 23 (56%) 40 (49%) 0.57 
Hypertension 21 (51%) 38 (46%) 0.75 
Diabetes mellitus 6 (15%) 11 (13%) 1.00 
Valvular heart disease  6 (15%) 15 (18%) 0.80 
Atrial fibrillation 4 (10%) 12 (15%) 0.58 
Ischemic heart disease 12 (29%) 15 (18%) 0.25 
Heart failure 7 (17%) 12 (15%) 0.93 
Lung disease 4 (10%) 14 (17%) 0.42 
Renal disease 4 (10%) 8 (10%) 1.00 
Liver disease 2 (5%) 10 (12%) 0.33 
Systemic disease 4 (10%) 8 (10%) 1.00 
    
Requested by Cardiologist 10 (24%) 26 (32%) 0.53 
Setting Ambulatory 
care/Outpatient 
20 (49%) 48 (58%) 0.41 
IQR= interquartile range, HHU= Hand held Ultrasound (Echocardiography), SE= Standard 
transthoracic echocardiography 
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Table 9- 3 outlines the result of all endpoints. The time to scan and subsequent decision for 
inpatients was significantly shorter in the HHU arm [0 vs. 2 days (p<0.001)]. There was no 
significant difference in relation to duration of inpatient stay between HHU 14 days and SE 9 
days (p=0.35). There was no significant difference between the time to scan for outpatients 
between the HHU and SE [32 vs. 35 (p= 0.54)]. 
As expected, more patients in the HHU arm, 41% required follow-up SE study, which was 
mandated due to results of HHU and our safety protocol [new major pathology (12 cases), 
minor pathology (3) and non-diagnostic HHU (2)]. In the SE arm, 11% required follow-up 
echocardiography. However, 5 of these were due to new clinically appropriate indications over 
the course of 6 months’ follow-up and these costs were not included in the SE costing 
assessment.  The mean cost of the HHU strategy was significantly less than the SE arm [$109 
vs. 181 USD (p<0.001)], resulting in a saving of $72 per study. 
During 6 months follow-up of the 123 cases (HHU and SE) 31/123 (25%) of all rarely 
appropriate requests had new major pathology. There was no significant difference (p=0.15) 
between HHU arm and the SE arm with respect to major pathology. Only 1 patient in the HHU 
arm and 0 patients in the SE arm had a documented incidental finding - a liver mass requiring 
an abdominal ultrasound. 
Of 123 requests, which were deemed “rarely appropriate”, 15% of results led to an active 
change in management using either HHU or SE. Furthermore, 64% of results led to the 
continuation of care. Thus only 21% of investigations resulted in absolutely no change in 
management. There were no significant differences between the two groups with regards to 
change in management (p=0.27).  
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Table 9- 3 Endpoints 
Endpoints HHU (n= 
41) 
SE (n= 82) p 
Time to scan days Inpatients, 
(median [IQR]) 
0 [0, 1] 2 [1, 4] <0.001 
LOS days Inpatients, (median 
[IQR]) 
14 [7, 28] 9 [5, 21] 0.35 
Time to scan days Outpatients, 
(median [IQR]) 
31 [31, 32] 35 [21, 108] 0.54 
    
Follow up SE within 6 months n 
(%) 
17 (41%) 9 (11%) <0.001 
Average cost USD, (mean (sd)) 
 
109 (86) 181 (37) <0.001 
New Major Pathology 12 (29%) 19 (23%) 0.15 
Change in management 
  
0.27 
No Change 8 (19%) 18 (22%) 
 
Continuation of Care 24 (58%) 55 (67%) 
 
Active change in management  9 (22%) 9 (11%) 0.18 
Change in Management or 
Continuation of Care 
33 (80%) 64 (78%) 0.94 
USD= US Dollar (Costs were calculated in Australian dollars and converted to US dollars. 1 
Australian dollar=0.75 USD), HHU= Hand Held Ultrasound, IQR= interquartile range, LOS= 
length of stay, sd= Standard Deviation, SE= Standard transthoracic echocardiography 
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Discussion 
The results of this study show that despite being classified as rarely appropriate, 25% of total 
requests had new major TTE abnormalities, which would have been missed if these tests were 
cancelled. The use of HHU to screen rarely appropriate echocardiography requests led to a 59% 
reduction in SE studies, without any compromise in outcomes related to management. To our 
knowledge this is the first study, which specifically provides an alternative imaging strategy to 
the performance or cancellation of rarely appropriate tests.  
The current rate of “rarely appropriate” echocardiography remains at 10-20% 6, 203. Various 
strategies have been proposed to enforce the AUC, including education, point of order software, 
and radiology benefit management 99. Ongoing rarely appropriate requests reflect the concern 
that these echocardiograms may still be clinically useful and influence management 35, 59, 204A 
HHU based approach would enable application of the AUC and reduce the performance of 
inappropriate echocardiograms while simultaneously creating a safety net to identify 
significant findings. Indeed, a HHU-backed approach to the AUC was a cost-saving strategy, 
with a saving of $72 per study. 
All inpatient referrals were non-cardiology admissions, and the longer duration of stay was 
unexpectedly higher than the expected 4 day length of stay 205.  The use of a HHU strategy in 
inpatients did not influence length of stay, reflecting the complex patient phenotype where that 
duration of stay is related to clinical factors. 
Although not specifically devoted to use of HHU in rarely appropriate tests, previous work 
supports the use of HHU in common situations associated with rarely appropriate tests. In a 
study of HHU and repeat TTE in 105 adult patients undergoing follow-up echocardiography, 
HHU showed good to excellent correlation with TTE202. In addition, a HHU protocol could 
save between $41-64 per study. Twelve percent of these patients were deemed rarely 
appropriate, but a subgroup analysis was not performed.  
Our study was not a direct comparison of HHU vs. SE, and cannot address the question of 
echocardiographic false negative scans, although the question of validation has been explored 
in great detail, including in recent studies 194, 202. A consensus statement published by the 
American Society of Echocardiography found that LV enlargement, LV hypertrophy, LV 
systolic function, LA enlargement, RV enlargement, RV systolic function, pericardial effusion 
and IVC size have all been accurately detected 206.  
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This is a case-control study; despite the patients in both arms being well matched, the lack of 
a randomised controlled trial may have resulted in potential selection bias. A randomised study 
should be considered, with head-to-head comparison of HHU with SE. From a practical 
standpoint, a cardiologist may not always be able to provide a consultation.  Finally, the 
categorization of “change in management” is a difficult task. In using the criteria proposed by 
Matulevicius et al. we recognise the limitations of relying on medical documentation and 
correspondence to differentiate between “No change in Management” and “Continuation of 
Care”.  
Conclusion 
Hand-held ultrasonography provides a safety net and cost-saving strategy that identifies 
potential important findings in inappropriate requests. 
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Chapter 10. Summary and conclusion 
 
The studies contained in this PhD thesis help us to comprehend that in Australia, the cardiac 
imaging techniques, particularly echocardiography, are not used “appropriately”. It is 
estimated that between 7% and 23% of transthoracic echocardiography requests are performed 
for “inappropriate” reasons (this estimation is only for transthoracic echocardiography, not 
other echocardiography techniques, cardiac tomography, cardiac resonance, or SPECT)6. In 
2015, Medicare reimbursed (only for transthoracic echocardiography) ~AUD$186.0 million8, 
76. Therefore, the cost to the Australian health system of inappropriate transthoracic 
echocardiography would be between AUD$13.0 and 37.2 million8. Consequently, it is 
mandatory to improve the appropriate use of cardiac imaging.  
Medical associations in the USA developed the Appropriate Use Criteria to help clinicians to 
improve appropriate use of imaging by choosing “appropriate” clinical scenarios26. Part of the 
work as this investigation was to assess if the Appropriate Use Criteria utilised by the American 
Associations were suitable to use in Australia. However, the studies included in this thesis 
indicated that the Appropriate Use Criteria would face several challenges, if used as currently 
designed, in Australia. These problems are based on the following facts found during in this 
research:  
First, the Criteria are not concordant with the cardiac guidelines, which can lead to 
misunderstandings and misinterpretations among our clinicians5. Second, the Criteria have not 
changed the physicians’ requesting behaviour over time because we did not find a decrease in 
the proportion of inappropriate tests since 20056. The third factor is that we did not find 
differences in survival time/readmission of patients with Heart Failure if doctors request 
echocardiograms following the criteria7, and lastly, the results of the qualitative research 
suggest there is a mismatch between the clinical reasoning of physicians and the AUC for 
echocardiography. 
However, it remains necessary to control the use of cardiac imaging and to decrease the amount 
of “inappropriate” testing. Because we see that the Appropriate Use Criteria would not help us 
to achieve the goal of “appropriate” use, we designed a questionnaire (4 binary (yes/no) 
questions) for utilisation in the echo laboratory, which helps us to determine a high proportion 
of possible “inappropriate” requests. Having at least two affirmative answers to the 
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questionnaire gives us a high probability of having an “inappropriate” echo request8. Instead 
of performing the expensive, time-consuming echocardiogram (which costs around AUD$250 
and needs around 45 minutes), we found that we could perform a hand-held echocardiogram 
to respond to the “inappropriate” requests9. This approach can be an effective gatekeeper to the 
standard echocardiogram for “inappropriate” tests, reducing time to echocardiography and cost 
while satisfying the referring physician and avoiding repeat requests for standard 
echocardiography9. 
The “appropriate” use of echocardiography is perhaps a hard aim to achieve. However, its 
achievement will be the result of the joint effort of clinicians, policy makers, government, and 
patients. Although this thesis does not give us all the possible solutions to this problem, it gives 
us an important tool to use at to decrease the overuse of echocardiography, answering the 
questions that our physicians need to manage their patients.  
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Appendix 
Appendix Table 1 . Population, number of doctors and burden of cardiovascular disease in Australian Medicare Locals 
Medicare 
Local 
Peer 
group 
State 
Region 
code 
Popula
tion 
2012 
Mea
n 
age 
%W
ome
n  20
12 
% 
≥65yea
rs old 
Numb
er 
Practi
tioner
s  
Non-
cardio
logists 
per 
1,000 
pop  
Cardi
ologist
s per 
100,00
0 pop 
CV 
death
s per 
1,000 
pop 
%popul
ation>18
years 
with 
Cardiov
ascular 
diseases 
% 
Peopl
e 
living 
near 
big 
cities  
%Least 
disadva
ntage 
people  
Eastern Sydney Metro 1 NSW ML101 388696 38.1 49.7 12.5 3779 9.58 13.72 1.2 16.16  99.9 66.2 
Inner West 
Sydney 
Metro 1 NSW ML102 590233 37.6 50.0 11.9 2860 4.75 9.37 1.4 19.1 100.0 44.3 
South Eastern 
Sydney 
Metro 2 NSW ML103 469806 39.1 50.7 15.1 1646 3.45 4.78 2.1 22.6 100.0 51.3 
South Western 
Sydney 
Metro 3 NSW ML104 887950 36.4 50.4 11.9 2499 2.78 3.36 1.7 16.0 100.0 21.3 
Western 
Sydney 
Metro 3 NSW ML105 862669 35.6 49.8 10.7 3299 3.77 5.37 1.2 21.1 100.0 40.0 
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Nepean - Blue 
Mountains 
Regional 1 NSW ML106 351262 37.3 50.3 12.3 1085 3.05 3.20 1.6 27.8 99.8 38.8 
Northern 
Sydney 
Metro 1 NSW ML107 404957 39.3 51.2 15.5 1725 4.21 4.81 2.2 12.4 100.0 83.9 
Sydney North 
Shore and 
Beaches 
Metro 1 NSW ML108 459529 39.1 51.1 14.7 2516 5.4 7.20 2.7 18.5 100.0 88.9 
Central Coast 
NSW 
Regional 1 NSW ML109 325295 40.8 51.4 19.2 1028 3.13 2.83 3.1 27.8 100.0 28.8 
Illawarra - 
Shoalhaven 
Regional 1 NSW ML110 387558 40.4 50.2 18.2 1140 2.91 2.92 2.8 26.1 99.9 28.5 
Hunter Regional 1 NSW ML111 701695 40.1 50.2 17.6 2526 3.56 3.66 2.5 26.7 98.6 27.2 
North Coast 
NSW 
Regional 2 NSW ML113 497721 42.6 50.9 20.7 1583 3.16 1.86 3.4 25.0 87.5 12.9 
New England Regional 2 NSW ML114 183341 39.6 50.3 17.4 440 2.40 0.00 2.9 23.2 39.8 20.6 
Western NSW Regional 2 NSW ML115 256476 39.0 49.9 16.8 685 2.67 2.00 2.5 29.9 61.3 24.3 
Murrumbidgee 
  Regional 
2 
NSW ML116 185911 38.9 49.7 16.4 437 2.35 3.28 3.7 22.5 56.4 25.5 
Southern NSW Regional 2 NSW ML117 198363 41.2 49.7 17.9 377 1.9 0.00 2.9 21.8 70.6 31.7 
Far West NSW Rural 1 NSW ML118 38530 39.8 48.9 16.9 100 2.6 0.00 2.7 27.0 0.0 5.6 
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Inner North 
West 
Melbourne 
Metro 1 VIC ML201 448879 37.2 50.7 12.1 4778 10.49 14.66 1.0 13.3 100.0 50.3 
Bayside Metro 1 VIC ML202 592709 39.5 51.1 14.9 2849 4.72 7.82 1.8 23.7 100.0 79.8 
South Western 
Melbourne 
Metro 2 VIC ML203 267603 34.6 50.0 9.1 435 1.61 1.12 3.2 21.6 100.0 36.2 
Macedon 
Ranges and 
North Western 
Melbourne 
Metro 3 VIC ML204 487218 35.9 49.9 10.5 1202 2.44 2.33 0.9 13.4 100.0 28.9 
Northern 
Melbourne 
Metro 3 VIC ML205 641238 36.8 50.6 12.2 2226 3.42 5.00 1.8 19.9 100.0 40.2 
Inner East 
Melbourne 
Metro 1 VIC ML206 624018 40.1 51.2 17.2 3073 4.84 8.14 2.1 19.7 100.0 72.7 
Eastern 
Melbourne 
Metro 2 VIC ML207 411822 38.5 50.7 13.6 915 2.2 1.47 1.9 28.2 100.0 57.1 
South Eastern 
Melbourne 
3. Metro 3 VIC ML208 492648 35.6 49.9 10.9 1019 2.05 1.25 1.4 20.6 100.0 26.4 
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Frankston - 
Mornington 
Peninsula 
Regional 1 VIC ML209 282319 40.6 51.2 18.3 879 3.08 3.29 2.6 24.2 100.0 39.7 
Barwon Regional 1 VIC ML210 280892 40 50.5 16.9 982 3.45 3.70 2.6 26.5 99.7 36.2 
Grampians Regional 2 VIC ML211 209600 40.6 50.4 17.9 540 2.54 3.46 3.0 34.9 79.0 22.1 
Great South 
Coast 
Regional 2 VIC ML212 101752 40.5 50.1 17.9 246 2.41 0.00 3.4 16.3 65.0 23.5 
Lower Murray Rural 1 VIC ML213 67141 39.3 49.9 16.5 181 2.65 4.47 2.0 28.7 0.0 11.5 
Loddon - 
Mallee - 
Murray 
Regional 2 VIC ML214 218299 40.9 50.2 18.6 569 2.57 3.33 2.9 23.9 79.7 20.1 
Goulburn 
Valley 
Regional 2 VIC ML215 150360 39.7 49.6 16.7 366 2.43 0.00 3.5 15.9 98.4 20.1 
Hume Regional 2 VIC ML216 201483 40.6 50.3 18 547 2.69 2.03 2.4 26.4 86.2 26.1 
Gippsland Regional 2 VIC ML217 262285 41.4 50.2 19.1 615 2.33 1.14 2.8 24.5 80.6 21.1 
Metro North 
Brisbane 
Metro 2 QLD ML301 907533 37.2 50.4 12.7 4962 5.37 9.52 1.9 17.5 99.9 56.4 
Greater Metro 
South Brisbane 
Metro 2 QLD ML302 932531 36.4 50.2 11.5 3625 3.84 4.41 1.8 22.8 99.4 47.2 
Gold Coast Metro 2 QLD ML303 539783 38.7 50.8 14.7 1842 3.36 5.04 1.7 20.4 100.0 39.2 
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Sunshine Coast Regional 1 QLD ML304 371780 41.2 51.1 18.6 1335 3.53 5.21 2.7 21.6 99.4 28.2 
West Moreton 
- Oxley 
Metro 3 QLD ML305 370234 35.6 49.9 11.2 769 2.07 0.83 1.4 20.0 100.0 29.5 
Darling Downs 
- South West 
Queensland 
Regional 2 QLD ML306 297513 38.5 50.3 15.9 793 2.65 1.24 2.2 20.6 70.3 23.9 
Wide Bay Regional 2 QLD ML307 208583 42.2 50.5 20.9 673 3.2 1.69 2.4 22.7 90.0 6.1 
Central 
Queensland 
Rural 1 QLD ML308 216470 36.1 48.5 11.4 593 2.72 1.71 1.2 22.0 75.9 34.2 
Central and 
North West 
Queensland 
Rural 2 QLD ML309 44865 34.2 46.9 8.8 125 2.78 0.00 1.8 _ 0.0 21.8 
Townsville - 
Mackay 
Rural 1 QLD ML310 409950 36.1 48.6 11 1414 3.41 3.57 1.7 24.2 19.8 33.5 
Far North 
Queensland 
Rural 2 QLD ML311 266286 36.9 49.5 11.9 903 3.36 2.94 1.8 18.9 0.0 23.9 
Northern 
Adelaide 
Metro 3 SA ML401 405065 37.6 50.2 13.6 976 2.4 1.03 2.0 31.1 100.0 22.6 
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Central 
Adelaide and 
Hills 
Metro 2 SA ML402 517032 40.5 51.0 16.9 3709 7.05 11.57 2.9 22.2 100.0 43.5 
Southern 
Adelaide - 
Fleurieu - 
Kangaroo 
Island 
Metro 2 SA ML403 401464 40.9 51.2 17.7 1501 3.67 6.48 2.6 25.0 98.9 41.4 
Country South 
SA 
Regional 2 SA ML404 133718 40.6 49.2 17.5 255 1.9 0.00 2.6 29.8 21.3 13.1 
Country North 
SA 
Rural 1 SA ML405 199020 40.5 48.9 17.5 312 1.56 0.00 2.9 23.9 23.1 18.5 
Perth Central 
and East Metro 
Metro 2 WA ML501 470311 37.8 49.7 12.7 4235 8.89 10.69 1.6 17.0 100.0 57.5 
Perth North 
Metro 
Metro 2 WA ML502 531958 36.8 50.3 11.8 985 1.84 0.96 1.3 18.4 100.0 60.9 
Fremantle Metro 2 WA ML503 240394 38.6 50.7 13.7 1114 4.58 5.19 2.6 10.8 99.9 66.7 
Bentley - 
Armadale 
Metro 2 WA ML504 418802 36.5 49.5 11.4 692 1.65 0.00 1.6 15.6 100.0 44.8 
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Perth South 
Coastal 
Regional 1 WA ML505 243056 37.6 50.2 14.7 472 1.93 1.23 0.9 23.3 100.0 34.0 
South West 
WA 
Regional 2 WA ML506 299005 39.2 50.0 15.2 639 2.13 0.00 2.0 28.5 59.2 29.8 
Goldfields - 
Midwest 
Rural 2 WA ML507 127272 36.3 47.8 10.5 256 2.01 0.00 1.5 19.7 0.0 28.3 
Kimberley - 
Pilbara 
Rural 2 WA ML508 101907 32.5 41.4 3.2 285 2.79 0.00 0.6 20.7 0.0 37.8 
Tasmania 
 Regional 
2 
TAS ML601 512333 40.2 50.1 16.8 1970 3.81 3.36 2.7 29.1 65.6 21.5 
Northern 
Territory 
Rural 2 NT ML701 235182 32.9 47.5 5.9 1068 4.52 1.28 0.9 14.7 0.0 37.1 
Australian 
Capital 
Territory 
Metro 1 ACT ML801 374909 36.4 50.2 11 1747 4.62 4.00 1.5 23.1 100.0 78.5 
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Appendix Table 2 .  Rates of cardiac imaging among Medicare Locals 
Medicare Local Peer group State Region 
TTE per 
100,000 
pop (age-
weighted) 
TTE 
rank 
TOE per 
100,000 
pop (age-
weighted) 
TOE 
rank 
SE per 
100,000 pop 
(age-
weighted) 
SE rank 
SPECT per 
100,000 pop 
(age-weighted) 
SPECT 
rank 
Central Adelaide and 
Hills 
2. Metro 2 SA ML402 7184.1 1 120.2 7 878.7 18 263.3 27 
Inner North West 
Melbourne 
1. Metro 1 VIC ML201 6894.0 2 197.1 2 2094 5 685.5 7 
Eastern Sydney 1. Metro 1 NSW ML101 6831.4 3 242.1 1 2852 2 316.7 24 
Wide Bay 
5. Regional 
2 
QLD ML307 6072.6 4 0  0  −  
Inner East 
Melbourne 
1. Metro 1 VIC ML206 5476.3 5 76.4 12 2366 3 262.2 28 
Fremantle 2. Metro 2 WA ML503 5281.0 6 97.1 10 1821 6 131.8 35 
Inner West Sydney 1. Metro 1 NSW ML102 5129.5 7 70.5 15 2105 4 389 19 
Perth Central and 
East Metro 
2. Metro 2 WA ML501 4912.0 8 143.3 4 976.7 16 313.9 25 
Appendix 
 
250 
 
Sunshine Coast 
4. Regional 
1 
QLD ML304 4874.8 9 0  420.2 30 805.7 3 
Central Coast NSW 
4. Regional 
1 
NSW ML109 4659.7 10 73.6 14 519 26 796.1 4 
Frankston - 
Mornington 
Peninsula 
4. Regional 
1 
VIC ML209 4583.8 11 0  264.9 33 531.7 9 
Gold Coast 2. Metro 2 QLD ML303 4538.4 12 108.5 9 1142 12 239.4 33 
Metro North 
Brisbane 
2. Metro 2 QLD ML301 4528.3 13 134.5 6 1115 13 442.5 15 
Loddon - Mallee - 
Murray 
5. Regional 
2 
VIC ML214 4461.2 14 55.2 22 0  259.6 29 
Grampians 
5. Regional 
2 
VIC ML211 4352.3 15 44.5 27 538.3 24 789.8 5 
Western Sydney 3. Metro 3 NSW ML105 4277.5 16 56.7 19 1637 10 244.8 31 
Sydney North Shore 
and Beaches 
1. Metro 1 NSW ML108 4202.4 17 116.2 8 1674 9 438.6 16 
South Eastern 
Sydney 
2. Metro 2 NSW ML103 4138.8 18 136.6 5 2992 1 371 20 
Bayside 1. Metro 1 VIC ML202 4024.5 19 43.6 28 827.7 20 453.1 13 
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Greater Metro South 
Brisbane 
2. Metro 2 QLD ML302 3908.6 20 80.1 11 1106 15 298.5 26 
Western NSW 
5. Regional 
2 
NSW ML115 3752.8 21 56.4 20 519.6 25 930.2 2 
Hume 
5. Regional 
2 
VIC ML216 3643.7 22 0  886.7 17 641.8 8 
North Coast NSW 
5. Regional 
2 
NSW ML113 3550.4 23 48.1 25 1817 7 240.5 32 
Northern Sydney 1. Metro 1 NSW ML107 3542.3 24 170.6 3 1334 11 453 14 
Southern Adelaide - 
Fleurieu - Kangaroo 
Island 
2. Metro 2 SA ML403 3453.6 25 46.3 26 830 19 −  
Lower Murray 6. Rural 1 VIC ML213 3276.1 26 _  0  −  
Illawarra - 
Shoalhaven 
4. Regional 
1 
NSW ML110 3210.3 27 67.4 16 762.6 21 955.8 1 
South Western 
Sydney 
3. Metro 3 NSW ML104 3146.6 28 56.4 21 1114 14 461.9 12 
Hunter 
4. Regional 
1 
NSW ML111 3141.4 29 34 30 719.9 23 422.8 17 
Townsville - Mackay 6. Rural 1 QLD ML310 3059.7 30 54.4 23 0  329.1 23 
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Nepean - Blue 
Mountains 
4. Regional 
1 
NSW ML106 2984.0 31 61.6 17 508 27 356.6 21 
Barwon 
4. Regional 
1 
VIC ML210 2729.2 32 0  0  −  
Australian Capital 
Territory 
1. Metro 1 ACT ML801 2611.2 33 0  253 34 253.8 30 
Eastern Melbourne 2. Metro 2 VIC ML207 2502.3 34 35.2 29 752.2 22 341.2 22 
Northern Melbourne 3. Metro 3 VIC ML205 2454.5 35 60.4 18 503 28 529 10 
Darling Downs - 
South West 
Queensland 
5. Regional 
2 
QLD ML306 2328.7 36 _  0 37 −  
Central Queensland 6. Rural 1 QLD ML308 2310.1 37 0  0  −  
Murrumbidgee 
5. Regional 
2 
NSW ML116 2215.0 38 74 13 1709 8 −  
Far North 
Queensland 
7. Rural 2 QLD ML311 2156.6 39 5.2 31 0  −  
Goulburn Valley 
5. Regional 
2 
VIC ML215 2073.9 40 0  0  740.5 6 
Tasmania 
5. Regional 
2 
TAS ML601 2001.5 41 48.9 24 311.2 32 502.3 11 
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Gippsland 
5. Regional 
2 
VIC ML217 1925.5 42 _  0  −  
West Moreton - 
Oxley 
3. Metro 3 QLD ML305 1896.1 43 0  0  −  
Northern Territory 7. Rural 2 NT ML701 1886.8 44 0  0  −  
Country South SA 
5. Regional 
2 
SA ML404 1824.4 45 −  0  −  
New England 
5. Regional 
2 
NSW ML114 1745.0 46 _  0  −  
Northern Adelaide 3. Metro 3 SA ML401 1708.8 47 0  0  105.8 36 
Macedon Ranges and 
North Western 
Melbourne 
3. Metro 3 VIC ML204 1681.5 48 0  350.7 31 −  
South Western 
Melbourne 
2. Metro 2 VIC ML203 1665.2 49 0  0  −  
South Eastern 
Melbourne 
3. Metro 3 VIC ML208 1630.5 50 0  200 35 171.4 34 
Country North SA 6. Rural 1 SA ML405 1592.1 51 0  0  −  
Perth South Coastal 
4. Regional 
1 
WA ML505 1565.9 52 _  471.4 29 −  
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Great South Coast 
5. Regional 
2 
VIC ML212 1316.1 53 0  0  −  
Goldfields - Midwest 7. Rural 2 WA ML507 1166.8 54 _  0  −  
Southern NSW 
5. Regional 
2 
NSW ML117 968.8 55 0  0  415.3 18 
Kimberley - Pilbara 7. Rural 2 WA ML508 937.1 56 _  0  0  
Bentley - Armadale 2. Metro 2 WA ML504 806.0 57 0  11.1 36 69.5 37 
Perth North Metro 2. Metro 2 WA ML502 671.7 58 0  0  57 38 
South West WA 
5. Regional 
2 
WA ML506 485.4 59 −  0  −  
Central and North 
West Queensland 
7. Rural 2 QLD ML309 382.8 60 _  _  0  
Far West NSW 6. Rural 1 NSW ML118 −  −  −  0  
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Appendix Table 3 . Association of population characteristics in Medicare Locals with age-weighted numbers of tests/100,000 persons. 
  TTE TOE SE SPECT 
  Beta 
95%CI       
(Lower-
Upper) 
p Beta 
95%CI       
(Lower-
Upper) 
p Beta 
95%CI       
(Lower-
Upper) 
p Beta 
95%CI       
(Lower-
Upper) 
p 
Women (%) 1.224 1.119 1.340 <0.001 1.119 0.791 1.581 0.525 1.118 0.694 1.799 0.646 1.967 1.598 2.420 <0.001 
Non-
cardiologists 
(/1,000) 
1.223 1.145 1.306 <0.001 1.199 1.106 1.299 <0.001 1.175 1.032 1.337 0.015 1.021 0.881 1.184 0.781 
Older 65years 
(%) 
1.052 1.012 1.093 0.010 0.943 0.870 1.022 0.153 0.989 0.900 1.086 0.817 1.155 1.069 1.247 <0.001 
CV disease (%) 0.989 0.962 1.016 0.420 0.936 0.908 0.965 <0.001 0.947 0.903 0.992 0.023 1.024 0.975 1.076 0.335 
CV deaths 
(/1,000) 
1.051 0.866 1.274 0.616 0.767 0.578 1.016 0.064 0.977 0.697 1.369 0.892 1.518 1. 009 2.284 0.045 
More 
disadvantaged 
(%) 
0.992 0.985 1.000 0.039 0.982 0.973 0.991 <0.001 0.988 0.976 1.000 0.054 1.008 1.000 1.017 0.059 
Peer group                  
- Metro 1 Ref - - - Ref - - - Ref - - - Ref - - - 
- Metro 2 0.751 0.488 1.156 0.194 0.767 0.530 1.110 0.160 0.689 0.365 1.301 0.251 0.622 0.363 1.066 0.084 
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- Metro 3 0.496 0.304 0.809 0.005 0.443 0.267 0.734 0.002 0.451 0.210 0.969 0.041 0.745 0.390 1.422 0.372 
- Regional 1 0.717 0.446 1.150 0.167 0.451 0.284 0.716 0.001 0.310 0.155 0.621 0.001 1.585 0.859 2.925 0.141 
- Regional 2 0.552 0.366 0.831 0.004 0.416 0.275 0.627 <0.001 0.571 0.277 1.178 0.129 1.390 0.788 2.450 0.256 
- Rural 1 0.529 0.296 0.944 0.031 0.416 0.189 0.916 0.029 †    0.413 0.167 1.022 0.056 
- Rural 2 0.270 0.157 0.463 <0.001 0.040 0.016 0.103 <0.001 †    †    
Region                 
- Metro Ref - - - Ref - - - Ref - - - Ref - - - 
- Regional 0.800 0.597 1.071 0.133 0.537 0.369 0.782 0.001 0.577 0.350 0.953 0.032 1.888 1. 101 3.240 0.021 
- Rural  0.508 0.340 0.758 <0.001 0.287 0.139 0.589 0.001 †    0.265 0.111 0.635 0.003 
Cardiologists 
(/100,000)* 
    0.338 0.179 0.637 0.001 0.411 0.255 0.661 
<0.00
1 
    
† Unable to estimate, no testing performed. * Estimates from inflation part of ZINB model. 
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Appendix Table 4 . Characteristics of studies included in the systematic review 
Study Test AUC 
Editi
on 
Type of 
Study 
AUC 
score 
mad
e by: 
Whe
re? 
Profes
sion of 
review
er 
Collecti
on of 
inform
ation 
for 
scoring 
Method
ology 
used for 
scoring 
Blinde
d to the 
Hypot
hesis of 
the 
study 
Ka
pp
a 
Acade
mic or 
Comm
unity 
setting 
Sam
ple 
n 
App 
tests 
n 
Classi
fied 
Studie
s 
%Cla
ssified 
Tests 
%App 
of 
total 
%App 
of 
classif
ied 
Ward  TTE 2007 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
0.8
2 
Acade
mic 
Medical 
Center 
1553 1228 1385 0.89 0.79 0.89 
Willens  TTE 2007 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Echoc
ardiog
rapher 
Review 
of 
medical 
records 
Single 
determin
ation 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Both 625 481 526 0.84 0.77 0.91 
Dharmara
jan  
TTE 2007 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Single 
determin
ation 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
58 51 58 1.00 0.88 0.88 
Kirkpatric
k  
TTE 2007 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Echoc
ardiog
rapher 
Review 
of 
medical 
records 
Single 
determin
ation 
Not 
specifie
d 
0.6
7 
Acade
mic 
Medical 
Center 
368 206 237 0.64 0.56 0.87 
Martin  TTE 2007 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
274 237 268 0.98 0.86 0.88 
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Bhave  TTE 2007 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Sonog
rapher
s and 
Physic
ians 
Review 
of 
medical 
records 
Not 
specified 
Not 
specifie
d 
0.8
4 
Acade
mic 
Medical 
Center 
258 199 221 0.86 0.77 0.90 
Rao  TTE 2007 Prospect
ive 
Not 
speci
fied 
Point 
of 
care 
Not 
specifi
ed 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Commu
nity 
Setting 
772 533 716 0.93 0.69 0.74 
Aggarwal  TTE 2007 Retrosp
ective  
revie
wers 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
0.5
5 
Acade
mic 
Medical 
Center 
329 278 299 0.91 0.84 0.93 
Gathak  TTE 2007 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Not 
specified 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
431 364 394 0.91 0.84 0.92 
Rahimi1  TTE 2007 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
177 143 164 0.93 0.81 0.87 
Parikh  TTE 2007 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
384 333 336 0.88 0.87 0.99 
Bhatia  TTE 2007 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
Not 
specifie
d 
No
t 
spe
Both 450 288 347 0.77 0.64 0.83 
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ied/disag
reement 
cifi
ed 
Alqarqaz  TTE 2007 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
170 131 147 0.86 0.77 0.89 
Silverman  TTE 2007 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Single 
determin
ation 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
485 442 485 1.00 0.91 0.91 
Bailey  TTE 2007 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
1080 933 945 0.88 0.86 0.99 
Willens  TTE 2011 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Both 625 479 617 0.99 0.77 0.78 
Patil  TTE 2011 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
1820 1493 1812 1.00 0.82 0.82 
Ballo  TTE 2011 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Multiple 
determin
ation 
Not 
specifie
d 
0.8
3 
Commu
nity 
Setting 
931 739 920 0.99 0.79 0.80 
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Mansour  TTE 2011 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
1553 1253 1525 0.98 0.81 0.82 
Matulevic
ius  
TTE 2011 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
0.8 Acade
mic 
Medical 
Center 
535 491 535 1.00 0.92 0.92 
Bhatia2  TTE 2011 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
1318 1105 1312 1.00 0.84 0.84 
Rao  TEE 2007 Retrosp
ective  
Not 
speci
fied 
Not 
speci
fied 
Not 
specifi
ed 
Not 
specifie
d 
Not 
specified 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
1235 1156 1235 1.00 0.94 0.94 
Ogbara  TEE 2007 Prospect
ive 
Revi
ewer
s 
Not 
speci
fied 
Not 
specifi
ed 
Review 
of 
medical 
records 
Not 
specified 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
389 321 389 1.00 0.83 0.83 
Bhatia  TEE 2007 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
202 156 166 0.82 0.77 0.94 
Grewal  TEE 2011 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Not 
specified 
Not 
specifie
d 
No
t 
spe
Acade
mic 
Medical 
Center 
671 639 659 0.98 0.95 0.97 
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cifi
ed 
McCully  SE 2008 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Nurses Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
0.7
2 
Acade
mic 
Medical 
Center 
298 159 241 0.81 0.53 0.66 
Mansour  SE 2008 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
289 180 253 0.88 0.62 0.71 
Bhatia  SE 2008 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
252 104 126 0.50 0.41 0.83 
Willens  SE 2008 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Single 
determin
ation 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Both 209 104 189 0.90 0.50 0.55 
Lin  SE 2008 Prospect
ive 
Orde
ring 
physi
cian 
Point 
of 
care 
Physic
ians 
criteria 
entered 
by 
ordering 
physicia
n 
Single 
determin
ation 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Commu
nity 
Setting 
111 50 92 0.83 0.45 0.54 
Schmitz  SE 2008 Retrosp
ective  
Not 
speci
fied 
Not 
speci
fied 
Not 
specifi
ed 
Not 
specifie
d 
Not 
specified 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
300 194 226 0.75 0.65 0.86 
Appendix 
 
262 
 
Cortigiani SE 2011 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Commu
nity 
Setting 
1552 984 1552 1.00 0.63 0.63 
Bhattacha
ryya   
SE 2011 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
both 100 49 100 1.00 0.49 0.49 
Gibbons1  SPECT 2005 Retrosp
ective  
revie
wers 
Point 
of 
servi
ce 
Nurses Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
0.5
6 
Acade
mic 
Medical 
Center 
284 182 253 0.89 0.64 0.72 
Mehta  SPECT 2005 Retrosp
ective  
Revi
ewer
s 
Not 
speci
fied 
Not 
specifi
ed 
Review 
of 
medical 
records 
Single 
determin
ation 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
1209 940 1173 0.97 0.78 0.80 
Hendel  SPECT 2005 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Nurses Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Commu
nity 
Setting 
6351 4192 5906 0.93 0.66 0.71 
Gibbons2  SPECT 2005 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Nurses Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
0.6
8 
Acade
mic 
Medical 
Center 
284 188 241 0.85 0.66 0.78 
Carryer  SPECT 2005 Retrosp
ective  
revie
wers 
Point 
of 
servi
ce 
Nurses Review 
of 
medical 
records 
Review 
only for 
unclassif
Not 
specifie
d 
No
t 
spe
Acade
mic 
Medical 
Center 
281 179 250 0.89 0.64 0.72 
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ied/disag
reement 
cifi
ed 
Gupta  SPECT 2005 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Not 
specified 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
314 263 314 1.00 0.84 0.84 
Gibbons3  SPECT 2005 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Nurses Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
0.7
4 
Acade
mic 
Medical 
Center 
273 164 232 0.85 0.60 0.71 
Gholamre
zanezhad  
SPECT 2005 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Multiple 
determin
ation 
Not 
specifie
d 
0.6
3 
Both 291 211 279 0.96 0.73 0.76 
Druz  SPECT 2005 Prospect
ive 
Not 
speci
fied 
Not 
speci
fied 
Not 
specifi
ed 
Not 
specifie
d 
Not 
specified 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
585 370 570 0.97 0.63 0.65 
Soine1  SPECT 2005 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Not 
specified 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
1377 950 1377 1.00 0.69 0.69 
Koh  SPECT 2009 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
0.6
4 
Acade
mic 
Medical 
Center 
1623 1331 1574 0.97 0.82 0.85 
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Nelson1  SPECT 2009 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Single 
determin
ation 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Commu
nity 
Setting 
150 101 148 0.99 0.67 0.68 
Koh  SPECT 2009 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
176 106 176 1.00 0.60 0.60 
Winchest
er  
SPECT 2009 Retrosp
ective  
Not 
speci
fied 
Not 
speci
fied 
Not 
specifi
ed 
Not 
specifie
d 
Not 
specified 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Commu
nity 
Setting 
332 259 328 0.99 0.78 0.79 
 Doukky  SPECT 2009 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Single 
determin
ation 
Not 
specifie
d 
0.8
3 
Commu
nity 
Setting 
1511 779 1491 0.99 0.52 0.52 
Moralidis  SPECT 2009 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
3032 2208 3008 0.99 0.73 0.73 
Aldweib  SPECT 2009 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Single 
determin
ation 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
1199 740 1194 1.00 0.62 0.62 
Ayyad 1  CCT 2006 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Single 
determin
ation 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Both 763 530 715 0.94 0.69 0.74 
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Miller  CCT 2006 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
0.3
1 
Acade
mic 
Medical 
Center 
251 69 136 0.54 0.27 0.51 
Murphy  CCT 2006 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
267 126 189 0.71 0.47 0.67 
El Sibai   CCT 2006 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Single 
determin
ation 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
100 8 100 1.00 0.08 0.08 
Chinnaiya
n  
CCT 2006 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Single 
determin
ation 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Both 2538
7 
5053 12853 0.51 0.20 0.39 
Rich  CCT 2006 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Not 
specifi
ed 
Review 
of 
medical 
records 
Not 
specified 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
1216 503 1069 0.88 0.41 0.47 
Mazimba  CCT 2006 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Not 
specified 
Not 
specifie
d 
0.8
4 
Acade
mic 
Medical 
Center 
243 36 243 1.00 0.15 0.15 
Wasfy  CCT 2006 Prospect
ive 
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
No
t 
spe
cifi
ed 
Acade
mic 
Medical 
Center 
267 119 189 0.71 0.45 0.63 
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Cullen  CCT 2010 Retrosp
ective  
Revi
ewer
s 
Point 
of 
servi
ce 
Physic
ians 
Review 
of 
medical 
records 
Review 
only for 
unclassif
ied/disag
reement 
Not 
specifie
d 
0.5
5 
Acade
mic 
Medical 
Center 
251 85 212 0.84 0.34 0.40 
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Appendix Table 5 . Clinical characteristics of patients according to appropriate use category. 
  No TTE Inappropriate Uncertain Appropriate p(a) p(b) p(c) p(d) p(e) 
n 409 41 19 81 
     
Age (median [IQR]) 79 [70, 84] 69 [63, 76] 76 [69, 79] 75 [68, 80] <0.01 0.06 0.14 0.02 0.82 
Male sex, n (%) 222 (54.3) 25 (61.0) 9 (47.4) 51 (63.0) 0.38 0.46 0.48 0.99 0.32 
Body mass index, median [IQR] 26 [23, 30] 27 [23, 33] 28 [24, 34] 28 [25, 31] 0.06 0.73 0.64 0.44 0.77 
Systolic blood pressure in 
mmHG, median [IQR] 
120 [105, 135] 120 [110, 130] 128 [106, 140] 121 [110, 136] 0.64 0.67 0.57 0.39 0.84 
Creatinine levels in µ/L, median 
[IQR] 
112 [86, 148] 88 [72, 117] 85 [67, 111] 106 [86, 126] <0.01 0.06 0.81 0.04 0.08 
Left ventricular ejection fraction 
%, median [IQR] 
0.45 [0.32, 
0.60] 
0.39 [0.35, 
0.50] 
0.43 [0.25, 0.51] 0.46 [0.35, 0.60] 0.14 0.06 0.89 0.03 0.11 
MAGGIC score, median [IQR]) 28 [23, 33] 24 [19, 27] 27 [21, 29] 25 [20, 28] <0.01 0.48 0.26 0.39 0.52 
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Risk of death 1 year, median 
[IQR] 
0.21 [0.13, 
0.32] 
0.15 [0.09, 
0.19] 
0.19 [0.11, 0.24] 0.16 [0.10, 0.21] <0.01 0.48 0.25 0.41 0.52 
Risk of death 3 years, median 
[IQR] 
0.46 [0.32, 
0.63] 
0.34 [0.23, 
0.43] 
0.43 [0.28, 0.50] 0.37 [0.25, 0.46] <0.01 0.48 0.26 0.39 0.52 
Betablockers, n (%) 225 (55.0) 26 (63.4) 12 (63.2) 52 (64.2) 0.34 0.99 1.00 1.00 1.00 
Diuretics, n (%) 369 (90.2) 38 (92.7) 15 (78.9) 69 (85.2) 0.22 0.30 0.27 0.37 0.75 
Mineralocorticoids, n (%) 124 (30.3) 19 (46.3) 5 (26.3) 25 (30.9) 0.20 0.17 0.23 0.14 0.91 
Angiotensin-converting-enzyme 
inhibitor/ angiotensin-II receptor 
blockers, n (%) 
304 (74.3) 34 (82.9) 15 (78.9) 57 (70.4) 0.48 0.29 0.99 0.20 0.64 
Calcium antagonists, n (%) 82 (20.0) 5 (12.2) 3 (15.8) 16 (19.8) 0.70 0.63 0.70 0.43 1.00 
Antiarrhythmics, n (%) 44 (10.8) 2 (4.9) 2 (10.5) 13 (16.0) 0.31 0.19 0.59 0.09 0.73 
Digoxin, n (%) 84 (20.5) 8 (19.5) 6 (31.6) 13 (16.0) 0.49 0.30 0.48 0.82 0.22 
Statins, n (%) 210 (51.3) 16 (39.0) 10 (52.6) 48 (59.3) 0.21 0.11 0.48 0.06 0.79 
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Hypertension, n (%) 292 (71.4) 24 (58.5) 11 (57.9) 66 (81.5) 0.03 0.01 1.00 0.01 0.06 
Dyslipidaemia, n (%) 194 (47.4) 14 (34.1) 11 (57.9) 52 (64.2) 0.01 0.01 0.15 <0.01 0.80 
History of angina, n (%) 119 (29.1) 8 (19.5) 9 (47.4) 38 (46.9) <0.01 0.01 0.06 0.01 1.00 
History of atrial fibrillation, n (%) 203 (49.6) 19 (46.3) 9 (47.4) 47 (58.0) 0.51 0.41 1.00 0.30 0.56 
Arrhythmia, n (%) 68 (16.6) 5 (12.2) 5 (26.3) 16 (19.8) 0.51 0.38 0.32 0.43 0.75 
Cardiomyopathy, n (%) 153 (37.4) 10 (24.4) 9 (47.4) 29 (35.8) 0.29 0.19 0.14 0.28 0.50 
Dilated cardiomyopathy, n (%) 115 (28.1) 8 (19.5) 8 (42.1) 22 (27.2) 0.34 0.19 0.13 0.48 0.32 
Hypertrophic cardiomyopathy, n 
(%) 
25 (6.1) 1 (2.4) 1 (5.3) 6 (7.4) 0.77 0.60 0.54 0.42 1.00 
Restrictive cardiomyopathy, n 
(%) 
13 (3.2) 1 (2.4) 0 (0.0) 1 (1.2) 0.89 1.00 1.00 1.00 1.00 
Deep vein thrombosis, n (%) 20 (4.9) 1 (2.4) 0 (0.0) 4 (4.9) 0.95 0.84 1.00 0.66 1.00 
Angioplasty, n (%) 78 (19.1) 9 (22.0) 5 (26.3) 19 (23.5) 0.71 0.93 0.97 1.00 1.00 
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Myocardial infarction, n (%) 178 (43.5) 11 (26.8) 11 (57.9) 30 (37.0) 0.07 0.07 0.04 0.36 0.16 
Cerebrovascular disease, n (%) 93 (22.7) 6 (14.6) 0 (0.0) 25 (30.9) 0.01 <0.01 0.16 0.09 <0.01 
Renal disease, n (%) 106 (25.9) 5 (12.2) 5 (26.3) 21 (25.9) 0.28 0.20 0.32 0.13 1.00 
Valvular disease, n (%) 152 (37.2) 15 (36.6) 7 (36.8) 29 (35.8) 1.00 0.99 1.00 1.00 1.00 
Cardiac catheterisation, n (%) 53 (13.0) 2 (4.9) 2 (10.5) 15 (18.5) 0.20 0.09 0.59 0.05 0.52 
Diabetes mellitus, n (%) 166 (40.6) 12 (29.3) 9 (47.4) 32 (39.5) 0.48 0.35 0.28 0.36 0.71 
Chronic obstructive pulmonary 
disease, n (%) 
167 (40.8) 21 (51.2) 6 (31.6) 34 (42.0) 0.49 0.34 0.25 0.44 0.57 
NYHA class, n (%) 
    
0.01 0.63 0.46 0.73 0.39 
1 78 (19.1) 10 (24.4) 2 (10.5) 24 (29.6) 
     
2 111 (27.1) 12 (29.3) 9 (47.4) 28 (34.6) 
     
3 142 (34.7) 16 (39.0) 7 (36.8) 25 (30.9) 
     
4 78 (19.1) 3 (7.3) 1 (5.3) 4 (4.9) 
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NHYA class 3 and 4, n (%) 220 (53.8) 19 (46.3) 8 (42.1) 29 (35.8) 0.02 0.52 0.98 0.35 0.80 
Active change in management 
after follow-up TTE (%) 
_ 10 (24.4) 2 (10.5) 18 (22.2) _ 0.45 0.37 0.97 0.41 
 
Data in bold denote statistically significant results  
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Appendix 6- 1 . Interview Schedule 
Opening 
1. (Establish rapport) Hello Dr_________, I am Ricardo Fonseca, the PhD candidate 
who contacted you for the appropriate use of echocardiography study. How are you? 
2. (Purpose) I would like to ask you some questions about your background, some 
experiences you have had when requesting an echocardiogram and some of your 
possible decisions in some situations when a patient was referred for an 
echocardiogram. 
3. (Motivation) Your comments will help us to learn more about factors that affect the 
process of decision-making and appropriate use of echocardiography, and to develop 
more efficient recommendations or educational campaigns to avoid inappropriate 
testing. 
4. (Time line) The interview should take about 30 minutes. Are you available to respond 
to some questions at this time? 
(Transition: Let me begin by asking you some questions about your background and 
experiences with patients who needed echocardiograms)  
Body 
1. (Topic) Background 
a. What is your specialty? 
b. Do you usually have patients who need echocardiograms? Or is it rare?  
c. During a month, how many echocardiograms you usually request? No need for an 
exact number, just an approximation.  
d. What is more common to you: requesting an echocardiogram for inpatients or 
outpatients? For new findings or follow-up?  
 
2. (Topic) Experiences when requesting an echocardiogram:  
a. In what percentage of cases, you order a test due to a cause other than medical 
indication?  
b. There is an interesting manuscript written more than 30 years ago in the NEJM by 
an author called Joseph Hardison. I have provided the 10 questions he asked his 
colleagues. Could you please indicate if you have experienced the following 
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reasons to perform an echocardiogram? Can you rank these in the order of 
frequency or the percentage of requests in each category? 
“To be complete” 
-  
A superior or colleague said the patient needed it. 
-  
“Fear” of getting into trouble (perhaps by missing something) 
-  
Because the patient is here and it is better to order everything at once 
-  
Because the patient is hospitalised 
-  
Academic reasons 
-  
Protocols 
-  
Malpractice 
-  
“How do I know the patient does have it?” 
-  
“If the patient was my father/mother/partner/relative, I would want it done” 
-  
- Do you have any other reason to order an echocardiogram?  
 
3. (Topic) I would now like to provide you with some clinical situations and discuss 
whether or not you would order an echocardiogram in these circumstances and the 
reasons why. Can you please talk through you’re decision making/reasoning process 
when considering each of the five scenarios presented here.  (The following scenarios 
will be presented in writing to each participant).  
a. 44 year old business man who presented to GP for health insurance check-up and was 
found to have an incidental murmur. Patient is slightly overweight. Rest of physical 
exam is normal. He has reasonable exercise tolerance and walks his dog 5 times a 
week without any problems. His echocardiogram shows mild mitral valve prolapse 
and mild mitral regurgitation. You see him in one year time for follow-up. He is doing 
well; continues to walk his dog without any problems. However has gained 5 
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kilograms of weight. His physical examination is normal except for the cardiac 
murmur found previously.  
b. 37 year old male with high grade fevers, IVDU. Cellulitis around injection site. 
Examination shows low body weight. Normal cardiovascular exam. Blood cultures 
negative so far. Query echocardiogram for infective endocarditis?  
c. 50 year old female with dilated cardiomyopathy well treated with medications. 
Ejection fraction 40%. Mildly dilated left ventricle. Exercise tolerance 1 km on flat. 
Mild shortness of breath up hills, similar to 6 months ago. Presents for follow-up after 
6 months for titration of medications.   
d. 88 year old female, living in low level care hostel, no significant co-morbidities, and 
walks assisted with walk-stick. Non-severe aortic stenosis on echocardiogram 14 
months ago. Reports she is asymptomatic for annual follow –up and echocardiogram.  
e. 20 year old male, presents with chest pain following recent flu. ECG shows 
widespread ST elevation consistent with pericarditis. WCC, CRP, ESR, are all 
elevated. Echocardiogram is normal. Except for small pericardial effusion. Patient is 
followed up in cardiology clinic three months later following a course of NSAIDs and 
colchicine. He feels well, has not had chest pain for two months. Repeat 
echocardiogram to assess resolution for pericardial effusion.  .  
For each scenario provide prompts such as:  
What is the most important consideration in making this decision (i.e. age, severity of 
symptoms, previous test results)? What other factors would influence your decision to order an 
echocardiogram? 
If an echocardiogram is recommended by the interviewee, how urgently does the test need to 
be conducted? 
 
4. (Topic) What do you do if the echocardiogram result shows an incidental finding? 
(Example scenario: 23 year old female, G1 P0, 27 weeks pregnant, seen in obstetric 
clinic with incidental murmur. Referred for echo which shows query small linear 
aortic valve mass (this could be an artefact).)  
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5. (Topic) Assessing awareness of guidelines and AUC: When making decisions about 
ordering an echocardiogram, do you consider any guidelines/criteria/protocols? Are 
you familiar with the Guidelines for Clinical Application of Echocardiography? And 
the Appropriateness Criteria for Echocardiography?  
 
6. (Topic) Patient involvement in decision making: When making the decision to order 
an echocardiogram do you discuss the possibility of requesting an echo with your 
patient? Does this discussion involve consideration of possible benefits and harms? If 
the response is no to patient involvement / discussion of benefits-harms then follow 
up with: under what circumstances would you involve the patient in the decision 
making process about their care? 
 
7. (Topic) Patient desires: Have you ever had a patient ask for an echocardiogram? If 
yes, then ask: How does this request impact your decision making about ordering an 
echocardiogram?  
 
8. (Topic) Harms of echocardiography: Are you aware of harms of echocardiogram? 
Could you say some?  
 
9. (Topic) Awareness of costs: Do you know how much Medicare pays for a 
transthoracic echocardiogram? Trans-oesophageal? Stress echo? Other cardiac 
imaging (SPECT, cardiac tomography-angiography)? Do you take this into account 
when you are ordering a test? 
  
10. (Topic) When you order an echocardiogram, are you always aware of its result? 
Where are the test results recorded? How do the test results impact on your 
management of the patient? 
(Transition: Well, it has been a pleasure finding out more about your thoughts when you are 
considering the possibility of requesting an echocardiogram) 
Closing 
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- (Maintain Rapport) I appreciate the time you took for this interview. Is there anything 
we haven’t discussed that you consider influences your decision making about 
ordering echocardiograms?  
- (Action to be taken) I should have all the information I need. Would it be alright to 
contact you again if I have any more questions? Thanks again. I look forward to 
analysing the data and to finding efficient recommendations to improve appropriate 
use criteria for testing. 
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Appendix 6- 2 . Clinical scenarios 
a. 44 year old business man who presented to GP for health insurance check-up and was 
found to have an incidental murmur. Patient is slightly overweight. Rest of physical 
exam is normal. He has reasonable exercise tolerance and walks his dog 5 times a 
week without any problems. His echo shows mild mitral valve prolapse and mild 
mitral regurgitation. You see him in one year time for follow-up. He is doing well; 
continues to walk his dog without any problems. However has gained 5 kilograms of 
weight. His physical examination is normal except for the cardiac murmur found 
previously.  
b. 37 year old male with high grade fevers, IVDU. Cellulitis around injection site. 
Examination shows low body weight. Normal cardiovascular exam. Blood cultures 
negative so far. Query echo for infective endocarditis?  
c. 50 year old female with dilated cardiomyopathy well treated with medications. 
Ejection fraction 40%. Mildly dilated left ventricle. Exercise tolerance 1 km on flat. 
Mild shortness of breath up hills, similar to 6 months ago. Presents for follow-up after 
6 months for titration of medications.   
d. 88 year old female, living in low level care hostel, no significant co-morbidities, and 
walks assisted with walk-stick. Non-severe aortic stenosis on echo 14 months ago. 
Reports she is asymptomatic for annual follow –up and echo.  
e. 20 year old male, presents with chest pain following recent flu. ECG shows 
widespread ST elevation consistent with pericarditis. WCC, CRP, ESR, are all 
elevated. Echocardiogram is normal. Except for small pericardial effusion. Patient is 
followed up in cardiology clinic three months later following a course of NSAIDs and 
colchicine. He feels well, has not had chest pain for two months. Repeat echo to 
assess resolution for pericardial effusion.  .  
For each scenario provide prompts such as:  
What is the most important consideration in making this decision (i.e. age, severity of 
symptoms, previous test results)? What other factors would influence your decision to order an 
echo? 
If an echo is recommended by the interviewee, how urgently does the test need to be conducted? 
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Appendix 6- 3 . Approach letter 
Dear Doctor ____________. 
Researchers at the Menzies Institute for Medical Research, University of Tasmania, are 
investigating the factors leading to a physician requesting echocardiograms and its relationship 
with the appropriateness of the study. The aim of this work is to understand the decision making 
process around cardiac imaging.  You are being invited to participate in this important research 
because you have: 
 Requested an echocardiogram in the last year at the Royal Hobart Hospital.  
Health care expenditure has increased considerably, jeopardising the limited healthcare 
resources. The appropriate use of medical services has been one of the major concerns to secure 
a sustainable health care system. In the context of limited resources, health resources should 
be used appropriately. Although guidelines for the use of cardiac imaging have been developed 
and the appropriate use criteria have been used for a decade, around 10-15%% of the 
echocardiograms are still inappropriate. In Australia, up to 20% of transthoracic 
echocardiograms are inappropriate. The Medicare reimbursement for all echocardiography 
modalities in 2014 in Australia was over 235 million dollars, and around 178 million dollars 
were reimbursed only for transthoracic echocardiography (TTE): improving appropriate TTE 
ordering may result in significant health care savings.  
The researchers want to talk to doctors who have requested echocardiograms at the Royal 
Hobart Hospital. The research will be conducted using face to face interviews that will take 
place at a central location near you and will last for 30 minutes. Understanding the factors that 
influence decisions about cardiac imaging will contribute to the development of more efficient 
recommendations or educational campaigns to avoid inappropriate testing.  
Doctor __________, being involved in this research will provide you with an opportunity to 
make a difference to our health system and contribute to how future research in this area will 
be done. 
Participation in this study is voluntary. It is completely up to you whether or not you participate. 
All data will be kept confidential and access limited to the researchers. Doctors will not be 
identifiable in any reporting or publication.  
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If you would like to participate in the interviews, please read the information sheet attached 
and contact Doctor Ricardo Fonseca at Ricardo.Fonseca@utas.edu.au.  
Kind regards, 
 
Dr Tom Marwick 
MBBS, PhD, MPH 
Adjunct Professor, Menzies Institute for Medical Research 
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Appendix 6- 4 . Information sheet 
Understanding Cardiac imaging decision making: appropriate testing determinants   
Information sheet for health care professionals individual interviews 
What is the purpose of this study? 
The purpose of this study is to understand the factors that influence physicians in their decision-making 
related to echocardiography and its impact on the appropriateness of the test.  
Aim 
Our research aim is to explore the various influences on appropriate cardiac imaging decision-making 
by doctors to identify areas in which interventions are needed to improve health outcomes and health 
care expenditure, and areas in which further research is needed.  
Why have I been invited to participate? 
You have been invited to participate in this study because you: 
 Have referred a patient for echocardiography in the past year. 
 You are a physician currently working at the Royal Hobart Hospital. 
If you choose to participate, this decision, along with personal information that you provide the 
researchers, will be kept confidential. Participation in this study is voluntary. It is completely up to you 
whether or not you participate.  
What will I be asked to do? 
We will ask you to complete an interview. The interview may be conducted face to face. The interview 
may take up to 30 minutes and will be recorded. The interview will be about requesting cardiac imaging 
and its appropriateness and will cover topics such as: 
 Knowledge and understanding about appropriateness criteria of cardiac imaging. 
 Decision making about echocardiography. 
 Factors that influence cardiac imaging testing practices. 
 Possible solutions to some of the challenges in referral for echocardiography. 
 Decisions after an inappropriate test which shows abnormal results.  
Are there any possible benefits from participation in this study? 
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 The identification of common challenges when requesting a test, will help us to 
understand why doctors request tests and its impact on appropriateness. The results may 
also influence policy and clinical practice interstate and internationally. 
 It is an opportunity to provide input into future research that will be done in this area. 
Are there any possible risks from participation in this study? 
There are no foreseeable risks associated with your participation in this study.   
What if I change my mind during or after the study? 
You are free to withdraw from the study at any time, and you can do so without providing an explanation.  
If you choose to withdraw after you have participated in the interview we will delete your interview 
data.   
What will happen to the information when this study is over? 
The study data will be kept for 5 years from the first date of publication in a secure location in the 
Menzies Institute for Medical Research at the University of Tasmania in Hobart.  The researchers will 
have the right to access this data for the purpose of publication.  Your data will be treated in a 
confidential manner.  The anonymised transcripts of the interview may be passed to other researchers 
for use in other projects but before doing so, we will endeavour to remove all identifying information. 
How will the results of the study be published? 
The results of this study will be published: 
 As a summary on the Menzies Institute for Medical Research website 
http://www.menzies.utas.edu.au.  
 In peer reviewed scientific journals 
Participants or their practices will not be identifiable in the publication of the results. 
What if I have questions about this study? 
If you have any questions about this study or if you would like to contribute to this area of research in 
other ways, you can contact: 
 Dr Ricardo Fonseca (PhD candidate, Menzies Institute for Medical Research), email: 
Ricardo.Fonseca@utas.edu.au  
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 Dr. Kim Jose (Post Doctoral Research Fellow, Menzies Institute for Medical Research) 
Email: kim.jose@utas.edu.au 
 Professor Tom Marwick (Menzies Institute for Medical Research ,University of 
Tasmania) 
Email: tom.marwick@utas.edu.au  
‘This study has been approved by the Tasmanian Health and Medical Human Research Ethics 
Committee.  If you have concerns or complaints about the conduct of this study should contact the 
Executive Officer of the HREC (Tasmania) Network on (03) 6226 7479 or email 
human.ethics@utas.edu.au.  The Executive Officer is the person nominated to receive complaints from 
research participants. You will need to quote HREC project number H0015516. 
This information sheet is for you to keep. You will be provided with a written consent form, which 
you will need to complete and sign prior to participation in this study.  
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Appendix 6- 5 . Consent form 
 
Understanding Cardiac imaging decision making: appropriate testing determinants   
  Consent form for individual interviews  
 
1. I agree to take part in the research study named above. 
2. I have read and understood the Information Sheet for this study. 
3. The nature and possible effects of the study have been explained to me. 
4. I understand that the study involves engaging in an interview. The interview will be 
face to face. Interviews will be recorded. 
5. There are no foreseeable risks associated with my participation in this study. The 
information will be stored in de-identified format and information that permits re-
identification will be kept securely. 
6. I understand that all research data will be securely stored on the Menzies Institute for 
Medical Research, University of Tasmania premises for fifteen years from the 
publication of the study results, and will then be destroyed. 
7. Any questions that I have asked have been answered to my satisfaction. 
8. I understand that the researcher(s) will maintain confidentiality and that any 
information I supply to the researcher(s) will be used only for the purposes of the 
research.  
9. I understand that the results of the study will be published in such a way that I cannot 
be identified as a participant. My practice will also not be identifiable. 
10. I understand that my participation is voluntary and that I may withdraw at any time 
without any effect.  
 
Participant’s name:  ______________________________________________________________________ 
Participant’s signature: ______________________________________Date:  ________________________ 
Statement by Investigator 
I have explained the project and the implications of participation in it to this volunteer and I believe that 
the consent is informed and that he/she understands the implications of participation. 
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If the Investigator has not had an opportunity to talk to participants prior to them participating, the following must 
be ticked. 
The participant has received the Information Sheet where my details have been provided so participants 
have had the opportunity to contact me prior to consenting to participate in this project. 
Investigator’s name:  ________________________________________________________________________  
 
Investigator’s signature: _________________________________________Date:  _______________________ 
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Appendix Table 6. Diagnostic tests for each of the questions in each of the groups 
 
 
  
  
  
  
Sensitivity 
Estimate[lower-
upper] 
Specificity 
Estimate[lower-
upper]  
  
Odds ratio  
Estimate [lower-
upper] 
  
Positive 
predictive value 
Estimate 
[lower-upper] 
Negative 
predictive 
value  
Estimate 
[lower-upper] 
Positive 
likelihood ratio 
Estimate[lower-
upper] 
Negative 
likelihood ratio 
Estimate[lower
-upper] 
Prospe
ctive 
cohort 
≥2 affirmative 
answers 
0.84[0.68,0.94] 0.87[0.83,0.90] 33.96[13.61,84.78] 0.34[0.24,0.44] 0.98[0.97,1.00] 6.34[4.83,8.34] 0.19[0.09,0.39] 
Question 1 
answered as "yes" 
0.96[0.82,0.99] 0.79[0.75,0.83] 66.72[15.77,282.32] 0.27[0.19,0.35] 0.99[0.98,1.00] 4.55[3.75,5.53] 0.07[0.02,0.26] 
Question 2 
answered as "yes" 
0.73[0.39,0.94] 0.89[0.82,0.94] 21.33[5.10,89.27] 0.35[0.16,0.57] 0.98[0.93,0.99] 6.54[3.60,11.91] 0.31[0.12,0.81] 
Question 3 
answered as "yes" 
0.68[0.50,0.82] 0.79[0.75,0.82] 7.74[3.75,15.95] 0.20[0.14,0.29] 0.97[0.95,0.98] 3.19[2.40,4.23] 0.41[0.26,0.66] 
Question 4 
answered as "yes" 
0.11[0.03,0.25] 1.00[0.99,1.00] Infinite 1.00[0.28,1.00] 0.93[0.91,0.95] Infinite 0.89[0.80,1.00] 
Extern
al 
retrosp
ective 
validat
ion 
cohort 
≥2 affirmative 
answers 
0.80[0.69,0.88] 0.95[0.84,0.97] 83.3[43.13,159.83] 0.62[0.51,0.72] 0.98[0.97,0.99] 
17.41[12.46,24.
32] 
0.21[0.13,0.33] 
Question 1 
answered as "yes" 
0.95[0.87,0.99] 0.91[0.89,0.93] 
177.99[63.19,501.3
2] 
0.49[0.41,0.58] 0.99[0.99,1.00] 
10.44[8.33,13.0
8] 
0.06[0.02,0.15] 
Question 2 
answered as "yes" 
0.53[0.41,0.65] 0.96[0.94,0.97] 26.74[15.09,47.37] 0.55[0.43,0.66] 0.96[0.94,0.97] 
13.01[8.76,19.3
2] 
0.49[0.38,0.62] 
Question 3 
answered as "yes" 
0.37[0.28,0.51] 0.93[0.91]0.94] 7.97[4.67,13.61] 0.33[0.23,0.44] 0.94[0.92,0.96] 5.28[3.62,7.69] 0.66[0.55,0.79] 
Question 4 
answered as "yes" 
0.23[0.14,0.38] 1.00[0.99,1.00] Infinite 1.00[0.73,1.00] 0.93[0.91,0.95] Infinite 0.77[0.68,0.87] 
